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         SYNOPSIS
The work incorporated in the thesis with the title “SEARCHING DRUG
TARGETS FOR MICROBES USING NITROGEN HETEROCYCLES” has been
described in three parts.
[A] STUDIES ON 1,2,4-TRIAZOLES
[B] STUDIES ON PYRAZOLES
[C] STUDIES ON MICROWAVE INDUCED SYNTHESIS OF 2,3-DIHYDRO-1,3,4-
      THIADIAZOLOTRIAZOLES
[A] STUDIES ON 1,2,4-TRIAZOLES
Compounds bearing 1,2,4-triazole nucleus shows variety of biological
activities such as anti-tubercular, amoebicidal, hypnotic, fungicidal, anti-inflammatory,
CNS depressant, anticonvulsant, antitumor etc.
Due to the wide range of biological activity, it was contemplated to synthesise
some novel thiadiazoles, dihydrothiadiazoles, thiadiazepines, aryltriazoles,
oxadiazoles and azomethines bearing triazole nucleus, which have been described
as under.
PART - I : STUDIES ON 1,3,4-THIADIAZOLOTRIAZOLES
Thiadiazole derivatives have been found to be potent drug in pharmaceutical
and possess a wide spectrum of biological activity such as antifungal, antibacterial,
anticonvulsant, pesticidal, herbicidal and antithyroid.  Some novel triazoles with 1,3,4-
thiadiazole ring system have been prepared as under.
1
 N
N N
S
Cl N
N
R
SECTION – I : Synthesis and biological evaluation of 2-Aryl-4-o-
cholorobenzyl–1,2,4-triazolo[3, 4–b]-1,3,4-thiadiazoles.
Substituted triazolo-1,3,4-thiadiazoles of type (I) have been prepared by
condensation of 3-mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole with different
aromatic acid in presence of phosphorous oxychloride.
PART - II : STUDIES ON 1,3,4-THIADIAZEPINES
Thiadiazepine derivative have attracted considerable attention in view of their
great therapeutic importance as antifungal, antibacterial, antiamoebic, anti-HIV and
anticancer agents.  To approach these goal preparation of some novel thiadiazipines
have been undertaken as under.
SECTION - I : Synthesis and biological evaluation of 4-o-cholorobenzyl-
1,2,4-triazolo[3,4-b] substituted quinolino [2,3-f]-1,3,4-
thiadiazepines
Type (II)          R = Aryl
N
N N
N
S
RCl
Type (I)               R = Aryl
2
Thiadiazepine derivative of type (II) have been prepared by the condensation
of 3-mercapto-4,N-amino-5-o-cholorobenzyl-1,2,4-triazole with substituted 2-chloro-
3-formyl-quinolines.
PART - III : STUDIES ON 4-ARYLTRIAZOLES
4-Aryltriazole derivatives are important class of heterocycles having interesting
pharmacological activities such as analgesic, CNS depressant, pesticidal, anti-
inflammatory and antihypertensive.  These valid observations led us to synthesize
some new 1,2,4-triazole derivative which have been described as under.
SECTION – I : Synthesis and biological evaluation of 3-mercapto-4,N-aryl-
5-o-cholorobenzyl-1,2,4-triazoles
Type (III)         R = Aryl
The synthesis of triazole derivatives of type (III) have been undertaken by heating
of potassium o-chlorophenylaectamido dithiocarbamate with different aromatic
amines.
PART - IV :  STUDIES ON 1,3,4-OXADIAZOLES
Oxadiazole derivative are endowed with different therapeutic activities such
as hypnotic, anaesthetic, antibacterial, antifungal, insecticidal and preservatives.  In
view of these facts, it was contemplated to synthesize some new oxadiazoles, which
have been described as under.
N
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Type (III) R = Aryl
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SECTION - I : Synthesis and biological evaluation of 2-Aryl-5-o-
cholorobenzyl 1,3,4-oxadiazoles
Type (IV)       R = Aryl
The oxadiazole derivative of type (IV) have been prepared by the condensation
of o-chlorophenylaceto hydrazide with different aromatic acid in presence of
phosphorous oxychloride.
PART - V : STUDIES ON AZOMETHINES
Azomethine derivatives represent one of the modest class of compounds
possessing wide range of therapeutic activities, such as antimicrobial, antibacterial,
antibiotics and with a view to getting better therapeutic agent and to evaluate its
pharmacological profile, different types of azomethine derivatives have been
prepared, which have been described as under.
SECTION – I : Synthesis and biological evaluation of 4,N-substituted
benzalamino-3-mercapto-5-o-cholorobenzyl-1,2,4-triazoles
Type (V)          R = Aryl
4
The azomethine derivatives of type (V) have been prepared by the
condensation of 3-mercapto-4,N-amino-5-o-cholorobenzyl-1,2,4-trizole with
different aromatic aldehydes in presence of sulphuric acid.
[B] STUDIES ON PYRAZOLES
Pyrazole derivatives are known to exhibit wide number of biological and
pharmacological activities such as antitubercular, antimicrobial, anti-inflammatory,
antitumor, antiarthritic, antidepressant, plant growth regulator and also used as
herbicidal and insecticidal.
Considering the increasing importance of pyrazole nucleus we have
undertaken the synthesis of some novel Thiazolidinones, Pyrimidinones,
Thiopyrimidines, Cyanopyridones, Imidazolinones, and acetonitriles bearing pyrazole
nucleus.
PART – I : STUDIES ON PYRIMIDINES
The emerging role of pyrimidines in pharmaceutical chemistry as well as in
biochemistry stimulated tremendous interest in the synthesis of pyrimidines with
therapeutic potential.
In order to achieving better therapeutic activity, we have synthesised some
new pyrimidine derivatives bearing pyrazole nucleus which is described as under.
SECTION – I : Synthesis and biological evaluation of 2-arylimino-3,N-aryl-
5-(1’,N-phenyl-3’-p-bromophenyl-4’-pyrazolylmethino)-4-
Thiazolidinones
5
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Type (VI)          R = Aryl
The arylidines of type (VI) have been prepared by condensation of 1,N-phenyl-
3-p-bromophenyl-4-formyl pyrazole with different thiazolidinones in glacial acetic
acid.
SECTION – II : Synthesis and biological evaluation of 6-arylimino-7,N-aryl-
2- oxo-4-(1’,N-phenyl-3’-p-bromophenyl pyrazol-4’-
yl)1,2,3,4–tetrahydro thiazolidino-[4, 5-d]-pyrimidines.
Type (VII)          R = Aryl
Pyrimidinones of type (VII) have been prepared by the condensation of 2-
arylimino-3,N-aryl-5-(1’,N-phenyl-3’-p-bromophenyl-4’-pyrazolylmethino)4-
thiazolidinones with urea in glacial acetic acid with fused sodium acetate.
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SECTION – III : Synthesis and biological evaluation of 6-arylimino-7, N-aryl-
2-thio-4-(1’,N-phenyl-3’-p-bromophenyl pyrazol-4’-yl)-
1,2,3,4-tetrahydro-thiazolidino-[4, 5-d] pyrimidines
Type (VIII)          R = Aryl
Thiopyrimidines of Type (VIII) have been synthesized by the condensation of
2-arylimino-3,N-aryl-5-(1’,N-phenyl-3’-p-bromophenyl-4’-pyrazolylmethino)4-
thiazolidinone with thiourea in glacial acetic acid with fused sodium acetate.
PART - II : STUDIES ON CYANOPYRIDONES
The group of compounds containing the cyanopyridone ring system have a
prominent feature in medicinal chemistry and possess biological activities such as
analgesic, antidiabetic, anticonvulsant, insecticidal and antibacterial etc.  In view of
these facts, it was contemplated to synthesise cyanopyridone derivatives which have
been described as under.
SECTION – I : Synthesis and biological evaluation of 3-cyno-4-[1’, N-
phenyl-3’-p-bromophenyl pyrazol-4’-yl]-6-aryl-1, 2-dihydro-
2-pyridones
7
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Type (IX)          R = Aryl
The cyanopyridones of type (IX) have been prepared by condensation of 1-
aryl-3-(1’,N-phenyl-3’-p-bromophenyl pyrazol-4’-yl)-2-propene-1-ones with
ethylcyanoacetate and ammonium acetate.
PART - III : STUDIES ON IMIDAZOLINONES
Imidazolinone derivatives plays a vital role owing to their wide range of
biological activities such as anticonvulsant, sedative, hypnotic, anti-inflammatory,
antihistamine and antithyoid.  In order to develop medicinally important compounds,
we have synthesised some new imidazolinones shown as under.
SECTION – I : Synthesis and biological evaluation of 1, N-Aryl-2-alkyl/aryl-
4-(1’, N-phenyl-3’p-bromophenyl-4’-pyrazolylmethino)-
imidazolin-5-ones
8
NN
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12
Type (X)          R1 = Aryl, R2 = Alkyl/Aryl
The imidazolinone derivatives of Type (X) have been prepared by the
condensation of 5-oxo-2-phenyl-4-(1’,N-phenyl-3’-p-bromophenyl-4’-
pyrazolylmethino)-oxazole with different aryl amines in pyridine.
PART - IV : STUDIES ON NITRILES
Recently substituted nitrile derivatives have been found to be biologically
versatile compounds which possess a broad spectrum of pharmacological activities
viz. cardiovascular, sedative, antifungal and antibacterial.  By considering these valid
observations, we have synthesised some new nitriles which have been described
as under.
SECTION - I : Synthesis and biological evaluation of á-Arylamino-(1’,N-
phenyl-3’-p-bromophenyl-4’-pyrazolyl)-acetonitriles
9
NN
Br
NH
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R
Type (XI)          R = Aryl
The nitriles of type (XI) have been prepared by the condensation of 1,N-phenyl-
3-p-bromophenyl-4-formyl pyrazole with different aromatic amines in presence of
sodium cyanide and glacial acetic acid at 0-5oC.
[C] STUDIES ON MICROWAVE INDUCED SYNTHESIS OF
      2,3-DIHYDRO-1,3,4-THIADIAZOLOTRIAZOLES
In the recent year, MORE (Microwave Induced Organic Reaction
Enhancement) technique has become very popular due to substantial reduction in
reaction time, operational time, operational simplicity and formation of clear reaction
products.  Keeping this in view, we investigated the synthesis of the
dihydrothiadiazoles using microwave irradiation and also by conventional method.
PART - I : STUDIES ON 2,3-DIHYDRO-1,3,4-THIADIAZOLOTRIAZOLES BY
CONVENTIONAL AND MICROWAVE INDUCED SYNTHESIS
Dihydrothiadiazoles possess remarkable pharmacological importance and
biological activities such as antifungal, antibacterials, pesticidal, herbicidal, and
antithyroid.  In view of these facts, it appeared of interest to design and synthesise
thiadiazole derivatives which have been described as under.
10
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SECTION – I : Synthesis and biological evaluation of 2-Aryl-4-o-
cholorobenzyl-2,3-dihydro-1,2,4-triazolo[3,4–b]-1,3,4-
thiadiazoles by conventional method.
Type (XII)       R = Aryl
The compounds of type (XII) have been prepared by the condensation of 3-
mercapto-4,N-amino-5-o-cholorobenzyl-1,2,4-triazole with different aromatic
aldehydes in presence p-toluenesulphonic acid.
SECTION - II : Synthesis and biological evaluation of 2-Aryl-4-o-
cholorobenzyl-2,3-dihydro-1,2,4-triazolo[3,4–b]-1,3,4-
thiadiazoles by microwave method.
 Type (XIII)          R = Aryl
The compounds of type (XIII) have been prepared by the condensation of 3-mercapto-
4,N-amino-5-o-cholorobenzyl-1,2,4-triazol with different aromatic aldehydes in
presence p-toluenesulphonic acid under microwave irradiation in few minutes.  The
advantages of microwave synthesis has been reported.
The constitution of newly synthesised products have been supported by using
11
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.  Purity of all the compounds have
been checked by thin layer chromatography.
In vitro study on multiple biological activities :
(i) All the compounds have been evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg.  The biological activity of
the synthesised compounds have been compared with standard drugs.
(ii) Selected compounds have been evaluated for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Ríat a concentration of 6.25 µg using Rifampin as a standard drug, which
have been tested by Tuberculosis Antimicrobial Acquisition Coordinating Facility
(TAACF), Alabama, U.S.A.
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NITROGEN
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"SEARCHING DRUG TARGETS FOR MICROBES USING NITROGEN
HETEROCYCLES"
Heterocyclic chemistry has seen unparalled progress owing to their wide
natural occurance, specific chemical reactivity and broad spectrum utility.
The known organic compounds have an enormous diversity of structure.
Many of these structures contain ring systems. If the ring system is made up of
atoms of carbon and atleast one other element, the compound can be classed as
heterocyclic.
Most of the alkaloids which are nitrogeneous bases occuring in plants and
many antibiotics including penicillin and strptomycin have also heterocyclic ring
system. Many natural pigments such as indigo, haemoglobin and enthocyanin
are heterocycles. Most of the sugars and their derivatives including vitamin-C for
intance, exist largely in the form of five membered, vitamine B6 (pyridoxine) is a
derivatives of pyridine essential in amino acid metabolism. Important drugs,
poisons and medicines (both natural and synthetic) such as sulphathiazole,
pyrethrin, rotenmone, strychnine, reserpine, certain of the antihistaminics, the
ergot alkaloids caeffine,  cocaine, barbiturates etc. are heterocyclic compounds.
Medicinal chemistry concerns the discovery, the development, the
identification of action of biologically active compound at the molecular level.
Emphasis is put on drugs, but the interest of the medicinal chemistry is also
concerned with the study, identification, and synthesis of the metabolic products
of drugs and related compounds.
Medicinal chemistry is a part of pharmacology, this latter taken in its
etymological sense 'pharmakon' + 'logs' : study of drugs. The activity of a given
drug depends on a sequence of physio-chemical events that begin when the
active molecule penetrates into the living organism and which culminates when
13
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the active molecule reaches its target and elicits the appropriate biological
response. Classically it is addmitted that three characteristic phases govern the
biological activity of a drug in a living organism. They are as under.
(I) The pharmaceutical phase
Sometimes it is also called biopharmaceutical phase, deals with the choice
of the appropriate route of administrat ion and with the choice of the
pharmaceutical formulation most suited to the desired medical treatment.
(II) The pharmacokinetic phase
It controls the different parameters that govern the random walk of the drug
between its application point and its final site of action and which ensure the
destruction and/or the elimination once the effect is produced.
(III) The pharmacodynamic phase
It is the phase of the greatest interest to the medicinal chemist as it deals
with the nature and the quality of the interaction of the drug with its biological
target.
Modern medicinal chemistry began in the 1950s when organic chemists
began to apply newly developed steric & electronic structure active relactionship
of the steroids. During the second half of the twentieth century, chemistry and
biology made possible the discovery of a steady stream of important new
medicines. Chemistry contributed to these discoveries through impactful
advantaces in both theory & practice of this art/science. Notable examples include
invaluable advances in physical measurements, computational techniques,
inorganic catalysis, stereochemical control of synthesis & the application of
physical organic chemical concepts, typified by the transition state analog
principle, to enzyme inhibitor design. At the same time biology continued to
contribute through the discoveries of new concepts and understanding at a rate
that may well be termed explosive.
AIMS AND OBJECTIVES
In the pharmaceutical field, there has always been and will continue to be a
need for new and novel chemical entities with diverse biological activities. Our
efforts are focused on the introduction of chemical diversity in the molecular frame
work in order to synthesising pharmacologically interesting compounds of widely
different composition.
During the course of research work, several entities have been designed,
generated and characterised using spectral studies. The details are as under.
v To generate several derivatives like 1,3,4-thidiazolotriazoles, 1,3,4-
thiadiazepines, 4-aryltriazoles, 1,3,4-oxadiazoles and azomethines bearing
1,2,4-triazole nucleus.
v To synthesise  biologically active 2,3-dihydro-1,3,4-thiadiazolotriazoles
bearing 1,2,4-triazole nucleus using microwave induced synthesis method.
v To generate several derivatives like thiazolidinones, pyrimidinones,
thiopyrimidines, cyanopyridones, imidazolinones and nitriles bearing
pyrazole nucleus.
v To check purity of all the compounds using thin layer chromatography.
v To characterise these products for stucture elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
v To evaluate new product for better drug potential against different strains of
bacteria, fungi and for antitubercular activity against Mycobacterium
Tuberculosis H37 Rv.
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                               [A]
                        STUDIES  ON
          1,2,4-TRIAZOLES
INTRODUCTION
Triazole is one of the class of heterocyclic compounds with composition
C2H3N3 having five membered diunsaturated ring sytem containing three
nitrogen and two carbon atoms. Triazole molecule is having following isomers
viz υ-trizoles or 1,2,3-triazoles (I), s-triazoles or 1,2,4-triazoles (II).
The chemistry of triazole derivatives have attained greater interest because
of its useful application in medicine, agriculture and industrial chemistry. Bladin1,2
is a pioneer worker in the filed of triazoles, synthesised the first derivatives in
1885.
1,2,4-Triazole derivatives are not only known for their medicinal applications,
but also used as analytical reagents3, photographic chemicals4 and in polymer5
synthesis.
SYNTHETIC ASPECTS
Several methods have been reported in the literature for the preparation of
1,2,4-triazoles. The procedure for synthesising 1,2,4-triazoles have been described
as under.
(II)
s-Triazole or 1,2,4-Triazole
N
N
N
H
N
NH
N
(I)
N
N
H
N
NH
N
N
N
N
NH
16
υ-Triazole or 1,2,3-Triazole
1. C. S. Andotra and Sukhbinder Kaur6 synthesised triazole pyrimidine by the
reaction of aromatic acid with substituted hydrazino pyrimidine.
2. Ivanka Kolenc et. al.7 synthesised 6-chloro-1,2,4-triazolo [4,3-b] pyridazin
from 3-chloro-6-hydrazino pyridazin in presence of bis-o-(diethoxymethyl)
dimethyl glyoxime.
3. A. Krutosikova and M. Dandarova8 prepared 1,2,4-triazole by the reaction
of hydrazone and triethyl orthopropionate in dry dimethyl sulfoxide at
170oC for 3 hrs.
4. Ahmad S. Shawali et. al.9 synthesised 1,2-bis (4-amino-5-mercapto-4H-
1,2,4-triazol-3-yl) ethane by heating succinic acid with two molar equivalents
of carbonothioic dihydrazide in an oil bath at 170oC.
5. Reid and Heindel10 reported that the reaction of aryl acid hydrazide with
CS2 / KOH and hydrazine hydrate furnished triazoles.
N
N
NH
NH2
R
R1
R2
O
OH N
N
R
R1
N
N R2
(III)
NN
Cl NH
NH2 NN
Cl N
N
(IV)
HOOC
COOH
+
2 NH2 NH
S
NH
NH2
- 4 H2O
N
NNH
NH2
S
N
N NH
NH2
S
(V)
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THERAPEUTIC IMPORTANCE
1,2,4-Triazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having 1,2,4-triazole nucleus with good
activity are listed as under.
R
O NH
NH
S
S  K
NH2.NH2.H2O
N
N
N
SH
NH2
R
CS2
KOH
R
O NH
NH2
(VI)
1. Fluotrimazole 2. Rifavirin
N
N
N
CF3
Fungicide
N
N
N
O
OH
OH
OH
ONH2
Antiviral, Antiinfections
3. Amitrole 4. Triazbutil
N
NH
N
NH2
N
N
N
CH3
Antithyroid activity Fungicides
5. Rilmazafone 6. Flusilazole
Antifungal
SiF F
CH3
N
N
N
O
Cl
Cl
N
N
N
O
N
CH3
CH3
Sedative, hypnotic
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7. Azocyclotin 8. Triadimenol
Sn
N
N
N
CH3
CH3
CH3
CO
O
Cl
N
N
N
Pesticide Fungicide
9. Triazolam 10. Azaconazole
O
O
N
N
N
Cl
Cl
Antifungal
N
N
N
N
CH3
Cl
Plant growth regulator
Literature survey reveals that various 1,2,4-triazole derivatives have resulted
in many potential drugs and are known to exhibit a broad spectrum of biological
activities.
3-Amino-1,2,4-triazole known as amitrole was the first triazole manufactured
on large scale from aminogunidine formate, useful as herbicides11 especially in
wineyards and orchards and brain catalase activity12.
Therapeutic activity of 1,2,4-triazoles are listed as under.
1. Antimicrobial13
2. Antiviral14
3. Antiinflammatory15
4. Antihypertensive16
5. Anticonvulsant17
6. Anticancer & Anti-HIV18
7. Antileishmanial19
19
8. Antitumor20
9. Antidepressant & Anxiolytic21
10. Anthelmintics22
11. Bactericidal23
12. Diuretic24
13. Fungicidal25
14. Herbicidal26
15. Insecticidal & Acaricidal27
16. Plant growth regulator28
Synthesis of 1,2,4-triazole fused to another heterocyclic ring has focused
attention due to their diverse applications as antibacterial, antidepressant,
antiviral, antitumor and antiinflammatroy, pesticides, herbicides, lubricant and
analytical reagent.29,30
Andreina Liendo et. al.31 have investigated both enantiomers of 2-(2,4-
difluorophenyl)-1-(3-[(z)-4-(2,2,3,3-tetrafluoropropoxy)styryl]-1,2,4-triazol-1-yl)-
3-(1,2,4-triazol-1-yl)-propan-2-ol. It has recently been shown that the R(+)
enantiomer of bis triazole derivatives (VII) can induce radical parasitological cure
in marine mouldes of the acute and chronic forms of the disease.
Radwan M. and El-Zemity32 have investigated a new series of 1,2,4-triazole
derivatives and screened for their moluscicidal activity against two type of
terrestrial Snail. Kalluraya B. et. al.33 have formulated triazole derivatives
possessing potential antimicrobial activity.
F
F
N
N
N N
N
N
O
CF2
CHF2(VII)
20
Daniele Binchi et. al.34 have screened pure stereoisomer of two new triazole
derivatives (VIII, IX) for their antifungal activity against variety of fungi showing
an activity ratio R-form /S-form upto 400.
Yaseen A. et. al.35 have prepared 1,5-dialkyl-3-(5-mercapto-4,N-aryl-1H-
1,2,4-triazol-3-yl-methylene)-1H-1,2,4-triazole which exhibited remarkable
activity against nine type of cancer and also antiviral activity. Bozena et. al.36
have discovered triazole derivatives and tested their anticonvulsant and
antinociceptive activity. Nesl ihan Demirbas and his co-workers37 have
documented antimicrobial activity of some newly synthesised 1,2,4-triazole
derivatives. Sylvie Larrat et al.38 investigated that ribavarin in combination with
alpha-2-interferon is the consensus treatment for ehronic hipatitis C. and E. De
Clercq. et. al.39 screened ribavarin (X) for their antiviral and antimetabolic
activities.
L. Z. Xu and co-workers40 have synthesised an important class of triazole
derivatives (XI) which are highly efficient low poisonous and inward absorbent41-43
and studied their antifungal activity. Dawer Cui et. al.44 have prepared some
new triazoles (XII) and reported them as significant antifungal agent. M. Dincer
et. al.45 have synthesised triazole derivatives (XIII) as potential antimicrobial agent.
Cl
Cl
N
N
N
OCF2CHF2
Cl
Cl
OH
N
N
N
(IX)(VIII)
O
OH
OH
OH
N
NNH
H2NOC
N
N
N
O
R S
S
N
R'
R
(XI)(X)
21
L. Labanauskas et. al.46 have documented antiinflammatory activity of some
triazoles. Vera Klimesova et.al.47 have repor ted 1,2,4-triazoles useful for
tuberculosis inhibition. B. Shivarama Holla et al.48 have investigated some triazole
derivatives as anticancer agent. Damien Boeglin et. al.49 have suggested 3,4,5-
trisubstituted-1,2,4-triazole derivatives useful as antimicrobial agent. L. H.
Mckendry and co-workers50 have synthesised triazole derivatives (XIV) and
reported them as broad spectrum broadleaf herbicides.
Ilkay Kuaikguzel et. al.51 have formulated some new triazole derivative
possessing anticonvulsant activity B. Pirotte et. al.52 have investigated triazoles
as potential antibiotics. R. Pignatello et. al.53 have documented analgesic,
antipyretic, antimycotic and antiinflammatory activity of 1,2,4-triazoles. Neslihan
Demirbas  e t .  a l .54  have sc reened t r iazo le  der iva t ives  (XV)  for  the i r
antiinflammatory, anticancer, antituberculosis and  antihypertensive acitivities.
Yaseen A. Al-Soud et. al.55 have documented antitumor activity of triazole
derivatives. Chu, Chang-Hu et. al.56 have investigated some new triazole
derivatives and studied their antifungal activity. Neikamura, Hiroshi et. al.57 have
N
NN
NH
SCH3
NH R1
R2
R3
(XII)
NN
N
CH3 NH
Cl Cl
(XIII)
NNN
N F
Oet
NH.SO2Cl
Cl
(XIV)
N
N
N
NH2
R
O
N
N
N
NH2 SH
(XV)
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investigated 1,2,4-triazole derivatives use for treatment of hyperuricemia.  She,
Dongmer et. al.58 have reported plant growth regulatory activity of triazoles.
Recently, Krzysztof W. et. al.59 have discovered 1,2,4-triazoles and reported
their antimycobacterial activity. Balkovee et. al.60 have formulated triazoles as
ant idiabet ic  agent.  Maarouf et .  a l .61 have documented analgesic and
antiinflammatory activity of triazoles. Dae-Kee Kim et. al.62 have been synthesised
1,2,4-triazole derivatives (XVI) and screened for their significant ALKS inhibitory
activity. Fisher, Karl J. et. al.63 have synthesised 1,2,4-triazole derivatives (XVII)
to study their pesticidal and herbicidal activity.
In view of this and in continuation of our studies, it was thought judicious to
investigate several derivatives like 1,3,4-thiadiazoles, 1,3,4-thiadiazepines, 4-aryl
triazoles, azomethines and dihydrothiadiazoles bearing 1,2,4-triazole nucleus and
other 1,3,4-oxadiazoles in order to achieving better therapeutic agents which
have been described as under.
[A] STUDIES ON TRIAZOLES
PART-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZOLOTRIAZOLES
PART-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZEPINES
PART-III : SYNTHESIS AND BIOLOGICAL EVALUATION  OF 4-ARYL
TRIAZOLES
PART-IV : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
OXADIAZOLES
PART-V : SYNTHESIS AND BIOLOGICAL EVALUATION OF AZOMETHINES
N
R2
N
N
N
R1
R3
(XVI)
N
H
N
N
H
F3C
S
Et
NH
O
Cl
Cl
(XVII)
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                        PART-I
                   STUDIES ON
        1,3,4-THIADIAZOLO
                       TRIAZOLES
INTRODUCTION
1,3,4-Thiadiazole derivatives have been found to be potent drug in
pharmaceutical industries and exhibited various biological activities due to the
presence of the –N=C–S group29. In thiadiazole ring system one sulphur and
two nitrogen atoms are present in a five membered ring. According to their
position, thiadiazole systems are classified as 1,2,3-thiadiazoles (I), 1,2,4-
thiadiazoles (II), 1,3,4-thiadiazoles (III), and 1,2,5-thiadiazoles (IV).
Fischer has described the first 1,3,4-thiadiazole in 1882 and further
developed by Busch and co-workers. Due to the wide range of therapeutic
activities, the compounds having thiadiazole nucleus have greatly accelerated
the rate of progress in the field of pharmaceutical.
SYNTHETIC ASPECT
Literature survey reveals that several publications and patents64 described
the synthesis of 1,3,4-thiadiazoles as under.
1. Alaa Hassan et al.65 synthesised 1,3,4-thiadiazoles by the cyclization of
tetracyanoethene and 4-phenyl thiosemicarbazides.
2. Khosrow Zamani  e t .  a l .66  have prepared th iad iazo le  f rom the
thiosemicarbazide by the cyclization in sulphuric acid.
N
N
S
N
S
N
N
S
N
(I) (III) (IV)
N
S
N
(II)
R
NH
S
NH
NH2 +
N
NN
N
N
S
N
N
NRHN
(V)
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3. Li-Xue Zhang et. al.67 have synthesised 1,3,4-thiadiazoles by the cyclisation
of aromatic acid with triazole in presence of catalyst like POCl3.
4. Jag Mohan et. al.68 have prepared thiadiazole derivatives by the cyclisation
of amino mercapto triazole and aryl aldehyde in presence of p-Ts-OH.
THERAPEUTIC IMPORTANCE
Extensive research has been carried out to enhance the activity and reduce
toxicity of thiadiazole drugs. Various thiadiazole derivatives have resulted in many
potential drugs and are known to exhibit numerous pharmacological activities
like.
1. Amoebicidal69
2. Antiviral70
3. Antibacterial71
4. Antagonist agent72
5. Antiaflatoxigenic73
6. Antitumor74
(VI)
N
O
NH
NH
S
NH CH3
con. H2SO4
N
N N
S NH
CH3
O N N
N SH
NH2
Ar - COOH
POCl3
O
N N
N
N
S
Ar(VII)
R
N
N
N
NH2
Ar - CHO
P-Ts-OH
N
N
N
N
H
S
R
R1
(VIII)
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7. Algaecides and Antifouling75
8. Antitubercular76
9. Antipyretic77
10. Antinelmintic78
11. Antischistosomal79
12. CNS depressant80
13. Herbicidal81
14. Hypoglycemic82
15. Insecticidal83
16. Pesticidal84
Alireza Foroumadi and co-workers85 have documented antituberculosis
activity and cytotoxicity of 1,3,4-thiadiazoles. Hatice Dogan et. al.86 have
prepared 2,5-disubstituted-1,3,4-thiadiazolo derivatives as anticonvulsant and
antimicrobial agent. Nalan Terzioglv and Aysel Gursoy87 have discovered
thiadiazoles and studied their anticancer activity.
Athansia Varvaresou et. al.88 suggested thiadiazoles and reported them as
antidepressant. Pradeep Mishra et. al.89 have screened 1,3,4-thiadiazoles for their
potent spasmolytic activity and anti-inflammatory activity.  Acetazolamide (IX)
was reported as diuretics and antiglaucoma by Celine Chazalete et. al.90 and as
Anticonvulsant by E. E. Chufan et. al.91 Bernard Masercel et. al.92 have
synthesised 1,3,4-thiadiazoles possessing potent carbonic anhydrase inhibitor
properties and also prepared 5-valproylamido 1,3,4-thiadiazole-2-sulfonamide
(IX) useful as strong anticonvulsant.
N
S
N
SO2NH2
MeHNOC
N
S
N
SO2NH2
NH
O
CH3
CH3
(X)(IX)
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Metin Bulbul et. al.93 have reported thiadiazoles as carbonic anhydrase
inhibitor. Marina Kritsanida et. al.94 have investigated thiadiazoles as antiviral
activity. Fatemeh Soltani et. al.95 synthesised thiadiazoles and studied their
antibacterial activity. Andanappa K. Gadad et. al.96 have prepared thiadiazoles
possessing antituberculosis activity.
Erhan Palaska et. al.97 synthesised thiadiazoles containing antiinflammatory
activity. J. M. Colacino et. al.98 have documented anti-influenza virus activity of
thiadiazoles. Claudiu T. Supuran and Andrea Scozzafava99 have reported 1,3,4-
thiadiazole derivatives as carbonic anhydrase inhibitors and antitumor.
Laddi U. V. et. al.100 have discovered thiadiazoles possessing antimicrobial
and antituberculosis activity. Gamill Ronald B. et. al.101 have reported
thiadiazoles as antiinflammatory agents. Mobinikhaledi, A. et. al.102 have
investigated 1,3,4-thiadiazoles and tested for insecticidal activity. Che, Chao et.
al.103 have prepared thiadiazole derivatives showed antifungal and plant growth
regulating effect, Vergne, Fabrice et. al.104 have synthesised 1,3,4-thiadiazole
derivatives (XI) and screened for their antiinflammatory anticacer and anti AIDS
activity.
Recently, S. Karakus and S. Rollas105 have screened thiadiazoles for their
antituberculosis activity. Jui-Yi Chou et. al.106 have synthesised thiadiazoles and
reported them as anticancer. Zahra Kiani et. al.107 have discovered thiadiazoles
as antituberculosis agent. Lisa M. Thomasco et. al.108 have prepared 1,3,4-
thiadiazole (XII) possessing potent antibacterial activity against Gram positive
and Gram negative organisms. Samir A. Carvalho and co workers109 have
(XI)
N N
S
N
Me
Cl
SO2
NH2
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documented antitrypanosomal profile of 1,3,4-thiadiazole derivatives (XIII).
Alireza faroumadi et. al.110 have synthesised 1,3,4-thiadiazoles (XIV) and studied
their leishmanicidal activity.
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have used substituted thiadiazolinone111, 4-pyridyl112 moieties
at 5-position (y) in 1,3,4-thiadiazole ring system and at 2-position (X) was
substituted aryl, amino and s-triazine113 H. H. Parekh et. al. have synthesised
1,3,4-thiadiazole having dapson114,115 bis moiety at 5-position (y) and
benzalamino, benzoylamino and sulphonamido116, aryl117 moiety substituted
at 2-position (X). H. H. Parekh et. al.118 have formulated some new thiadiazoles
as biologically active agents. General structure for above references are as under.
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N
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In view of the therapeutic activities of 1,3,4-thiadiazoles, it was contemplated
to synthesise 1,3,4-thiadiazolo triazoles in search of agents possessing higher
biological activity with least side effects, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
2-ARYL-4-o-CHLOROBENYL-1,2,4-TRIAZOLO [3,4-
b]-1,3,4-THIADIAZOLES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-o-
CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b]-1,3-4-THIADIAZOLES
The study of 1,3,4-thiadiazoles have revealed that thiadiazole derivatives
are valuable drugs for various diseases. These valid observations led us to
synthesise 1,3,4-thiadiazolo triazole of type (I) by the cyclisation of 3-mercapto-
4,N-amino-5-o-chlorobenzyl-1,2,4-triazole with different aromatic acids in
presence of phosphorous oxychloride.
The constitution of the synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have moderate activity
as compared to known antibiotics recorded on Graphical Chart No. 1.
R = Aryl
Cl
N
N
N
S
N R
Type - (I)
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REACTION SCHEME
Cl
N
N
N
S
N R
R - COOH
POCl3
Cl
N N
N
SH
NH2
NH2.NH2.H2O
Cl
O
NH NH
S
S   K
+-
EtOH, KOH
CS2
Cl
O
NH NH2
NH2.NH2.H2O
MeOH
Cl COOC2H5
EtOH
H2SO4
Cl COOH
Type - (I) R = Aryl
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IR SPECTRAL STUDY OF 2-p-METHYLPHENYL-4-o-CHLOROBENZYL-1,2,4-
TRIAZOLO-[3,4-b]-1,3,4-THIADIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2972 2975–2950 545
–CH
3
C – H str. (sym.) 2860 2880–2860 ''
C – H def. (asym.) 1463 1470–1435 ''
C – H def. (sym.) 1369 1385–1370 ''
Aromatic C – H str. 3045 3080–3030 ''
C = C str. 1579 1585–1480 ''
C – H i.p. def. 1091 1125–1090 503
1016 1070–1000 ''
C – H o.o.p.def. 817 835–810 ''
Triazole C = N str. 1600 1612–1593 498
C – N str. 1336 1350–1200 503
C – N – C str. 1143 1156–1132 498
N – N str. 1016 1050–1010 505
overlapped
C – Cl str. 786 800–600 498
Thiadiazole C – S – C str. 692 720–570 ''
Cl
N
N
N
S
N
CH3
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PMR SPECTRAL STUDY OF 2-p-METHYL-4-o-CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-
b]-1,3,4-THIADIAZOLES
Internal Standard : TMS; Solvent : CDCl3;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 2.44 3H singlet Ar-CH
3
2. 4.62 2H singlet -CH
2
3. 7.22-7.25 2H multiplet Ar-Hb,Ar-Hc
4. 7.32 Jef=9 2H doublet Ar-Hee'
5. 7.38-7.43 2H multiplet Ar-Ha, Ar-Hd
6. 7.72 Jfe=9 2H doublet Ar-Hff'
Cl
N
N
N
S
N
CH3
a
b
c
d
e
f
e'
f'
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EXPANDED AROMATIC REGION
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N
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N
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+
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-o-
CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b]-1,3-4-THIADIAZOLES
[A] Synthesis of Ethyl-o-chlorophenylacetate119
A mixture of o-chlorophenylacetic acid (1.70g, 0.01M) in ethanol (20 ml)
and con. H2SO4 (1 ml) was refluxed for 15 hrs. The reaction mixture was poured
into ice cold water. The product was isolated and crystallised from ethanol. Yield
1.4g, 82%, m.p. 134oC.
[B] Synthesis of o-Chlorophenylacetohydrazide120
A mixture of ethyl-o-chlorophenylacetate (1.98g, 0.01M) in ethanol (20 ml)
and hydrazine hydrate (0.5g, 0.01M) was refluxed for 7 hrs. The reaction mixture
was poured into ice cold water. The product was isolated and crystallised from
ethanol. Yield 1.7g, 85%, m.p. 158oC.
[C] Synthesis of Potassium o-chlorophenylacetamido dithiocarbamate
A mixture of potassium hydroxide (0.84g, 0.015M) in absolute ethanol (25
ml), o-chloro phenyl acetohydrazide (1.85g, 0.01M) and carbon disulfide (1.14ml,
0.015M) was stirred for 18 hrs. The product was precipitated by adding dry ether
(150 ml). Yield 3.0g, 95%.
[D] Synthesis of 3-Mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole
A suspension of potassium o-chlorophenylacetamido dithiocarbamate
(2.98g, 0.01M) hydrazine hydrate (95%, 1ml, 0.02M) and water (1 ml) was
refluxed with stirring for 5 hrs. The content was dilute with water and acidified
with acetic acid to get the product. It was crystllised from DMF/Ethanol. Yield
1.65g, 55%, m.p. 210oC, (C9H9ClN4S : required : C, 44.91; H, 3.77; N, 23.28;
found : C, 44.88; H, 3.73; N, 23.24%).
TLC solvent system : Acetone : Benzene (3 : 7).
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[E] Synthesis of 2-p-Methylphenyl-4-o-chlorobenzyl-1,2,4-triazolo
[3,4-b]-1,3,4-thiadiazoles
A mixture of 3-mercapto-4,-N-amino-5-o-chlorobenzyl-1,2,4-triazole (2.40g,
0.01M)  and p-methyl benzoic acid (1.36g, 0.01M) in phosphorous oxychloride
(20 ml) was refluxed for 10 hrs. The resulting mixture was poured onto crushed
ice and neutralised with sodium bicarbonate. The product was crystallised from
ethanol. Yield, 1.9g, 79%, m.p. 218oC (C17H13ClN4S : required : C, 59.91 ; H,
3.84 ; N, 16.44, found : C, 59.94 ; H, 3.88; N, 16.41%).
TLC solvent system Acetone : Benzene (3 : 7)
Similarly ohter 1,3,4-thiadiazolotrizole derivatives were synthesised. The
physical data are recorded in Table No. 1.
[F] Antimicrobial activity of 2-Aryl-4-o-chlorobenzyl-1,2,4-triazolo
[3,4,-b]-1,3,4-thiadiazoles
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
Antimicrobial activity was carried out by cup-plate agar diffusion method121
which has been described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method was inoculated aseptically with
0.5 ml of 24 hrs old subcultures of B. coccus, B. subtilis, P. vulgaris, E. coli in
seperate conical flasks at 40-50oC and mixed well by gently shaking. About 25
ml content of the flask were poured and evenly spreaded in a petridish (13 cm in
diameter and allowed to set for 2 hrs. The cups 10 mm in diameter were formed
by the help of borrer in agar medium and filled with 0.04 ml (40 µg) solution of
sample in DMF.
The plates were incubated at 37oC for 24 hrs and the control was also
maintained with 0.04ml of DMF in a similar manner and zones of inhibition of
the bacterial growth were measured in millimeter and are recorded in Graphical
Chart No. 1.
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The antibacterial activity data of the synthesised compounds have been
compared with standard antibiotics l ike amoxyci l l in, benzoylpenici l l in,
ciprofloxacin and erythromycin.
(II) Antifungal activity
Aspergillus niger was employed for testing antifungal activity using cup-
plate method. The culture was maintained on Sabouraud's agar slants. Sterilised
Subouraud's agar medium was incoulated with 72 hrs old 0.5 ml suspension of
fungal spores in separate flask. About 25 ml of the inoculated medium was evenly
spreaded in a petridish and allowed to set for two hrs. The cups (10 mm in
diameter) were punched and filled with 0.04 ml (40 µg) solution of sample in
DMF. The plates were incubated at 30oC for 48 hrs. After the completion of
incubation period, the zones of inhibition of growth of fungi in the form of diameter
in mm were measured. Along the test solution in each petridish one cup was
filled up with solvent act as control. The zones of inhibition were compared with
standard antifungal Greseofulvin. The zones of inhibition are recorded in
Graphical Chart  No. 1.
(b) Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and co-ordinating Facility (TAACF),
U.S.A., primary screening of the compounds for antitubercular activity have been
conducted at 6.25 µg towards Mycobacterium Tuberculosis H37Rv in BACTEC
12B medium using the BACTEC 460 radiometric system. The compounds
demostrating atleast > 90% inhibition in the primary screen have been retested
at lower Mycobacterium Tuberculosis H37Rv to determine the actual minimum
inhibition concentration (MIC) in the BACTEC 460.
The antitubercular activity data have been compared with standard drug
Rifampin at 6.25 µg/ml concentration and it showed 98% inhibition.
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ANTIMICROBIAL ACTIVITY
Method : Cup-plate121
Gram positive bacteria : Bacillus coccus
Bacillus subtilis
Gram negative bacteria : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40 µg
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzoylpenicillin,
Ciprofloxacin,Erythromycin, Greseofulvin
The antibacterial activity was compared with standard drug viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin. The zones of inhibition measured
in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular activity was carried out at Tuberculosis Antimicrobial
Acquisition and Co-ordinating Facility (TAACF) U. S. A.
Method : BACTEC 460 Radiometric system
Bacteria : Mycobacterium tuberculosis H37Rv
Concentration : 6.25 µg
Standard drug : Rifampin
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TABLE NO. 1 : PHYSICAL CONSTANTS OF 2-ARYL-4-o-CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b]-1,3,4-
THIADIAZOLES
Sr.
No.
1
1a 2-CH
3
-C
6
H
4
- C
17
H
13
ClN
4
S 340.8 118 0.72 72 16.44 16.40
1b 4-CH
3
-C
6
H
4
- C
17
H
13
ClN
4
S 340.8 218 0.81 79 16.44 16.41
1c 3-OCH
3
-C
6
H
4
- C
17
H
13
ClN
4
OS 356.8 188 0.64 69 15.70 15.74
1d 4-OCH
3
-C
6
H
4
- C
17
H
13
ClN
4
OS 356.8 166 0.62 76 15.70 15.68
1e 4-Cl-C
6
H
4
- C
16
H
10
Cl
2
N
4
S 361.2 110 0.71 78 15.51 15.55
1f 4-F-C
6
H
4
- C
16
H
10
ClFN
4
S 344.7 136 0.80 65 16.25 16.21
1g 4-Br-C
6
H
4
- C
16
H
10
BrClN
4
S 405.7 158 0.58 59 13.81 13.85
1h 4- NO
2
-C
6
H
4
- C
16
H
10
ClN
5
O
2
S 371.8 180 0.77 67 18.84 18.80
1i 2-NH
2
-C
6
H
4
- C
16
H
12
ClN
5
S 341.8 116 0.82 73 20.49 20.45
1j 2-OH-C
6
H
4
- C
16
H
11
ClN
4
OS 342.8 >200 0.79 61 16.34 16.38
1k 2-OCOCH
3
-C
6
H
4
- C
18
H
13
ClN
4
O
2
S 384.8 160 0.54 70 15.19 15.14
1l 2,4-(OH)
2
-C
6
H
3
- C
16
H
11
ClN
4
O
2
S 358.8 145 0.70 55 15.61 15.65
1m -CH
2
-C
6
H
4
C
17
H
13
ClN
4
S 340.8 182 0.66 80 16.14 16.18
1n -CH=CH-C
6
H
5
C
18
H
13
ClN
4
S 352.8 152 0.51 84 15.88 15.84
1o C
5
H
4
N- C
15
H
10
ClN
5
S 327.7 126 0.68 52 21.37 21.33
*TLC Solvent System : Acetone : Benzene (3 : 7)
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3
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4
Rf*
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6
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%
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B.coccus 16 9 14 8 11 11 13 17 9 16 10 8 11 9 10 17 21 16
B.subtilis 15 9 13 16 9 13 11 17 18 17 13 14 14 10 21 15 21 22
P.vulgaris 10 13 12 17 17 10 18 14 19 16 10 13 14 11 17 16 19 15
E.coli 16 21 10 18 10 13 11 9 14 14 12 16 17 20 8 19 18 20
A.niger 21 17 18 16 14 10 13 16 15 12 18 17 14 17 13 0 0 0
1a 1b 1c 1d 1e 1f 1g 1h 1i 1j 1k 1l 1m 1n 1o
Amoxy
cillin
Benzoy
lpenicilli
n
Cipro
xac
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
From the experimental data, it has been observed that the compounds
bearing R=2-methylphenyl, 4-nitrophenyl, 2-hydroxy phenyl have displayed
signi f icant  act iv i ty  against  B.coccus .  The compounds bear ing R=4-
methoxyphenyl, 4-nitrophenyl, 2-aminophenyl, 2-hydroxyphenyl have shown
good activity against B.subtilis.
In case of Gram negative bacterial strains, the maximum activity was
displayed by the compounds bearing R=4-bromophenyl and 2-aminophenyl
against P.vulgaris .  While the compounds with R=4-methylphenyl,  4-
methoxyphenyl, benzyl and cinnamyl have shown considerable activity against
E.coli.
Antifungal activity :
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=2-methylphenyl have displayed
highest activity against A.niger.
The antibacterial activity was compared with standard drug viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
                      PART-II
                  STUDIES ON
  1,3,4-THIADIAZEPINES
INTRODUCTION
1,3,4-Thiadiazepine derivatives are studied extensively because it represents
one of the most active class of compounds possessing a wide spectrum of
pharmacological activities. The thiadiazepine ring system have one sulphur atom
and two nitrogen atoms at 1,3,4-position (I) in seven membered heterocyclic ring
system.
1,3,4-Thiadiazepines have attracted attention of chemists for both with regards
to heterocyclic chemistry and the pharmacological activities associated with them.
SYNTHETIC ASPECT
Different methods for the preparation of 1,3,4-thiadiazepine derivatives
documented  in literature are as follows.
1. Om Prakash et. al.122 have synthesised thiadiazepine by Michael type
addition of 4-amino-3-mercapto-1,2,4-triazole to α,β,-unsaturated carbonyl
compounds.
S
N
N
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7
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(II)
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N
N
SH
NH2
R
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O
R'
N
N
S
NN
R
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2. T. E. Glotova et. al.123 have synthesised 1,3,4-thiadiazepine by treating α-
acetylenic ketones with 4-amino-3-mercapto-1,2,4-triazole in glacial acetic
acid.
3. R. Gururaja et. al.124 have synthesised quinolinethiadiazepine derivatives
by condensation of 2-chloro-6-substituted quinoline-3-carboxaldehyde with
thiocarbohydrazide in pyridine.
4. Sinegibskaya A. D. et. al.125 have synthesised thiadiazepine by reaction of
4-amino-3-hydrazino-1,2,4-triazoline-5-thione with α-and β-dicarbonyl
compounds, then the treatment of Br-CH2-CO-Ph.
Several methods have also documented in literature126-129.
N
N
N
SH
NH2
R
+
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O
R'
gl. AcOH
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N S
N N
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(III)
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R CHO
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+
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N
R N
S
N
NH NH2
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N
N
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N
N CH3
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S
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(IV)
THERAPEUTIC IMPORTANCE
Literature survey reveals that 1,3,4-thiadiazepine derivatives possess
remarkable pharmacological importance. Biological activities described are as
under.
1. Antitumor130
2. Antidepressant131
3. Antiviral132
4. Antiarrythmic133
5. Anti psychotic134
6. Anti HIV135
7. Anticonvulsant136
8. CCK antagonists137
9. Gastrin receptor antagonists138
Borsini F. et. al.139 have investigated thiadiazepines useful as potent
antidepressant drugs. B. S. Holla and co-workers140 have investigated some
thiadiazepines as potent antimicrobial agents. Ammar Y. A. et. al.141 have preared
triazolo thiadiazepines as antifungal agents. Swati Sharma and co-workers142 have
discovered  thiadiazepine derivatives as possible potential drug for cancer
metastatics. Denis Pires di Lima143 have synthesised thiadiazepines (VI) useful
as angiotensin-converting enzyme (ACE) inhibitors and Bolos. J. et. al.144
reported them as an important class of antihypertensive drugs.
 Giannotti D. and co-workers145 have screened thiadiazepines for their
antidepressant activity Khalil and Habib146 have documented antimicrobial and
anticancer activities of thiadiazepine derivatives. Marfe G. et. al.147 have
investigated thiadiazepines useful as anticancer agent.
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Recently, M. Kidwai et. al.148 have reported thiadiazepines as potential
antimicrobial agent B. Shivarama Holla et. al.149 have documented antibacterial
and antiviral activity of thiadiazepines. Robert J. Cherney and co-workers150 have
demonstrated benzothiadiazepines as selective tumor necrosis factor α-converting
enzyme inhibitors. Cherney R. J. et. al.151 have synthesised thiadiazepines and
reported them as selective tumor necrosis factor alpha converting enzyme
inhibitor. R. Gururaja and co-workers152 have synthesised 1,3,4-thiadiazepines
(VII) and screened for their anthelmintic activity and antibacterial activity.
Ashutosh Singh and Nizamuddin153 have prepared thiadiazepines (VIII) and
reported their molluscicidal activity.
Thus the important role displayed by 1,3,4-thiadiazepine derivatives for
various therapeutic and pharmaceutical activities prompted us to synthesise some
new 1,3,4-thiadiazepines bearing triazole moiety in order to achieving compounds
having better drug potential. This study is described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
o-CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b] -
SUBSTITUTED QUINOLINO [2,3- f ]  1 ,3,4-
THIADIAZEPINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-o-
CHLOROBENZYL-1,24-TRIAZOLO [3,4,-b] SUBSTITUTED QUINOLINO
[2,3-f] 1,3,4-THIADIAZEPINES
During the past years, considerable evidence has been accumulated to
demonstrate the efficiency of thiadiazepines in including variety of therapeutic
activity. To further assess the potential of such class of compounds as good
therapeutic agents, a series of 1,3,4-thiadiazepines of type (II) have been
synthesised by the condensation of 3-mercapto-4,N-amino-5-o-chlorobenzyl-1,2-
4-triazole with substituted 2-chloro-3-formyl-quinolines.
The constitution of newly synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have moderate activity
as compared to known antibiotics recorded on Graphical Chart No. 2.
Cl N N
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REACTION SCHEME
Cl N N
N
S
N
N
R
DMF
K2CO3
Cl
N N
N
SH
NH2
Cl
OHC
N
R
NH2.NH2.H2O
Cl
O
NH NH
S
S   K
+-
EtOH, KOH
CS2
Cl
O
NH NH2
Type - (II) R = Aryl
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IR SPECTRAL STUDY OF 4-o-CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b]-6-METHOXY
QUINOLINO [2,3-f]-1,3,4-THIADIAZEPINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2949 2975–2950 498
–CH
3
C – H str  (sym.) 2839 2880–2860 ''
C – H def. (asym.) 1469 1470–1435 ''
C – H def. (sym.) 1353 1385–1370 ''
Aromatic C – H str. 3047 3080–3030 ''
C = C str. 1510 1585–1480 ''
C – H i.p. def. 1101 1125–1090 503
C – H o.o.p. def. 810 835–810 498
Triazole C = N str. 1616 1640–1500 ''
overlapped
C – N str. 1330 1350–1200 504
N – N str. 1033 1050–1010 503
C – Cl str. 785 800–600 498
Ether C – O – C str. (asym.) 1245 1275–1200 503
C – O – C str. (sym.) 1056 1070–1020 ''
Thiadiazepine C – S – C str. 671 700–600 504
1218 1250–1003 ''
C = N str. 1596 1640–1500 498
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500.0750.01000.01250.01500.01750.02000.03250.0
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 972.1
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PMR SPECTRAL STUDY OF 4-o-CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b]-6-
METHOXY QUINOLINO [2,3-f]-1,3,4-THIADIAZEPINE
Internal Standard : TMS; Solvent : CDCl3;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 3.98 3H singlet Ar-OCH
3
2. 4.38 2H singlet -CH
2
3. 7.16 Jgf=3 1H doublet Quinolin g
4. 7.23-7.26 4H multiplet Ar-Ha,Ar-Hb,
Ar-Hc,Ar-Hd
5. 7.41-7.49 2H multiplet Quinoline f
Ar-Hi
6. 7.94 Jef=9 1H doublet Quinoline e
7. 8.72 1H singlet Quinoline h
N
N
N
S
N
N
Cl OCH3
a
b
c
d
i h g
e
f
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-o-
CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b]  SUBSTITUTED
QUINOLINO [2,3-f] 1,3,4-THIADIAZEPINES
[A] Synthesis of Potassium o-chlorophenylacetamido dithiocarbamate
See [A] Part-I, Section-I (C).
[B] Synthesis of 3-Mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
[C] Synthesis of Substituted 2-chloro-quinoline-3-carboxaldehydes154
These were prepared by the reaction of substituted acetanilide with DMF
and POCl3 a well known vilsmeierhaack rearrangement.
[D] Synthesis of 4-o-Chlorobenzyl-1,2,4-triazolo [3,4-b]-6-methoxy
quinolino [2,3-f]-1,3,4-thiadiazepines
A mixture of 3-mercapto-4, N-amino-5-o-chlorobenzyl-1,2,4-triazole (2.40g,
0.01M) 2-chloro-3-formyl-6-methoxy quinoline (2.20g, 0.01M) in dry DMF (20
ml) and anhydrous K2CO3 (2.09 g) was refluxed at 80
oC for 4 hrs. It was cooled
and poured onto crushed ice. The product was isolated and crystallised from
ethanol. Yield 1.87g, 77%, m.p. 132oC (C20H14ClN5OS ; required : C, 58.89;
H, 3.46; N, 17.17, found : C, 58.92; H, 3.42 ; N, 17.13%).
TLC solvent system : Acetone : Benzene (3 : 7).
Similarly other substituted 1,3,4-thiadiazepines were synthesised. The
physical data are recorded in Table No. 2.
[E] Antimicrobial activity of 4-o-chlorobenzyl-1,2,4-triazolo [3,4-b]
substituted quinolino [2,3-f] 1,3,4-thiadiazepines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 2.
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TABLE NO. 2 : PHYSICAL CONSTANTS OF 4-o-CHLOROBENYL-1,2,4-TRIAZOLO [3,4-b] SUBSTITUTED
QUINOLINO [2,3,f] 1,3,4-THIADIAZEPINES
Sr.
No.
1
2a H C
19
H
12
ClN
5
S 377.8 250 0.80 59 18.53 18.50
2b 6-CH
3
C
20
H
14
ClN
5
S 391.8 156 0.61 68 17.87 17.83
2c 8-CH
3
C
20
H
14
ClN
5
S 391.8 124 0.57 64 17.87 17.90
2d 6-OCH
3
C
20
H
14
ClN
5
OS 407.8 132 0.74 77 17.17 17.13
2e 8-OCH
3
C
20
H
14
ClN
5
OS 407.8 146 0.73 56 17.17 17.20
2f 6-Cl C
19
H
11
Cl
2
N
5
S 412.2 140 0.60 66 16.99 16.95
2g 7-Cl C
19
H
11
Cl
2
N
5
S 412.2 164 0.65 70 16.99 16.98
2h 8-Cl C
19
H
11
Cl
2
N
5
S 412.2 118 0.62 78 16.99 16.96
2i 8-F C
19
H
11
ClFN
5
S 395.8 128 0.59 57 17.69 17.65
2j 6,8-(CH
3
)
2
C
21
H
16
ClN
5
S 405.9 130 0.72 65 17.25 17.21
2k 6,7-(Cl)
2
C
19
H
10
Cl
3
N
5
S 446.7 152 0.63 55 15.68 15.64
2l 6-F,7-Cl C
19
H
10
Cl
2
FN
5
S 430.2 132 0.68 73 16.28 16.32
*TLC Solvent System : Acetone  :  Benzene (3 : 7)
Rf*
Value
6
Yield
%
7
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B.coccus 13 17 11 14 19 11 8 9 13 9 11 10 17 21 16
B.subtilis 14 19 11 8 13 17 11 19 12 10 11 17 15 21 22
P.vulgaris 15 14 17 19 21 12 14 10 17 16 19 12 16 19 15
E.coli 18 11 19 17 12 11 18 17 14 12 19 16 19 18 20
A.niger 17 11 19 18 16 12 14 21 19 17 11 12 0 0 0
2a 2b 2c 2d 2e 2f 2g 2h 2i 2j 2k 2l Amoxycillin
Benzoy
lpenicill
in
Ciprofl
oxacin
Ery
m
 GRAPHICAL CHART NO.  2 : 4-o-CHLOROBENZYL-1,2,4-TRIAZOLO [3,4-b]
                                                          SUBSTITUTED QUINOLINO[2,3-f]-1,3,4-THIADIAZEPINES
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
I t  has been concluded from the experimental data that the 1,3,4-
thiadiazepine derivatives of type (II) were found to be moderately active against
Gram positive bacteria like B.coccus and B.subtilis and show promising activity
against Gram negative bacteria like P.vulgaris and E.coli.
The maximum activity was observed in compounds bearing R=8-methoxy
against B.coccus. The significant activity was observed in compounds having
R=6-methyl,8-chloro and 6-fluoro, 7-chloro substituents against B.subtilis.
In case of P.vulgaris, all the compounds were least active except R=6-
methoxy, 8-methoxy, 6,7-dichloro. The compounds having R=8-methoxy, 6,7-
dichloro have shown good activity against E.coli.
Antifungal activity :
All the compounds exhibited mild activity against A.niger  except
compounds having R=8-chloro which showed highest activity against A. niger.
                    PART-III
                  STUDIES ON
         4-ARYLTRIAZOLES
INTRODUCTION
Amongst nitrogen containing five membered heterocycles, 1,2,4-triazoles
have proved to be the most useful framework for biological activities. The position
of nitrogen atoms at 1,2 and 4 position activates the ring and proved to be most
important pharmacological drugs. The medicinal chemists all over the world have
focused their attention to evaluate 4-aryltriazole ring system (I).
SYNTHETIC ASPECT
Several methods have been reported in the literatures for the preparation
of 4-aryltriazoles.
1. Khosrow Zamani et al.155 synthesised 4-aryltriazole from thiosemicarbazide
by ring closure reaction with 2N NaOH.
2. Alan R. Katritzky et. al.156 synthesised 4-aryltriazoles by the cyclization of
semicarbazide.
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THERAPEUTIC IMPORTANCE
4-Aryltriazoles have attracted considerable attention as they appeared of
interest to possess wide range of therapeutic activities. Different activity of 1,2,4-
triazoles have been already discussed.
Athansia Varvaresou et. al.157 have synthesised aryl triazoles possessing
antidepressant activity. S. C. Bahel et. al.158 have documented antifungal activity
of aryltriazoles. Yasuda N. et. al.159 have discovered aryltriazoles which have
been extensively investigated for their antibacterial properties. Chu Changhu et.
al.160 have screened 4-aryl triazoles (IV) for their antifungal activity.
Konosu T. and co-workers161 have prepared aryltriazoles as fungicides.
Varvaresou A. et al.162 have synthesised triazoles and reported their antimicrobial
potency and antidepressant activit ies. Papakonstantinou et. al.163 have
investigated some triazole derivatives possessing significant antiviral activity.
Crisan O. et. al.164 have screened antiinflammatory activity of triazoles. Chang
et. al.165 have synthesised aryl triazoles (V) and reported them as antifungal drugs.
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Recently, Lowe R. F & co-workers166 have reported aryltriazoles useful as
antagonists. Holla B. et. al.167 have documented anticancer activity of aryl
triazoles.  Wang Sheng et. al.168 have reported triazoles as herbicidal agents.
Some aryl triazoles possessing analgesic and diuretic activities have been
synthesised by Shrivastava S. K.169 Welsh et. al.170 have discovered aryl triazoles
(VI) & reported them as analgesic agents.
In view of above findings, it appeared of interest to design and synthesise
4-aryltriazole derivatives, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
MERCAPTO-4,N-ARYL-5-o-CHLOROBENZYL-1,2,4-
TRIAZOLES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-o-CHLOROBENZYL-1,2,4-TRIAZOLES
4-Ary l t r iazo le  der ivat ives  are associated wi th broad spectrum of
pharmacological activity. In view of these findings, it appeared of interest to
synthesise 3-mercapto-4,N-aryl-5-o-chlorobenzyl-1,2,4-triazoles. The synthesis
of triazole derivatives of type (III) have been undertaken by heating of potassium-
o-chlorophenyl acetamido dithiocarbamate with different aromatic amines.
The constitution of newly synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have moderate activity
as compared to known antibiotics recorded on Graphical Chart No. 3.
Cl
N N
N
SH
R
R = ArylType - (III)
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IR SPECTRAL STUDY OF 3-MERCAPTO-4,N-p-METHYLPHENYL-5-o -
CHLOROBENZYL-1,2,4-TRIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2974 2975–2950 498
–CH
3
C – H str  (sym.) 2864 2880–2860 ''
C – H def. (asym.) 1467 1470–1435 ''
C – H def. (sym.) 1384 1385–1370 ''
Aromatic C – H str. 3051 3080–3030 503
C = C str. 1575 1585–1570 ''
1490 1520–1480 ''
C – H i.p. def. 1116 1125–1090 ''
1047 1070–1000 ''
C – H o.o.p.def. 835 835–810 ''
Triazole C = N str. 1604 1612–1593 498
N – Ph str. 1504 1504–1495 ''
N – N str. 1033 1050–1010 ''
C – N str. 1259 1350–1200 504
C – S str. 686 700–600 ''
C – Cl str. 788 800–600 498
S – H str. 2574 2600-2500 504
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Cl
N N
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SH
CH3
PMR SPECTRAL STUDY OF 3-MERCAPTO-4, -N-p -METHYLPHENYL-5-o-
CHLOROBENZYL-1,2,4-TRIAZOLE
Internal Standard : TMS; Solvent : CDCl3;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 2.41 3H singlet Ar-CH
3
2. 3.93 2H singlet -CH
2
3. 7.07 Jef=9 2H doublet Ar-Hee'
4. 7.12 1H multiplet Ar-Hd
5. 7.14-7.22 2H multiplet Ar-Hb,Ar-Hc
6. 7.28 Jfe=9 2H doublet Ar-Hff'
7. 7.31 1H multiplet Ar-Ha
8. 11.52 1H broad singlet -SH
Cl
N N
N
SH
CH3
a
b
c
d
e
f
e'
f'
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-o-CHLOROBENZYL-1,2,4-TRIAZOLES
[A] Synthesis of Potassium o-chlorophenylacetamido dithiocarbamate
See [A] Part-I, Section-I (C).
[B] Synthesis of 3-Mercapto-4,N-p-methylphenyl-5-o-chlorobenzyl-
1,2,4-triazole
A mixture of potassium o-chlorophenylacetamido dithiocarbamate (2.98g,
0.01M) and p-toludine (1.07g, 0.01M) was heated till evalution of H2S gas
ceased. The product was dissolved in DMF (20 ml) and poured the reaction
mixture onto crushed ice. The product was crystallised from ethanol. Yield 2.4g,
80%, m.p. 202oC (C16H14ClN3S ; required :  C, 60.85 ; H, 4.47 ; N, 13.31,
found : C, 60.81; H, 4.43; N, 13.35 %).
Similarly other 4-aryl triazoles were synthesised. The physical data are
recorded in Table No. 3.
[C] Antimicrobial activity of 3-Mercapto-4,N-aryl-5-o-chlorobenzyl-
1,2,4-triazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I, (F).
The zones of inhibition of test solution are recorded in Graphical Chart No. 3.
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TABLE NO. 3 : PHYSICAL CONSTANTS OF 3-MERCAPTO-4,N-ARYL-5-o-CHLOROBENZYL-1,2,4-TRIAZOLES
Sr.
No.
1
3a C
6
H
5
- C
15
H
12
ClN
3
S 301.7 182 0.65 64 13.92 13.88
3b 2-CH
3
-C
6
H
4
- C
16
H
14
ClN
3
S 315.8 236 0.68 57 13.31 13.28
3c 4-CH
3
-C
6
H
4
- C
16
H
14
ClN
3
S 315.8 202 0.71 80 13.31 13.35
3d 4-OCH
3
-C
6
H
4
- C
16
H
14
ClN
3
OS 331.8 228 0.52 73 12.66 12.62
3e 2-Cl-C
6
H
4
- C
15
H
11
Cl
2
N
3
S 336.2 139 0.63 82 12.50 12.46
3f 3-Cl-C
6
H
4
- C
15
H
11
Cl
2
N
3
S 336.2 148 0.62 55 12.50 12.54
3g 4-Cl-C
6
H
4
- C
15
H
11
Cl
2
N
3
S 336.2 150 0.54 67 12.50 12.52
3h 2-F-C
6
H
4
- C
15
H
11
ClFN
3
S 319.7 190 0.60 75 13.14 13.18
3i 4-F-C
6
H
4
- C
15
H
11
ClFN
3
S 319.7 131 0.53 52 13.14 13.10
3j 3-NO
2
-C
6
H
4
- C
15
H
11
ClN
4
O
2
S 346.7 284 0.58 58 16.16 16.12
3k 4-NO
2
-C
6
H
4
- C
15
H
11
ClN
4
O
2
S 346.7 250 0.59 69 16.16 16.20
3l 2,5-(Cl)
2
-C
6
H
3
- C
15
H
10
Cl
3
N
3
S 370.6 180 0.74 77 11.34 11.30
3m 3,4-(Cl)
2
-C
6
H
3
- C
15
H
10
Cl
3
N
3
S 370.6 176 0.56 68 11.34 11.38
3n 2,4-(CH
3
)
2
-C
6
H
3
- C
17
H
16
ClN
3
S 329.8 190 0.61 79 12.74 12.70
3o 3-Cl, 4-F-C
6
H
3
- C
15
H
10
Cl
2
FN
3
S 354.2 188 0.64 83 11.86 11.84
*TLC Solvent System : Acetone  :  Benzene (4 : 6)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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B.coccus 14 17 16 13 9 8 11 8 14 17 18 12 20 22 9 17 21 16
B.subtilis 10 18 16 17 14 18 10 8 11 17 14 15 14 12 10 15 21 22
P.vulgaris 14 21 18 16 17 14 10 17 11 15 14 21 13 10 19 16 19 15
E.coli 14 10 18 21 15 8 11 9 10 13 14 18 17 14 12 19 18 20
A.niger 18 16 17 14 13 14 18 17 14 12 15 15 18 19 17 0 0 0
3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l 3m 3n 30 Amoxycillin
Benzo
ylpeni
cillin
Ciprof
loxaci
n
E
o
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
It has been observed from the experimental data that all compounds of type
(III) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However, the maximum activity was observed in compounds bearing
R=3,4-dichlorophenyl and 2,4-dimethylphenyl substituents against B.coccus.
The significant activity was observed in compounds bearing R=2-methylphenyl,
4-methoxyphenyl, 3-chlorophenyl and 4-nitrophenyl against B.subtilis.
The maximum act iv i ty  was disp layed by the compounds bear ing
R=2-methylphenyl, 2,5-dichlorophenyl and 3-chloro,4-fluorophenyl against
P.vulgaris. In case of E.coli all the compounds were least active except
R=4-methoxyphenyl.
Antifungal activity :
The antifungal data revealed that compounds were least toxic to the fungal
s t ra in.  However  mi ld  ac t iv i ty  was shown by the compounds bear ing
R=2,4-dimethylphenyl against A.niger.
The antibacterial activity was compared with standard drug viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
                     PART-IV
                  STUDIES ON
       1,3,4-OXADIAZOLES
INTRODUCTION
1,3,4-Oxadiazole is a thermally stable aromatic molecule171. They have
been known for about 80 years, it is only in the last decade that investigations in
this field have been intensified. This is because of large number of applications
of 1,3,4-oxadiazoles in the most diverse areas viz. drug synthesis, dye stuff
industry, heat resistant materials, heat resistant polymers and scintillators. Reviews
of the relevant literature prior to 1965 are available172.
SYNTHETIC ASPECT
Most 1,3,4-oxadiazoles are best obtained by synthesis from acyclic
precursors. Such reactions are 'one bond' or 'two-bond' cyclisation. Different
methods for the synthesis have been cited in literature173-180.
1. K. Mogilaiah and B. Sakram181 have prepared 1,3,4-oxadiazole from
acetophenone-2-trifluoromethyl-1,8-naphthyridine-3-carbonyl hydrazone in
presence of acetic anhydride.
2. D. Ramesh and B. Sreenivasan182 have synthesised 1,3,4-oxadiazoles from
semicarbazide in presence of POCl3.
N
O
N
(I)
N N CF3
O
NH
N CH3
Ar
AC2O
N N CF3
N N
O
CH3
Ar
O
CH3
(II)
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5. Hansong Chen et. al.183 have synthesised oxadiazoles by the reaction of
hydrazide and aromatic acid in presence POCl3.
THERAPEUTIC IMPORTANCE
2,5-Disubstituted,-1,3,4-oxadiazole derivatives have been tested for
various pharmacological properties, which have been summerised as under.
1. Antiproliferative184
2. Anticonvulsant185
3. Antihypertensive186
4. Antiviral & anticancer187
5. Analgesic188
6. Antiinflammatory189
7. Antibacterial190
8. Antifungal191
9. Cardiovascular192
10. Herbicidal193
11. Hypoglycemic194
12. Hypnotic and sedative195
13. MAO inhibitor196
14. Nematocidal and Insecticidal197
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N
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O
N
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(III)
NN
Et
Cl
CO
NH NH2
Me
+ R1 COOH
POCl3
NN
Et
Cl
Me
N N
O R1
(IV)
K. Subrahmanya Bhat et. al.198 have prepared new fluorine containing
1,3,4-oxadiazoles (V) and reported them as potential antibacterial and anticancer
agents. Sahin G. et. al.199 have reported antimicrobial activity of oxadiazole
derivatives. Maslat A.O. et. al.200 have documented antibacterial, antifungal and
genotixic activity of bis-1,3,4-oxadiazole derivatives. Mida Malvina Burbuliene
et. al.201 have investigated some oxadiazoles as anti-inflammatory agents. T.P.
Mohan et. al.202 have synthesied 2,5-disubstituted-1,3,4-oxadiazole derivatives
(VI) and screened for their insecticidal activity.
H. Liszkiewicz. et. al.203 have screened oxadiazoles for their antimicrobial
activity. A. El-Azzouny et. al.204 have synthesied 1,3,4-oxadiazole derivatives
and evaluated for their analgesic, antiinflammatory, ulcerogenic effects and
inhibitory activity on plasma prostaglandin E2 (PGE2) Level. Some 1,3,4-
oxadiazoles possessing insecticidal activity are synthesised by Xiumian Zheng
et. al.205 Takahiko Inoue et. al.206 have reported oxadiazoles useful as prolyl
aminopeptidase inhibitor.
Virginija Jakubkiene et. al.207 have screened 1,3,4-oxadiazoles for their
antiinflammatory activity. Song Cao et. al.208 have investigated some oxadiazoles
possessing insecticidal activity. S. Guniz Kucukguzel et. al.209 have discovered
oxadiazole derivatives and reported their antimycobacterial activity. Ali  Almasired
et. al.210 have prepared 1,3,4-oxadiazoles of type (VII) as anticonvulsant agent.
Maria Grazia Mamolo et. al.211 have synthesised 3-substituted-5-(pyridin-4-yl)-
3H-1,3,4-oxadiazole-2-one of type (VIII) and studied their antimycobacterial
activity.
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Recently, Ronald Kim et. al.212 have discovered oxadiazole derivatives
useful as protease inhibitors. Mohd Amir and Kumar Shikha213 have documented
antiinflammatory, analgesic and ulcerogenic activity of some newly  synthesised
oxadiazoles, Ali A. et. al.214 have investigated some oxadiazole derivatives
possessing antimicrobial and anti HIV-1- activity. Sherif A. et. al.215 have reported
oxadiazoles as potential antitumor and anti-HIV agents. Afshin Zarghi et. al.216
have synthesised R-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazoles (IX)
possessing anticonvulsant activity. Mahamud Tareq et. al.217 have synthesised
2,5-disubstituted-1,3,4-oxadiazoles (X) useful as tyrosinase inhibitors.
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have synthesised 1,3,4-oxadizoles having substitution of aryl
su lphonamido218 and ary l219 a t  2-pos i t ion (Y)  and 4 ' -pyr idy l ,
benzenesulphonamido phenyl, di-iodoquinolinoxy and aryl sulphonamido
phenyl at 5-position (X) as antimicrobial  agents. H. H. Parekh and co-workers
have prepared 1,3,4-oxadiazoles having substituted triazine220, phenyl
sulphonyl221, 2-isopropyl-5'-methylphenoxymethyl222 moieties at 5-position (X)
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and aryl, arylamino, arylsulphonamido, substituted benzalamino moeties at 2-
position (Y) and screened their antimicrobial activity. General Structure for above
references are as under.
H. H. Parekh et. al.223-229 have formulated some new oxadiazole as
biologically active agents. New 2,5-di substituted oxadiazoles were synthesised
and assessed for antimicrobial activity by Parikh et. al.230.
In view of the potential biological activities of 1,3,4-oxadiazole ring system,
it was of interest to us to prepare some new derivatives of this family of heterocyclic
ring, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
ARYL-5-o-CHLOROBENZYL-1,3,4-OXADIAZOLES
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N
O
N
X Y
NX = , SO2NH ,
SO2NH.R
, aryl
Y =NH–SO2–R,    Aryl,   –SH,   –NH2,  –NHCO – R,  –N = CH – R
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-5-o-
CHLOROBENZYL-1,3,4-OXADIAZOLES
Oxadiazole derivatives have drawn the attention of chemists due to
diversified biological activities associated with it. In view of these facts, it was
contemplated to synthesise some newer oxadiazole derivatives with better
potency. Oxadiazoles of type (IV) have been prepared by condensation of o-
chlorophenyl acetohydrazide with different aromatic acid in presence of POCl3.
The constitution of newly synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have moderate activity
as compared to known antibiotics recorded on Graphical Chart No. 4.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37 Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
Cl
N N
O
R
Type - (IV) R = Aryl
75
REACTION SCHEME
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POCl3
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Type - (IV) R = Aryl
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IR SPECTRAL STUDY OF 2-p-METHOXYPHENYL-5-o-CHLOROBENZYL-1,3,4-
OXADIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2933 2975–2950 498
–CH
3
C – H str  (sym.) 2845 2880–2860 ''
C – H def. (asym.) 1431 1470–1435 ''
C – H def. (sym.) 1374 1385–1370 ''
Aromatic C – H str. 3070 3080–3030 503
C = C str. 1498 1585–1480 ''
C – H i.p. def. 1116 1125–1000 ''
C – H o.o.p. def. 842 835–810 ''
Oxadiazole C = N str. 1615 1650–1580 498
N – N str. 1037 1050–1010 503
C – O – C str. 1087 1140–1070 ''
C – Cl str. 747 800–600 498
Ether C – O – C str. (asym.) 1255 1275–1200 503
C – O – C str. (sym.) 964 1075–1020 498
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmOX ADIAZOLE  4-CH3
 424.3
 521.7
 613.3
 704.9
 747.4
 842.8
 964.3
1037.6
1087.8
1116.7
1169.7
1255.6
1308.6
1374.2
1431.1
1498.6
1574.8
1615.3
2845.8
2933.5
3070.5
3446.6
Cl
N N
O
OCH3
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PMR SPECTRAL STUDY OF 2-p-METHOXYPHENYL-5-o-CHLOROBENZYL-1,3,4-
OXADIAZOLE
Internal Standard : TMS; Solvent : CDCl3;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 3.89 3H singlet Ar-OCH
3
2. 4.61 2H singlet -CH
2
3. 7.00 Jfe=9 2H doublet Ar-Hff'
4. 7.21-7.25 2H multiplet Ar-Hb,Ar-Hc
5. 7.37-7.43 2H multiplet Ar-Ha,Ar-Hd
6. 7.78 Jef=9 2H doublet Ar-Hee'
Cl
N N
O
OCH3a
b
c
d e f
e' f'
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-5-o-
CHLOROBENZYL-1,3,4-OXADIAZOLES
[A] Synthesis of o-chlorophenylaceto hydrazide
See [A] Part-I, Section-I (B).
[B] Synthesis of 2-p-methoxyphenyl-5-o-chlorobenzyl-1,3,4-oxadiazole
A mixture of o- chlorophenylaceto hydrazide (1.85g, 0.01M) and 4-methoxy
benzoic acid (1.52g, 0.01M) in phosphorous oxychloride (10 ml) was refluxed
for 6 hrs. The content was cooled and poured onto crushed ice. It was neutralised
with sodium bicarbonate solution. Product was isolated and crystallised from
ethanol. Yield 1.2g, 64%, m.p. 179oC (C16H13ClN2O2 : required : C, 63.90 ; H,
4.36 ; N, 9.31, found : C, 63.94; H, 4.32 ; N, 9.35%).
TLC solvent system : Acetone : Benzene (4 : 6).
Similarly other oxadiazoles were prepared. The physical data are recorded
in Table No. 4.
[C] Antimicrobial activity of 2-Aryl-5-o-chlorobenzyl-1,3,4-oxadiazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I, (F).
The zones of inhibition of test solution are recorded in Graphical Chart No. 4.
Antitubercular  screening of the compounds of type (IV) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-I
(F) and the percentage of inhibition data of the compounds are recorded in Table
No. 4a.
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TABLE NO. 4 : PHYSICAL CONSTANTS OF 2-ARYL-5-o-CHLOROBENZYL-1,3,4-OXADIAZOLES
Sr.
No.
1
4a 2-CH
3
-C
6
H
4
- C
16
H
13
ClN
2
O 284.7 177 0.74 56 9.84 9.80
4b 4-CH
3
-C
6
H
4
- C
16
H
13
ClN
2
O 284.7 172 0.85 61 9.84 9.88
4c 4-OCH
3
-C
6
H
4
- C
16
H
13
ClN
2
O
2
300.7 179 0.93 64 9.31 9.35
4d 2-Cl-C
6
H
4
- C
15
H
10
Cl
2
N
2
O 305.1 211 0.72 54 9.18 9.14
4e 4-Cl-C
6
H
4
- C
15
H
10
Cl
2
N
2
O 305.1 160 0.82 72 9.18 9.22
4f 4-F-C
6
H
4
- C
15
H
10
ClFN
2
O 288.7 138 0.84 63 9.70 9.66
4g 4-Br-C
6
H
4
- C
15
H
10
BrClN
2
O 349.6 184 0.79 55 8.01 8.05
4h 2-OH-C
6
H
4
- C
15
H
11
ClN
2
O
2
286.7 170 0.92 60 9.77 9.73
4i 4-OH-C
6
H
4
- C
15
H
11
ClN
2
O
2
286.7 166 0.81 57 9.77 9.80
4j 2-NH
2
C
6
H
4
- C
15
H
12
ClN
3
O 285.7 180 0.89 62 14.71 14.75
4k 4-NH
2
-C
6
H
4
- C
15
H
12
ClN
3
O 285.7 136 0.76 66 14.71 14.68
4l 4-NO
2
-C
6
H
4
- C
15
H
10
ClN
3
O
3
315.7 140 0.90 74 13.31 13.35
*TLC Solvent System : Acetone :  Benzene (4 : 6)
Rf*
Value
6
Yield
%
7
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B.coccus 7 11 13 14 17 20 16 14 15 11 12 10 17 21 16 23
B.subtilis 18 16 14 12 13 11 15 16 10 11 9 13 15 21 22 19
P.vulgaris 19 17 20 16 14 13 11 18 9 10 17 18 16 19 15 21
E.coli 10 11 13 7 8 16 14 13 11 10 17 19 19 18 20 22
A.niger 14 15 16 10 11 18 20 11 14 15 17 23 0 0 0 0
4a 4b 4c 4d 4e 4f 4g 4h 4i 4j 4k 4l Amoxycillin
Benzoy
lpenicill
in
Ciprofl
oxacin
Erythro
mycin 
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
From the experimental data it has been concluded that the compounds
bearing R=4-chlorophenyl and 4-bromophenyl have displayed considerable
act iv i ty  against  B.coccus .  The compounds bear ing R=2-methylphenyl ,
4-methylphenyl and 2-hydroxyphenyl have shown maximum activity against
B. subtilis.
In  case of  Gram negat ive bacter ia l  s t ra ins ,  the compounds bear ing
R=2-methylphenyl and 4-methoxyphenyl have fair ly inhibited the growth
of  P.vulgaris .  A l l  the compounds were inact ive agains t  E.coli  except
R=4-nitrophenyl.
Antifungal activity :
All the compounds were active against A.niger. Maximum activity was
shown by the compounds bearing R=4-bromophenyl and 4-nitrophenyl.
The antibacterial activity was compared with standard drugs viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
Antitubercular activity :
The compounds having R = 4-methylphenyl,4-methoxyphenyl and 4-
fluorophenyl have displayed percentage inhibition in the range of 74-84% and
compounds bearing R = 2-methylphenyl, 2-hydroxyphenyl and 4-nitrophenyl
showed percentage inhibition in the range of 45-58% against Mycobacterium
tuberculosis H37 Rv.
The antitubercular activity data have been compared with standard drug
Rifampin.
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Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295443 BSA-65 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 84 - Mic Rifampin =
0.25 µg/ml
@ 98% Inhibition
295444 BSA-66 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 80 -
295445 BSA-67 2-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 54 - "
295446 BSA-68 2-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 48 - "
295447 BSA-69 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 74 - "
295448 BSA-70 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 82 - "
295449 BSA-71 4-Br-C
6
H
4
- Alamar H
37
Rv >6.25 56 - "
295450 BSA-72 2-OH-C
6
H
4
- Alamar H
37
Rv >6.25 45 - "
295451 BSA-73 4-OH-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295452 BSA-74 2-NH
2
-C
6
H
4
- Alamar H
37
Rv >6.25 76 - "
295453 BSA-75 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 58 - "
295454 BSA-76 C
5
H
5
N- Alamar H
37
Rv <6.25 68 - "
Mtb
Strain
Mic
µg/ml
%
Inhib
Where,
R =
Activity
TABLE NO. 4a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Cl
N N
O
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                       PART-V
                  STUDIES ON
                AZOMETHINES
INTRODUCTION
A zomethine der ivat ives  have been found to be potent  drug in
pharmaceutical industries and possess a wide spectrum of biological activity.
Azomethines are also known as schiff bases and they are well known intermediates
for the preparation of azetidinones, thiazolidinone, formazan, arylacetamide and
many other entities of pharamaceutical potential. These are the compounds
containing characteristic –HC=N– group.
SYNTHETIC ASPECT
Several methods231-234 for the preparation of azomethine derivatives are
documented in literature.
1. General account of the summary of reaction of aldehydes with amine.
2. Imine formation involve two steps.
(a) Addition of the amine to the carbonyl group of the aldehyde gives aldol.
The aldol is rarely capable of isolation.
(b) The loss of water to give an imine (azomethine). This corresponds to the
"crotonaldehyde stage" of the aldol condensation.
R H
O
+ R' NH2
R N
R'
R H
O
+ R' NH2
R NH
R'
OH
(I)
(II)
R NH
R'
OH
R N
R'
+ H2O
(III)
86
THERAPEUTIC IMPORTANCE
Azomethines have widely been used as pharmacologically useful entities
because of their broad spectrum of biological activities which have been
described as under.
1. Antibacterial235
2. Antischistosomal236
3. Antifungal237
4. Antiinflammatory238
5. Antiparasitic239
6. Plant harmone activity240
7. Antiviral241
8. Antipyretic242
Azomethines are characterized by -N=CH-(imine) gp which is important
in elucidating the mechanism of transamination and recemisation reaction in
biological systems243,244. Due to the great flexibility and diverse structural aspects,
a wide range of azomethines have been synthesised and their complexation
behaviour studied245.
R. M. Metri et. al.246 have synthesised and studied the biological activity
of bis-triazole schiff bases. Komal Vashi and Naik247 have investigated some
azometh ines  as  ant ibac ter ia l  agents .  Some azometh ines  possess ing
antituberculosis activity has been reported by Hearn and Cynamon.248 Iana
Vazzana et. al.249 have synthesised azomethine derivatives (IV) and reported them
as antiinflammatory agents.
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N
X
Y
Z
R'
X = N; Y,Z = CH
Z = N, CF, OCH3
X,Y = CH
R' = 3-CF3, 4-SO2NH2,
4-SO2CH3
(IV)
Pandeya S. N. and co-workers250have documented antibacterial, antifungal
and anti HIV activity of some azomethine derivatives. Sabrina Castellano et. al.251
have prepared azomethine derivatives and evaluated in vitro against several
pathogenic fungi responsible for human disease.  Hou and Xu 252 have
investigated azomethine derivatives possessing bacteriostatic and fungistatic
activity. Popescu et. al.253 suggested some schiff bases useful as carbonic
anhydrase inhibitors. B. S. Holla et. al.254 have screened azomethines for their
antibacterial activity. Sabrin C. et al.255 have documented antifungal and
antimycotic activity of azomethines. Afaf H. and co-workers256 have prepared
azomethines (V) possessing potential antimicrobial activity.
Ulusoy N et. al.257 have discovered azomethine derivatives possessing
antimicrobial and antituberculosis activities. Wang Y. and co-workers258 have
screened some azomethines having goods plant harmone activity. Pascal Rotheist
et. al.259  have reported some new azomethines as antiparasitic agents. B.
Shivarama Holla et. al.260 have documented antibacterial, antifungal and
herbicidal activity of azomethine derivatives. C. T. Supuran et. al.261 have reported
azomethines useful as carbonic anhydrase inhibitors. Ergenc and co-workers262
have synthesised azomethine derivatives (VI) showing antifungal activity.
A. Scozzafava et. al.263 have suggested some azomethines useful as
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NN
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R
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carbonic anhydrase inhibitors.Das and co-workers264 have prepared azomethines
and were tested them for antiviral activity. Some Azomethine derivatives have
been extensively investigated for their antiinflammatory activity by Adnan A. et.
al.265 De-Biplab et al.266 have synthesised azomethines possessing significant
antibacterial and antifungal activities.
Recently, Ilkay Kucukguzel et. al.267 have screened azomethine derivatives
for their anticonvulsant activity. B. S. Holla et. al.268 have discovered azomethine
derivatives and studied their anticancer activity. Hojatollah M. et. al.269 have
reported azomethines useful as anticonvulsant agent.  Dimmoch J. et. al.270 have
reported azomethines as cytotoxic agents.  Neslihan and Reyhan271 have
synthesised azomethines (VII) and studied their antitumor activity. R. S. Varma272
has been synthesised a series of new azomethines (VIII) and evaluated them for
antileishmanial activity.
Thus with an effort to capitalize the biological potential of the heterocyclic
system and to provide more interesting compounds for biological study, we have
undertaken the synthesis of azomethines bearing triazole moiety.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
N-SUBSTITUTED BENZALAMINO-3-MERCAPTO-5-
o-CHLOROBENZYL 1,2,4-TRIAZOLES
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(VII)
N
N
N N
H
OR N N
N S
N
Ph
Cl
NH
O
CH3
(VIII)
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
B E N Z A L A M I N O - 3 - M E R CA P T O - 5 - o - C H LO R O B E N Z Y L - 1 , 2 , 4 -
TRIAZOLES
Much interest centres around azomethine derivatives because of their wide
range of pharmacological  properties. Hence, it was considered worthwhile to
synthesise azomethine derivatives of the type (V) for the better drug potential.
The azomethine derivatives were synthesised by the condensation of 3-mercapto-
4,N-amino-5-o-chlorobenzyl-1,2,4-triazoles with different aromatic aldehydes in
presence of sulphuric acid.
The constitution of the synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have moderate activity
as compared to known antibiotics recorded on Graphical Chart No. 5.
Cl
N N
N
SH
N
R R = ArylType - (V)
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REACTION SCHEME
R - CHO
H2SO4
Cl
N N
N
SH
NH2
NH2.NH2.H2O
Cl
O
NH NH
S
S   K
+-
EtOH, KOH
CS2
Cl
O
NH NH2
Cl
N N
N
SH
N
R
Type - (V) R = Aryl
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IR SPECTRAL STUDY OF 4,N-p-METHOXY BENZALAMINO-3-MERCAPTO-5-o-
CHLOROBENZYL-1,2,4-TRIAZOLES
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2975 2975–2950 498
–CH
3
C – H str  (sym.) 2860 2880–2860 ''
C – H def. (asym.) 1446 1470–1435 ''
C – H def. (sym.) 1359 1385–1370 ''
Aromatic C – H str. 3030 3080–3030 ''
C = C str. 1569 1585-1480 ''
C – H i.p. def. 1105 1125-1090 503
1041 1070–1000 ''
C – H o.o.p def. 813 835–810 498
Triazole C = N str. 1602 1612–1593 ''
C – N str. 1272 1350–1200 504
N – N str. 1010 1050–1010 503
C – S str. 690 700–600 504
C – Cl str. 767 800–600 498
S – H str. 2597 2600-2500 504
Ether C – O – C str. (asym.) 1242 1275–1200 503
C – O – C str. (sym.) 1075 1075–1020 ''
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N
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PMR SPECTRAL STUDY OF 4,N-p-METHOXY BENZALAMINO-3-MERCAPTO-5-o-
CHLOROBENZYL-1,2,4-TRIAZOLE
Internal Standard : TMS; Solvent : CDCl3 ;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 3.88 3H singlet Ar-OCH
3
2. 4.29 2H singlet -CH
2
3. 6.96 Jfe=9 2H doublet Ar-Hff'
4. 7.19-7.29 3H multiplet Ar-Hb, Ar-Hc
Ar-Hd
5. 7.39 1H double doublet Ar-Ha
6. 7.77 Jef=9 2H doublet Ar-Hee'
7. 10.12 1H singlet -CHg
8. 10.83 - 1H broad singlet -SH
Cl
N N
N
SH
N
OCH3
a
b
c
d
g
e
f
e'
f'
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EXPANDED AROMATIC REGION
Cl
N N
N
SH
N
OCH3
a
b
c
d
g
e
f
e'
f'
Cl
N N
N
SH
N
OCH3
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
B E N Z A L A M I N O - 3 - M E R CA P T O - 5 - o - C H LO R O B E N Z Y L - 1 , 2 , 4 -
TRIAZOLES
[A] Synthesis of Potassium o-chlorophenylacetamido dithiocarbamate
See [A] Part-I, Section-I (C).
[B] Synthesis of 3-Mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
[C] Synthesis  of  4 ,N-p-methoxybenzalamino-3-mercapto-5-o-
chlorobenzyl-1,2,4-triazole
A mixture of 3-mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole (2.40g,
0.01M) and p-methoxybenzaldehyde (1.36g, 0.01M) in absolute alcohol (25 ml)
in presence of sulphuric acid as a catalyst were refluxed for 8 hrs. The resulting
mixture was poured onto crushed ice. The product was isolated and crystallised
from ethanol. Yield 1.6g, 66%, m.p. 158oC (C17H15ClN4OS : required : C, 56.90;
H, 4.21 ; N, 15.61, found : C, 56.94 ; H, 4.18 ; N, 15.65%)
Similarly other derivatives have been synthesised. The physical data are
recorded in Table No. 5.
[D] Antimicrobial activity of 4,N-substituted benzalamino-3-mercapto-
5-o-chlorobenzyl-1,2,4-triazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I, (F).
The zones of inhibition of test solution are recorded in Graphical Chart No. 5.
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N N
SH
Cl N
O CH3
N
NH2
SH
Cl NH
OH
N
N
N SH
N
O CH3
m/z=358
m/z=337
m/z=324
N
H
N N
SH
Cl
m/z=225
CH3 N
N N
NH
OH
m/z=204
CH3
N
N
N
NH
m/z=190N
N N
N
CH3
N
NH2 CH3
NH
m/z=179m/z=158
NH
CH3
N
OH
m/z=150
CH3
Cl
m/z=126
+
+
+
+
+
+
+
+
+
BASE PEAK
+
Molecular
Weight
4
R
2
M.P.
oC
5
% of Nitrogen
Calcd.
8
Found
9
TABLE NO. 5 : PHYSICAL CONSTANTS OF 4,N-SUBSTITUTED BENZALAMINO-3-MERCAPTO-5-o-
CHLOROBENZYL-1,2,4-TRIAZOLES
Sr.
No.
1
5a C
6
H
5
- C
16
H
13
ClN
4
S 328.8 198 0.64 57 17.04 17.00
5b 4-OCH
3
-C
6
H
4
- C
17
H
15
ClN
4
OS 358.8 158 0.52 66 15.61 15.65
5c 2-Cl-C
6
H
4
- C
16
H
12
Cl
2
N
4
S 363.2 170 0.67 68 15.42 15.40
5d 4-Cl-C
6
H
4
- C
16
H
12
Cl
2
N
4
S 363.2 200 0.57 55 15.42 15.46
5e 4-F-C
6
H
4
- C
16
H
12
ClFN
4
S 346.8 252 0.70 58 5.48 5.44
5f 2-NO
2
-C
6
H
4
- C
16
H
12
ClN
5
O
2
S 373.8 172 0.66 72 18.73 18.69
5g 3-NO
2
-C
6
H
4
- C
16
H
12
ClN
5
O
2
S 373.8 180 0.68 62 18.73 18.77
5h 2-OH-C
6
H
4
- C
16
H
13
ClN
4
OS 344.8 165 0.53 65 16.25 16.21
5i 4-OH-C
6
H
4
- C
16
H
13
ClN
4
OS 344.8 205 0.55 59 16.25 16.29
5j 9-C
14
H
9
- C
24
H
17
ClN
4
S 428.9 202 0.63 77 20.37 20.33
5k 3-OH,4-OCH
3
-C
6
H
3
- C
17
H
15
ClN
4
O
2
S 374.8 170 0.71 54 14.95 14.91
5l 3,4-(OCH
3
)
2
-C
6
H
3
- C
18
H
17
ClN
4
O
2
S 388.8 132 0.59 56 14.41 14.37
*TLC Solvent System :Ethyl acetate : Hexane (2 : 8) (5a - 5l)
(3 : 7) (5c, 5k, 5l)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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05
10
15
20
25
30
Z
O
N
E
 O
F
 IN
H
IB
IT
IO
N
 IN
 m
B.coccus 12 19 14 17 11 9 8 19 10 12 17 14 17 21 16 2
B.subtilis 14 19 12 8 10 13 18 17 12 11 16 14 15 21 22 1
P.v ulgaris 13 10 18 17 14 19 12 11 17 14 19 21 16 19 15 2
E.coli 14 17 11 9 19 18 10 11 18 17 16 12 19 18 20 2
A.niger 14 17 13 11 18 20 24 14 17 19 20 12 0 0 0
5a 5b 5c 5d 5e 5f 5g 5h 5i 5j 5k 5l Am oxycillin
Benzoy
lpenicill
in
Ciprofl
oxacin
Ery
m y
   GRAPHICAL CHART NO. 5  :   4,N-SUBSTITUTED BENZALAMINO-3-MERCAPTO
                                                            -5-o-CHLOROBENZYL-1,2,4-TRIAZOLES
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
It was observed that most of the compounds were mild to moderately active
against Gram positive and Gram negative bacterial strains.
Maximum activity was observed in compounds bearing R=4-methoxyphenyl
and 2-hydroxyphenyl against B.coccus and B.subtilis.
In case of P.vulgaris, significant activity was displayed by compounds
bear ing R=2-ch lorophenyl ,  2-n i t rophenyl  and 3,4-d imethoxyphenyl .
Compounds with R=4-fluorophenyl, 2-nitrophenyl and 4-hydroxyphenyl showed
highest activity against E.coli.
Antifungal activity :
The compounds were tested against fungal species A.niger. It has been
concluded that all the compounds were active against A.niger. Maximum activity
was displayed by the compounds bearing R=2-nitrophenyl, 3-nitrophenyl and
3-hydroxy, 4-methoxyphenyl.
                               [B]
                        STUDIES  ON
                    PYRAZOLES
INTRODUCTION
Pyrazoles, which belong to an important class of heterocyclic compounds
have been extensively explored for their applications in the field of medicine,
agriculture and industrial chemistry. The pyrazole ring system (I) consists of a
diunsaturated five memberd ring containing two adjecent Nitrogen atoms.
Synthetic pyrazole derivatives contribute much to the searchable literature
of pyrazole derivatives, in huge libraries owing to their wide applicability in
different fields.
SYNTHETIC ASPECTS
Different methods for the preparation of pyrazoles are available in literature
which are as under.
1. H. V. Pechmann273 has synthesised pyrazoles by the reaction of acetylenes
and diazomethane.
2. L. Knorr274 has synthesised two structrually isomeric pyrazoles by the
condensation of substituted hydrazines with 1,3-dicarbonyl compounds.
N
H
N
(I)
NHN
CH CH + CH2 N+ N-
(II)
NH2.NH.Ar +
O
R
R1
O
R2
NN
R
R1
R2
Ar
+
NN
R
R1
R2
Ar
+ 2 H2O
(III) (IV)
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3. Afaf H. El-Masry et. al.275 have synthesised 1-[3-(2-methylbenzimidazol-
1-yl)propanoyl]-3,5-dimethyl pyrazole by the reaction of hydrazide with
acetylacetone.
THERAPEUTIC IMPORTANCE
Pyrazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having pyrazole nulceus with good
pharmacological activities are listed below.
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N
N
CH3
CH2CH2CONH.NH2
CH3COCH2COCH3
Acetylacetone
N
N
CH3
CH2CH2CO N
N
CH3
CH3
NN
CH3
N
CH3
O
SO3
Na
CH3 N
N
N
S
F
F
F
O
NH2
Cl Cl
CF3
Fipronil
(Pesticide)
Sulpyrin
(Antipyretic)
N
N
CH3
Cl
CH3
O
NHCH3
CH3
CH3
Tebufenpyraid
(Acaricides)
N
N
N
CH3
Cl
O
P
O
O
O
CH3
CH3
Chlorprazophos
(Insecticide)
Pyrazole derivatives exhibit broad spectrum of therapeutic activity. Several
biological activities associated with pyrazole derivatives have been described as
under.
1. Anticancer276
2. Antitumar277
3. Antiulcer278
4. Antimicrobial279
5. Antiparasitic280
6. CNS depressant281
7. Herbicidal282
8. Immunosuppresants283
9. Lipoxygenase inhibitor284
10. Neurotonsin receptor285
Joanna M. et. al.286 have prepared pyrazole derivatives (VI) and screened
for their antimycotic activity. Gerard Pinnel et. al.287 have discovered pyrazoles
useful as antitumor agent. Carbau Romuald and co-workers288 have reported
pyrazole derivatives useful as reverse transcriptase inhibitors for the treatment of
HIV infection. Bernard Banks et. al.289 have reported antiparasitic activity of
pyrazoles. Dange Visaykymar et. al.290 have formulated pyrazoles as anticaner
agent. Virinder S. Parmar et. al.291 have synthesised  pyrazole derivatives (VII)
and studied their antiinvasive activity.
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N
CH3
CF3
S
O
O
NH2
Celecoxib
(Antiinflammatory)
N
N
O
(H2C)3CH3
O
OH
Oxyphenbutazone
(Antiarthritic)
Aldo Balsamo and co-workers292have documented COX-2 inhibitory and
antiinflammatory activity of pyrazoles. Grazid M. et. al.293 have tested pyrazole
derivatives for their antimicrobial activity. Florian P. et. al.294 have discovered
some pyrazole derivatives and studied their antitumor activity. Takehiro and
Toshio295 have reported antiinflammatory activity of pyrazoles. Baraldi et. al.296
have discovered pyrazole derivatives and studied their antimicrobial and
antitumor activity. Malisa J. et. al.297 have formulated pyrazoles as anticonvulsant
agent. Hitoshi O. et. al.298 have synthesised pyrimidinyl pyrazole derivatives (VIII)
and reported their antiproliferative activity against human lung cancer cell.
Maria M. et. al.299 have investigated some pyrazole derivatives showing
antimycobacterial activity S. Gupta et. al.300 have documented  antiinflammatory
activity of pyrazoles. R. Ranatunge et. al.301 have synthesised pyrazole derivatives
(IX) and screened for their COX-2 inhibitory activity.
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Recently,  Giuseppe D. et. al.302 have discovered pyrazole derivatives and
studied their antileukemic activity. Junzo Kamei et. al.303 have reported pyrazoles
useful as cyclooxygenase-2-inhibitor. Zainaba D. et. al.304 have investigated
pyrazoles and screened for their antifungal activity. Giulia M. et. al.305 have
demonstrated antimicrobial activity of pyrazoles. Zhao Zhong et. al.306 have
documented anticoagulant activity of pyrazoles. Moyed and Evelin307  have
suggested pyrazole useful as antibacterial agent. Pier G. Baraldi et. al.308 have
formulated pyrazoles as antitumor agent.  Adnan and Tarek309 have synthesised
pyrazole derivatives (X) and tested for their antiinflammatory, cyclooxygenase-
2-inhibitory and antimicrobial activities.
Looking to the diversified biological activities, it appeared of interest to
synthesise some pyrimidines,cyanopyridones, imidazolinones and nitriles bearing
pyrazole moiety, in order to achieving compounds having better therapeutic
importance. These study are described in following parts.
[B] STUDIES ON PYRAZOLES
PART-I : STUDIES ON PYRIMIDINES
PART-II : STUDIES ON CYANOPYRIDONES
PART-III : STUDIES ON IMIDAZOLINONES
PART-IV : STUDIES ON NITRILES
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                       PART-I
                  STUDIES ON
                  PYRIMIDINES
INTRODUCTION
Pyrimidine is a heterocylic aromatic organic compound, which contains
two nitrogen atoms at position 1 and 3 of the six membered ring. They are
occurring in nature in wide variety of forms. They include several nucleuic acid
constituents like uracil (I), cytosine (II) and thymine (III) which have remarkable
pharmaceutical importance because of their diverse biological activities.
Pyrimidine is the parent compound of many drugs, including the barbiturates.
SYNTHETIC ASPECT
Different methods for ther synthesis of pyrimidines have been cited in the
literature310.
1. Bigi and co-workers311 have synthesised pyrimidinones as shown under
solvent free condition.
2. B. K. Karale et. al.312 have synthesised pyrimidine by the condensation of
1(4-nitrophenyl)-2-(chromon-3-yl) ethenes with thiourea in presence of
alcoholic KOH.
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NH2 NH2
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CH3
O
(VI)
3. V. Alagarsamy et. al.313 have prepared pyrimidine from thiosemicarbazide.
MACHANISM
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R
O R1
NHNH2
N S
N
R
R
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. . . .
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THERAPEUTIC IMPORTANCE
Pyrimidines are excellent reservoir of bioactive substances. In the past years,
the literature is enriched with progressive findings about the synthesis and
pharmacological action of pyrimidine derivatives. The important activities are as
under.
1. Antibacterial314
2. Antiviral315
3. Antifilarial316
4. Antitumor317
5. Antiproliferative318
6. Antileishmanial319
7. Antimalarial320
8. Anticancer321
9. Antidepressant322
10. Herbicidal323
Hodgetts et. al.324 have discovered pyrimidinone derivatives as selective
modulators of CRF-1 receptors. Hamamoto Isami et. al.325 have reported
pyrimidines as pesticides. Drewes Mark Wilhelm et. al.326 have tested pyrimidines
as herbicides. Lagu Bharat et. al.327 have investigated pyrimidine derivatives
(IX) showing antagonist potency for melanine conc. hormone receptor.
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Eberie M. et. al.328 have formulated pyrimidines as pesticides. El-Agrody
A. M. et. al.329 have studied antimicrobial activity of pyrimidines. Gangjee Aleem
et. al.330 have tested pyrimidines for their antimycobacterium activity.
Veerachamy A. et. al.331 have reported pyrimidines as antihistaminic agent. Some
pyrimidine derivatives possessing antiviral activity have been synthesised by
Vadim A. M. et. al.332, David L. Evers et. al.333, Frank Staedtler et. al.334,
Nurolaini K. et. al.335 and Dana H. et. al.336 Jolanta et. al.337 have discovered
pyrimidine derivatives and studied their antitumor activity. Annette Angell
et. al.338 have synthesised pyrimidines (X) and tested them as antiviral agent.
Miroslav Otmar et.  al .339 have discovered pyrimidines possessing
antiproliferative activity. Antonia Nikitenko et. al.340 have prepared pyrimidine
derivatives useful as respiratory syncytial virus (RSV) inhibitors. Gergely Keszler
et. al.341 have reported pyrimidines as Tyrosine Kinase inhibitors. James Kempson
et. al.342 have demonstrated pyrimidines as phosphodiesterase (PDE-7) inhibitors.
Botta M. et. al.343 have formulated pyrimidines as anti-HIV-1 agents. Khachatryan
V. E. et. al.344 have synthesised oxopyrimidines (XI) as antitumor agents.
Recently, S. K. Hadjikou et. al.345 have discovered pyrimidines showing
antitumor activity. Anu Agarwal et. al.346 have prepared pyrimidines possessing
antimalarial activity. Katsuhide Kamer et. al.347 have documented remarkable
neuroprotective activity of pyrimidines. Sham M. Sondhi et. al.348 have
synthesised thiopyrimidines (XII), (XIII), (XIV) and (XV) and reported their anti-
inflammatory, analgesic and proten kinase inhibitory activities.
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Frank Biittner et. al.349 have synthesised pyrimidines and evaluated for their
antimicrobial and cytotoxic activities. Yasushi M. et. al.350 have discovered some
new pyrimidine derivatives and reported them as anticancer agents. Naveen
Chandra et. al.351 have screened pyrimidines for their antileishmanial activity.
Richard J. et. al.352 have prepared pyrimidines as adenosine kinase inhibitor.
S.Chandrasekaran et. al.353 have studied antibacterial activity of some newly
synthesised pyrimidines. Brian A. Johus et. al.354 have investigated pyrimidines
as antiherpetics. Franck Amblard et. al.355 have synthesised oxopyrimidines (XVI)
and (XVII) possessing antiviral activity.
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Thus, diverse biological activities have been encountered in compounds
containing pyrimidine ring system. To further assess the potential of such type of
compounds, study of pyrimidines have been carried out as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
2-ARYLIMINO-3,N-ARYL-5-(1 ' ,N-PHENYL-3' -p-
BROMOPHENYL-4 ' -PYRAZOLYL METHINO)-4-
THIAZOLIDINONES
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-
ARYLIMINO-7,N-ARYL-2-OXO-4-(1',N-PHENYL-3'-p-
B R O M O P H E N Y L - P Y R A Z O L - 4 ' - Y L ) - 1 , 2 , 3 , 4 -
TETRAHYDRO THIAZOLIDINO-[4,5,-d]-PYRIMIDINES
SECTION-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF
6-ARYLIMINO-7,N-ARYL-2-THIO-4-(1',N-PHENYL-3'-
p -BROMOPHENYL-PYRAZOL-4 ' -YL ) -1 ,2 ,3 ,4 -
TETRAHYDRO THIAZOLIDINO-[4,5-d]-PYRIMIDINES
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SECTION-I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-(1',N-PHENYL-3'-p-BROMOPHENYL-4'-PYRAZOLYLMETHINO)-
4-THIAZOLIDINONES
Arylidenes are associated with broad spectrum of pharmacological activity
and it is a good synthon for various heterocyclic rings. With a view to obtaining
compounds having  better therapeutic activities, we have synthesied 2-arylamino-
3 -N -a r y l - 5 - [1 ' ,N -pheny l - 3 ' - p -b romopheny l - 4 ' - py ra zo l y lme th ino ] -4 -
thiazolidinones by the condensation of 1,N-phenyl-3-p-bromophenyl-4-formyl
pyrazole with various thiazolidinone derivatives.
The constitution of the synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have moderate activity
as compared to known antibiotics recorded on Graphical Chart No. 6.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37 Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
111
N
N
Br
S
N
N R
R
O
R = ArylType - (VI)
REACTION SCHEME
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IR SPECTRAL STUDY OF 2-p-ANISYLIMINO-3,N-p-ANISYL-5-(1',N-PHENYL-3'-p-
BROMOPHENYL-4'-PYRAZOLYLMETHINO)-4-THIAZOLIDINONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2974 2975–2950 498
–CH
3
C – H str  (sym.) 2860 2880–2860 "
C – H i.p. (def.) 1438 1470–1435 "
C – H o.o.p (def.) 1367 1385–1370 "
Aromatic C – H str. 3066 3080–3030 503
C = C str. 1562 1585–1480 "
C – H i.p. (def.) 1112 1125–1090 "
1043 1070–1000 "
C – H o.o.p (def.) 815 835–810 "
Pyrazole C = N str. 1629 1630–1590 499
moiety C – N str. 1203 1230–1020 "
C – Br str. 561 600–500 498
Thiazolidinone C = O str. 1712 1760–1655 502
ring C – S – C str. 675 700–600 "
C – N str. 1170 1220–1020 "
C = N str. 1587 1640–1590 "
N – H str. 3429 3500–3350 "
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PMR SPECTRAL STUDY OF 2-(p-ANISYLIMINO)-3-N-p-ANISYL-5-(1'-N-PHENYL-3'-p-
BROMOPHENYL-4'-PYRAZOLYL-METHINO)-4-THIAZOLIDINONE
Internal Standard : TMS; Solvent : CDCl3;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 3.82 3H singlet Ar-OCH
3
2. 3.84 3H singlet Ar-OCH
3
3. 6.92 4H doublet Ar-Hii', Ar-Hkk'
4. 7.03 Jhi=9 2H doublet Ar-Hhh'
5. 7.34-7.38 2H + 1H doublet Ar-Hff'+Ar-Hc
6. 7.47-7.51 2H triplet Ar-Hb,d
7. 7.54-7.56 Jgf=8.4 2H doublet Ar-Hgg'
8. 7.60-7.63 Jjk=8.4 2H doublet Ar-Hjj'
9. 7.73-7.76 2H doublet Ar-Ha,e
10. 7.76 1H singlet -CHy
11. 8.09 1H singlet Ar-Hx
N
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y
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-(1',N-PHENYL-3'-p-BROMOPHENYL-4'-PYRAZOLYLMETHINO)-
4-THIAZOLIDINONES.
[A] Synthesis  o f  N-Phenylamine-α -methyl - α -p -bromophenyl
azomethine356
A mixture of phenylhydrazine (1.08, 0.01M) and 4-bromoacetophenone
(1.99g, 0.01M) in absolute ethanol was refluxed in waterbath for 2 hrs. in presence
of 1 ml glacial acetic acid. Product obtained after cooling was crystalized from
absolute ethanol yield 2.43g, 99%; m.p. 39oC. (C14H13BrN2 Required C : 58.15;
H, 4.53; N, 9.69; Found C : 58.11; H, 4.57; N, 9.73%)
TLC solvent system : Acetone : Benzene (0.5 : 9.5).
[B] Synthesis of 1,N-phenyl-3-p-bromophenyl-4-formyl pyrazole
A compound N-phenylamine-α-methyl-α-p-bromophenyl-azomethine
(2.88g, 0.01M) was added in a mixture to vilsmeier-Haack reagent (prepared by
dropwise addition of 3 ml POCl3 in ice cooled 25 ml DMF) and refluxed for 6
hrs. The reaction mixture was poured onto crushed ice followed by neutralization
using sodium bicarbonate. Crude product was isolated and crystallized from
methanol. Yield, 88%, 2.6g ; m.p. 126oC.  (C16H11BrN2O Required C : 58.74;
H: 3.39; N: 8.56 Found C: 58.71 ; H: 3.36; N: 8.52%).
TLC solvent system : Acetone : Benzene  (2 : 8).
[C] Sythesis of N1, N3-Bis-p-anisyl thioura357
A mixture of p-anisidine (24.6g, 0.2M), carbon disulphide (7.6ml, 0.1M)
and absolute alcohol (20 ml) was heated on waterbath for 5-6 hrs. On completion
of reaction the excess of carbon disulphide and alcohol was removed by
distilation. The product was treated with dilute hydrochloric acid to remove excess
of amine present and crude product was isolated and crysallised in rectified spirit.
Yield, 20.9g, 85%; m.p. 123
o
C. (C15H16N2O2S ; Found : C, 62.48%; H, 5.59%;
N, 9.71g Required : C, 62.46%; H, 5.54%; N, 9.73%).
TLC solvent system : Ethylacetate : Hexane (2 : 8).
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[D] Synthesis of 2-p-Anisylimino-3-p-anisyl-5H-4-thiazolidinones358
A mixture of N1,N3-bis-p-anisyl thiourea (2.64, 0.01M) and chloroacetic
acid (0.94, 0.01M) in glacial acetic acid (15 ml) was refluxed with fused sodium
acetate (1.25g, 0.15M) for 8 hrs. The reaction product was poured onto crushed
ice, kept overnight, crude product was isolated, crystallised from acetic acid. Yield
2.05g, 78%; m.p. 178oC (C17H16N2O3S : Found : C, 62.18%; H, 4.91%; N,
8.53%; Required : C, 62.17%; H, 4.47%; N, 8.52%).
TLC solvent system : Acetone : Benzene (0.5 : 9.5).
[E] Synthesis of 2-p-Methoxyphenylimino-3-p-methoxyphenyl-5-(1',N-
phenyl-3'-p-bromophenyl-4'-pyrazolylmethino)-4-thiazolidinone
A mixture of  2-p-methoxyphenyl imino-3-p-methoxyphenyl -5H-4-
thiazolidinone (3.28g, 0.01M) 1,N-phenyl-3-p-bromophenyl-4-formyl pyrazole
(3.26g, 0.1M) and fused sodium acetate (1.25g, 0.015g) was refluxed in glacial
acetic acid (15 ml) for 10 hrs. Cooled, poured onto crushed ice and treat with
ammonia to remove excess of glacial acetic acid. The solid thus obtained was
filtered, dried and crystallised from acetic acid. Yield, 2.3g, 71%, m.p. 222oC
(C33H25BrN4O3S : Required C: 62.17; H: 3.95; N: 8.79; Found C: 62.20; H:
3.91; N: 8.83%).
TLC solvent system : Ethyl acetate : Hexane (1 : 9)
Similarly, other thiazolidinones were prepared. The physical data are
recorded in Table No. 6.
[F] Antimicrobial activity of 2-Arylimino-3-aryl-5-(1',N-phenyl-3'-p-
bromophenyl-4'-pyrazolylmethino)-4-thiazolidinones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F).
The zones of inhibition of the test solution are recorded in Graphical Chart No. 6.
Antitubercular  screening of the compounds of type (VI) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I,
Section-I (F) and the percentage of inhibition data of the compounds are
recorded in Table No. 6a.
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TABLE NO. 6 : PHYSICAL CONSTANTS OF 2-ARYLIMINO-3,N-ARYL-5-(1',N-PHENYL-3'-p-BROMOPHENYL-
4'-PYRAZOLYLMETHINO)-4-THIAZOLIDINONES
Sr.
No.
1
6a C
6
H
5
- C
32
H
21
BrN
4
OS 577.4 183 0.64 54 9.70 9.74
6b 2-CH
3
-C
6
H
4
- C
33
H
25
BrN
4
OS 605.5 178 0.59 65 9.25 9.21
6c 4-CH
3
-C
6
H
4
- C
33
H
25
BrN
4
OS 605.5 254 0.62 62 9.25 9.29
6d 4-OCH
3
-C
6
H
4
- C
33
H
25
BrN
4
O3S 637.5 222 0.60 71 8.79 8.83
6e 4-Cl-C
6
H
4
- C
31
H
19
BrCl
2
N
4
OS 646.3 180 0.58 56 8.67 8.63
6f 4-F-C
6
H
4
- C
31
H
19
BrF
2
N
4
OS 613.4 152 0.63 79 6.19 6.15
6g 4-NO
2
-C
6
H
4
- C
31
H
19
BrN
6
O
5
S 667.4 130 0.71 72 12.59 12.63
6h 4-COOH-C
6
H
4
- C
33
H
21
BrN
4
O
5
S 665.5 136 0.67 57 8.42 8.46
6i 3-Cl,4-F-C
6
H
3
- C
31
H
17
BrCl
2
F
2
N
4
OS 682.3 >280 0.66 82 8.21 8.20
6j 2,4-di-Cl-C
6
H
3
- C
31
H
17
BrCl
4
N
4
OS 715.2 188 0.57 66 7.83 7.80
6k 2,5-di-Cl-C
6
H
3
- C
31
H
17
BrCl
4
N
4
OS 715.2 190 0.59 59 7.83 7.87
6l 3,4-di-Cl-C
6
H
3
- C
31
H
17
BrCl
4
N
4
OS 715.2 192 0.70 67 7.83 7.79
*TLC Solvent System :Ethyl acetate : Hexane (1 : 9)
Rf*
Value
6
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%
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B.coccus 15 12 14 16 18 10 11 17 15 21 12 13 17 21 16
B.subtilis 18 13 12 9 16 12 15 10 8 20 14 11 15 21 22
P.vulgaris 13 11 16 11 19 12 17 20 11 15 14 10 16 19 15
E.coli 17 14 22 11 17 12 21 16 15 20 13 16 19 18 20
A.niger 19 13 11 14 15 12 20 9 16 22 17 10 0 0 0
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GRAPHICAL CHART NO. 6 :  2-ARYLIMINO-3,N-ARYL-5-(1’,N-PHENYL-3’-p-BROMOPHENYL-
                                                          4’-PYRAZOLYLMETHINO)-4-THIAZOLIDINONES
RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
It has been observed from the experimental data that all the thiazolidinones
of type (VI) markedly inhibited the growth of Gram positive and also Gram
negative bacteria.
However, comparatively significant activity was observed in compounds with
R=4-chlorophenyl and 2,4-dichlorophenyl against B.coccus and R=phenyl and
2,4-dichlorophenyl against B.subtilis. Compounds bearing R=4-chlorophenyl,
2,5-dichlorophenyl showed good activity against P.vulgaris. Maximum activity
was observed in compounds bearing R=4-methylphenyl, 4-nitrophenyl and 2,4-
dichlorophenyl against E.coli.
Antifungal activity :
All the compounds were active against A.niger. Maximum activity was
shown by the compounds bearing R=4-nitrophenyl and 2,4-dichlorophenyl.
The antibacterial activity was compared with standard drugs viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
Antitubercular activity :
Al l  the  compounds  o f  type (VI )  d i sp layed less  ac t iv i ty  aga ins t
Mycobacterium tuberculosis H37Rv.
The antitubercular activity data have been compared with standard drug
Rifampin.
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Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295467 BSA-89 C
6
H
4
- Alamar H
37
Rv >6.25 26 - Mic Rifampin =
0.25 µg/ml
@ 98% Inhibition
295468 BSA-90 2-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 23 -
295469 BSA-91 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295470 BSA-92 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295471 BSA-93 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 28 - "
295472 BSA-94 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 18 - "
295473 BSA-95 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 5 - "
295475 BSA-97 2,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 0 - "
295476 BSA-98 2,5-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 0 - "
295477 BSA-99 3,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 7 - "
295478 BSA-100 4-COOH-C
6
H
4
- Alamar H
37
Rv >6.25 12 - "
Mtb
Strain
Mic
µg/ml
%
Inhib
Where,
R =
Activity
TABLE NO. 6a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
N
N
Br
S
N
N R
R
O
122
SECTION-II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-OXO-4-(1',N-PHENYL-3'-BROMOPHENYL PYRAZOL-4'-YL)-
1,2,3,4-TETRAHYDRO THIAZOLIDINO-[4,5-d]-PYRIMIDINES
Many pyrimidinone derivatives are associated with diversified biological
properties. It was thought of interest that a pyrimidinone ring couple to pyrazole
nucleus and thioazolidinone nucleus, the resulting compounds may possess
significant biological potency. Pyrimidinones of type (VII) have been prepared
by the condensation of 2-arylimino-3-p-aryl-5-(1',N-phenyl-3'-p-bromophenyl-
4'-pyrazolyl methino)-4-thiazolidinone with urea in glacial acetic acid with fused
sodium acetate.
The constitution of the newly synthesised compounds have been supported
by using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared with
standard drugs. Some compounds have been found to have moderate activity as
compared to known antibiotics recorded on Graphical Chart No. 7.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37 Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
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IR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-OXO-4-(1',N-PHENYL-3'-
p-BROMOPHENYL PYRAZOL-4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINONE-(4,5-d)
PYRIMIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2920 2975–2950 498
–CH
3
C – H str  (sym.) 2875 2880–2860 "
C – H i.p. (def.) 1440 1470–1435 "
C – H o.o.p (def.) 1338 1385–1370 "
Aromatic C – H str. 3026 3080–3030 503
C = C str. 1502 1585–1480 "
C – H i.p. (def.) 1105 1125–1090 "
1006 1070–1000 "
C – H o.o.p (def.) 829 835–810 "
Pyrazole C = N str. 1595 1610–1590 499
moiety C – N str. 1182 1230–1020 "
C – Br str. 592 600–500 498
Pyrimidinone C = O str. 1703 1750–1600 506
ring N – H str. 3417 3500–3350 "
C – N str. 1651 1650–1550 "
C – S – C str. 756 800–700 "
Ether C – S – C str (asym.) 1226 1275–1200 "
C – S – C str. (asym.) 1064 1075–1020 "
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmOX OPYRIM IDINE  P-CH3
 484.1
 555.5
 592.1
 673.1
 723.3
 756.0
 829.3
 954.7
1006.8
1064.6
1105.1
1155.3
1182.3
1226.6
1338.5
1440.7
1502.4
1595.0
1651.0
1703.0
2815.9
2920.0
3026.1
3417.6
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NH NH
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PMR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-OXO-4-(1',N-PHENYL-3'-
BROMOPHENYL PYRAZOL-4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-
PYRIMIDINE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 2.36 3H singlet Ar-CH
3
2. 2.41 3H singlet Ar-CH
3
3. 6.86-6.89 Jkj=9 2H doublet Ar-Hkk'
4. 7.16-7.18 Jih=8.1 2H doublet Ar-Hii'
5. 7.34-7.38 5H multiplet Ar-Hc,Ar-Hhh'
Ar-Hff'
6. 7.48 2H triplet Ar-Hb,d
7. 7.53-7.56 Jgf=8.7 2H doublet Ar-Hgg'
8. 7.60-7.63 Jjk=8.7 2H doublet Ar-Hjj'
9. 7.74 2H doublet Ar-Ha,e
10. 7.77 1H singlet -CHy
11 8.08 1H singlet Ar-Hx
N
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N
N
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-OXO-4-(1',N-PHENYL-3'-p-BROMOPHENYL PYRAZOL-4'-YL)-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINE
[A] Sythesis of 2-p-Methylphenylimino-3-p-methylphenyl-5-(1',N-
phenyl-3'-p-bromophenyl-4'-pyrazolylmethino)4-thiazolidinone
See, [B] Part-I, Section-I [E].
[B] Synthesis of 6-p-Methylphenylimino-7,N-p-methylphenyl-2-oxo-4-
(1',N-phenyl-3'-p-bromophenyl pyrazol-4'-yl)-1,2,3,4-tetrahydro
thiazolidino-[4,5-d] pyrimidine
A mixture of 2-p-methylphenylimino-3-p-methylphenyl-5-(1',N-phenyl-3'-
p-bromophenyl-4'-pyrazolylmethino)-4-thiazolidinone (6.05, 0.01M) and urea
(0.60g, 0.01M) were taken in glacial acetic acid (20 ml) with fused sodium acetate
(1.25g, 0.015g). The reaction mixture was refluxed for 12 hrs. Cooled and poured
onto crushed ice. The solid thus obtained was filtered, dried and product was
crystallised from methanol-DMF. Yield, 4.4g, 74% m.p. 248oC, (C34H27BrN6OS :
Required : C: 63.06; H: 4.20; N: 12.98; Found : C: 63.02; H: 4.24; N: 12.94%)
TLC solvent system : Acetone : Benzene (2 : 8).
Similarly, other pyrimidinones were prepared. The physical data are recorded
in Table No.7.
[C] Antimicrobial activity of 5-Arylimino-7,N-aryl-2-oxo-4-(1',N-phenyl-
3'-p-bromophenyl pyrazol-4'-yl)-1,2,3,4-tetrahydro-thiazolidinon-
[4,5-d]-pyrimidines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I, (F).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.7.
Antitubercular  screening of the compounds of type (VII) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-
I (F) and the percentage of inhibition data of the compounds are recorded in
Table No. 7a.
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TABLE NO. 7 : PHYSICAL CONSTANTS OF 6-ARYLIMINO-7,N-ARYL-2-OXO-4- [1 ' ,N-PHENYL-3 ' -p -
BROMOPHENYL PYRAZOL-4'-YL]-1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d] PYRIMIDINES
Sr.
No.
1
7a C
6
H
5
- C
32
H
23
BrN
6
OS 619.5 280 0.72 59 13.57 13.59
7b 2-CH
3
-C
6
H
4
- C
34
H
27
BrN
6
OS 647.5 179 0.75 62 12.98 12.96
7c 4-CH
3
-C
6
H
4
- C
34
H
27
BrN
6
OS 647.5 248 0.69 74 12.98 12.94
7d 4-OCH
3
-C
6
H
4
- C
34
H
27
BrN
6
O
3
S 679.5 226 0.73 55 12.37 12.33
7e 4-Cl-C
6
H
4
- C
32
H
21
BrCl
2
N
6
OS 688.4 232 0.70 83 12.21 12.25
7f 4-F-C
6
H
4
- C
32
H
21
BrF
2
N
6
OS 655.5 144 0.74 70 12.82 12.86
7g 4-NO
2
-C
6
H
4
- C
32
H
21
BrN
8
O
5
S 709.5 160 0.71 53 15.79 15.83
7h 4-COOH-C
6
H
4
- C
34
H
23
BrN
6
O
5
S 707.5 140 0.68 69 11.88 11.84
7i 3-Cl,4-F-C
6
H
3
- C
32
H
19
BrCl
2
F
2
N
6
OS 724.4 196 0.77 72 11.60 11.64
7j 2,4-di-Cl-C
6
H
3
- C
32
H
19
BrCl
4
N
6
OS 757.3 186 0.67 58 11.10 11.14
7k 2,5-di-Cl-C
6
H
3
- C
32
H
19
BrCl
4
N
6
OS 757.3 126 0.60 55 11.10 11.8
7l 3,4-di-Cl-C
6
H
3
- C
32
H
19
BrCl
4
N
6
OS 757.3 194 0.65 66 11.10 11.6
*TLC Solvent System : Acetone : Benzene (2 : 8)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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B.coccus 12 14 12 16 13 18 12 15 19 13 11 10 17 21 16
B.subtilis 10 13 11 15 19 9 18 12 20 14 16 14 15 21 22
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E.coli 11 12 14 13 15 10 13 15 12 11 20 12 19 18 20
A.niger 16 13 15 18 12 20 10 21 11 12 14 17 0 0 0
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in
Ciprofl
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GRAPHICAL CHART NO. 7 : 6-ARYLIMINO-7,N-ARYL-2-OXO-4-(1’,N-PHENYL-3’-p-
BROMOPHENYL PYRAZOL-4’-YL)1,2,3,4-TETRAHYDRO
THIAZOLIDINO-[4,5-d]PYRIMIDINES
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
From the experimental data it has been observed that all the compounds of
type (VII) were active against Gram positive and Gram negative bacterial species.
It was observed that the compounds showed good activity against Gram
positive bacteria. Maximum activity was observed in compounds having R=4-
methylphenyl, 4-nitrophenyl, 2,4-dichlorophenyl against B.coccus. The
compounds bearing R=4-fluorophenyl and 2,4-dichlorophenyl have fairly
inhibited the growth of B.subtilis. Compounds with R=4-carboxyphenyl and
2,5-dichlorophenyl showed highest activity against P.vulgaris. Almost all
compounds were found to be inact ive against  E.col i  except  R=3,4-
dichlorophenyl.
Antifungal activity :
It has been found that all compounds were moderately active against
A.niger. The maximum activity was displayed by the compounds bearing R=3,4-
dichlorophenyl against A.niger.
The antibacterial activity was compared with standard drugs viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
Antitubercular activity :
All the compounds of type (VII) were found to be less activite against
Mycobacterium tuberculosis H37Rv.
The antitubercular activity data have been compared with standard drug
Rifampin.
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295479 BSA-101 C
6
H
4
- Alamar H
37
Rv >6.25 14 - Mic Rifampin =
0.25 µg/ml
@ 98% Inhibition
295480 BSA-102 2-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 28 -
295481 BSA-103 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295482 BSA-104 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 3 - "
295483 BSA-105 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 19 - "
295484 BSA-106 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 25 - "
295485 BSA-107 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 27 - "
295486 BSA-108 3-Cl,4-F-C
6
H
3
- Alamar H
37
Rv >6.25 26 - "
295487 BSA-109 2,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 19 - "
295488 BSA-110 2,5-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 8 - "
295489 BSA-111 3,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 18 - "
295490 BSA-112 4-COOH-C
6
H
4
- Alamar H
37
Rv >6.25 33 - "
Mtb
Strain
Mic
µg/ml
%
Inhib
Where,
R =
Activity
TABLE NO. 7a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
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SECTION-III
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-THIO-4-(1',N-PHENYL-3'-p-BROMOPHENYL PYRAZOL-4'-YL)-
1,2,3,4-TETRAHYDRO THIAZOLIDINO-[4,5-d]-PYRIMIDINES
Thiopyrimidines represent one of the most active classes of the compounds
possessing a wide spectrum of biological activities such as significant in vitro
activity against unrelated DNA and RNA viruses including polio and Herper
viruses, diuretic, antitubercular spermidical etc. These valid observation led us
to synthesise thiopyrimidines of type (VIII) by the condensation of 2-p-arylimino-
3-p-aryl-5-(1',N-phenyl-3'-p-bromophenyl-4'-pyrazolylmethino)-4-thiazolidinone
with thiourea in glacial acetic acid with fused sodium acetate.
The constitution of the newly synthesised compounds have been supported
by using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared with
standard drugs. Some compounds have been found to have moderate activity as
compared to known antibiotics recorded on Graphical Chart No. 8.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37 Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
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REACTION SCHEME
Type - (VIII) R = Aryl
N
N
Br
S
N
N R
R
NH NH
S
NH2
NH2
S
N
N
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S
N
N R
R
O
gl. acetic acid
CH3COONa
S
N N
RR
O +
N
N
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IR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-THIO-4-(1',N-PHENYL-3'-
p-BROMOPHENYL PYRAZOL-4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINON-[4,5-d]-
PYRIMIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2950 2975–2950 498
–CH
3
C – H str  (sym.) 2860 2880–2860 "
C – H i.p. (def.) 1448 1470–1435 "
C – H o.o.p (def.) 1384 1385–1370 "
Aromatic C – H str. 3043 3080–3030 503
C = C str. 1571 1585–1480 "
C – H i.p. (def.) 1114 1125–1090 "
1031 1070–1000 "
C – H o.o.p (def.) 829 835–810 ''
Pyrazole C = N str. 1624 1630–1590 499
moiety C – N str. 1205 1230–1020 "
C – Br str. 565 600–500 498
Pyrimidine C = S str. 750 750–700 502
ring N – H str. 3421 3500–3350 "
C – N str. 1560 1650–1550 "
C – S – C str. 785 800–700 "
Ether C – S – C str. (asym.) 1269 1275–1200 "
C – S – C str. (sym.) 1031 1075–1020 "
overlapped
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PMR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-THIO-4-(1',N-PHENYL-
3'-p-BROMOPHENYL PYRAZOL-4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-
PYRIMIDINE
Internal Standard : TMS; Solvent : CDCl3;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 2.36 3H singlet Ar-CH
3
2. 2.40 3H singlet Ar-CH
3
3. 6.87 Jkj=9 2H doublet Ar-Hkk'
4. 7.16 Jih=8.1 2H doublet Ar-Hii'
5. 7.33-7.38 5H multiplet Ar-Hc, Ar-Hhh'
Ar-Hff'
6. 7.48 2H triplet Ar-Hb,d
7. 7.56 Jgf=8.4 2H doublet Ar-Hgg'
8. 7.60 Jjk=8.7 2H doublet Ar-Hjj'
9. 7.74 2H doublet Ar-Ha,e
10. 7.77 1H singlet -CHy
11 8.08 1H singlet Ar-Hx
N
N
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S
N
N
NH NH
S
CH3
CH3
ab
c
d e
f
g
g'
f'
x
y
j'
k'
kj
h i
i'h'
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
-ARYL-2-THIO-4-(1',N-PHENYL-3'-p-BROMOPHENYL PYRAZOL-4'-YL)-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINE
[A] Synthesis of 2-p-Methylphenylimino-3-p-methylphenyl-5-(1',N-
phenyl-3'-p-bromophenyl-4'-pyrazolylmethino)4-thiazolidinone
See, [B] Part-I, Section-I [E].
[B] Synthesis of 6-p-methylphenylimino-7,N-p-methylphenyl-2-thio-4-
(1',N-phenyl-3'-p-bromophenyl pyrazol-4'-yl)-1,2,3,4-tetrahydro
thiazolidino-[4,5-d] pyrimidine
A mixture of 2-p-methylphenylimino-3-p-methylphenyl-5-(1',N-phenyl-3'-
p-bromophenyl-4'-pyrazolylmethino)-4-thiazolidinone (6.05, 0.01M) thiourea
(0.76gm, 0.01M) were taken in glacial acetic acid (20 ml) with fused sodium
acetate (1.25g, 0.015M). The reaction mixture was refulxed for 12 hrs. Cooled
and poured onto crushed ice. The solid thus obtained was filtered, dried and
crystallised from methanol-DMF. Yield, 4.3g, 72%, m.p. 186oC (C34H27BrN6S2
: Required : C: 61.53; H: 4.10; N: 12.66; Found : C: 61.50; H: 4.14; N: 12.70%)
TLC solvent system : Acetone : Benzene (2.5 : 7.5).
Similarly, other thiopyrimidines were prepared. The physical data are
recorded in Table No. 8.
[C] Antimicrobial activity of 6-Arylimino-7,N-aryl-2-thio-4-(1',N-
phenyl-3 ' -p-bromophenyl pyrazol-4 ' -yl) -1,2,3,4-tetrahydro-
thiazolidinon-[4,5-d]-pyrimidines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I, (F).
The zone of inhibition of the test solutions are recorded in Graphical Cahrt No.8.
Antitubercular  screening of the compounds of type (VIII) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I,
Section-I (F) and the percentage of inhibition data of the compounds are
recorded in Table No. 8a.
140
Molecular
Weight
4
R
2
M.P.
oC
5
% of Nitrogen
Calcd.
8
Found
9
TABLE NO. 8 : PHYSICAL CONSTANTS OF 6-ARYLIMINO-7,N-ARYL-2-THIO-4- [1 ' ,N-PHENYL-3 ' -p -
BROMOPHENYL PYRAZOL-[4,5-d] PYRIMIDINES
Sr.
No.
1
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
8a C
6
H
5
- C
32
H
23
BrN
6
S
2
635.6 194 0.56 74 13.22 13.26
8b 2-CH
3
-C
6
H
4
- C
34
H
27
BrN
6
S
2
663.6 132 0.54 71 12.66 12.62
8c 4-CH
3
-C
6
H
4
- C
34
H
27
BrN
6
S
2
663.6 186 0.63 72 12.66 12.70
8d 4-OCH
3
-C
6
H
4
- C
34
H
27
BrN
6
O
2
S
2
695.6 180 0.58 80 12.08 12.04
8e 4-Cl-C
6
H
4
- C
32
H
21
BrCl
2
N
6
S
2
704.4 126 0.65 73 11.93 12.97
8f 4-F-C
6
H
4
- C
32
H
21
BrF
2
N
6
S
2
671.5 134 0.55 70 5.66 12.70
8g 4-NO
2
-C
6
H
4
- C
32
H
21
BrN
8
O
4
S
2
725.5 190 0.60 82 15.44 15.40
8h 4-COOH-C
6
H
4
- C
34
H
23
BrN
6
O
4
S
2
723.6 120 0.67 76 11.61 11.65
8i 3-Cl,4-F-C
6
H
3
- C
33
H
19
BrCl
2
F
2
N
6
S
2
740.4 193 0.57 68 11.35 11.31
8j 2,4-di-Cl-C
6
H
3
- C
32
H
19
BrCl
4
N
6
S
2
773.3 182 0.59 84 10.87 10.83
8k 2,5-di-Cl-C
6
H
3
- C
32
H
19
BrCl
4
N
6
S
2
773.3 174 0.61 72 10.87 10.90
8l 3,4-di-Cl-C
6
H
3
- C
32
H
19
BrCl
4
N
6
S
2
773.3 196 0.56 66 10.87 10.85
*TLC Solvent System :Acetone : Benzene (2.5 : 7.5)
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BROMOPHENYL PYRAZOL-4’-YL)1,2,3,4-TETRAHYDRO
THIAZOLIDINO-[4,5-d]PYRIMIDINES
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B.coccus 12 10 11 20 13 18 10 15 14 10 16 11 17 21 16
B.subtilis 17 13 15 10 11 21 16 11 19 12 14 13 15 21 22
P.vulgaris 11 18 12 16 11 13 12 16 10 19 13 18 16 19 15
E.coli 14 10 20 14 15 10 18 15 11 14 12 11 19 18 20
A.niger 13 12 15 10 18 17 12 20 13 16 10 14 0 0 0
8a 8b 8c 8d 8e 8f 8g 8h 8i 8j 8k 8l Amoxycillin
Benzoy
lpenicill
in
Ciprofl
oxacin
E
143
RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
It has been observed from the experimental data that all compounds of type
(VIII) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However, comparatively good activity was observed in compounds with
R=4-methoxyphenyl and 4-fluorophenyl against B.coccus; R=4-fluorophenyl
and 3-chloro,4-fluorophenyl against B.subtilis.
In case of Gram negative bacterial strains, the maximum activity was
displayed by the compounds bearing R=2-methylphenyl, 2,4-dichlorophenyl and
3,4-dichlorophenyl against P.vulgaris. While the compounds bearing R=4-
chlorophenyl and 4-nitrophenyl have shown considerable activity against E.coli.
Antifungal activity :
The antifungal data revealed that compounds were least toxic to the fungal
strain. However mild activity was shown by the compounds bearing R=4-
carboxyphenyl against A.niger.
The antibacterial activity was compared with standard drugs viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
Antitubercular activity :
Al l  the  compounds  o f  type (VI I I )  showed mi ld  ac t iv i ty  aga ins t
Mycobacterium tuberculosis H37Rv,
The antitubercular activity data have been compared with standard
drug Rifampin.
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295491 BSA-113 C
6
H
4
- Alamar H
37
Rv >6.25 5 - Mic Rifampin =
0.25 µg/ml
@ 98% Inhibition
295492 BSA-114 2-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 21 -
295493 BSA-115 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295494 BSA-116 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 4 - "
295495 BSA-117 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 42 - "
295496 BSA-118 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 37 - "
295497 BSA-119 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 27 - "
295498 BSA-120 3-Cl,4-F-C
6
H
3
- Alamar H
37
Rv >6.25 28 - "
295499 BSA-121 2,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 0 - "
295500 BSA-122 2,5-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 14 - "
295501 BSA-123 3,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 16 - "
295502 BSA-124 4-COOH-C
6
H
4
- Alamar H
37
Rv >6.25 20 - "
Mtb
Strain
Mic
µg/ml
%
Inhib
Where,
R =
Activity
TABLE NO. 8a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
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                     PART-II
                  STUDIES ON
       CYANOPYRIDONES
INTRODUCTION
Cyanopyridones, which belongs to an important group of heterocyclic
compounds have been extensively explored for their applications in the field of
medicine, cyanopyridones, with a carbonyl group at position-2 and cyano group
at position-3 (I) have been subject of extensive study in recent past. Numerous
reports have appeared in the literature which highlight their chemistry and use.
SYNTHETIC ASPECTS
Different methods for preparation of cyanopyridones are as follows :
1. Rajul Jain et. al.359 have synthesised 3-cyano-2-pyridone by the reaction of
various enones with cyanoacetamide in presence of t-BuOK in DMSO under
O2 atmosphere.
2. K. Follkers and S. A. Harris360 have synthesised 3-cyano-2-pyridone by the
condensation of cyanoacetamide with 1,3-diketone or 3-ketoester.
R1
R2
R3
O
+
NH2 O
N
t-BuOK
DMSO
O2
N
H
R3
R2
R1 O
N
( II )
N
H
CH2OC2H5
N
O
CH3
O
NH2
N
+
O
CH3
H5C2OH2C
O
( III )
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3. W. Russel Bowman et. al.361 have synthesised cyanopyridone from 2,6-
dibromopyridine in presence of chlorotrimethylsilane and sodium iodide
in acetonitrile.
MECHANISM
The addition reaction between ethylcyanoacetale and α,β-unsaturated
ketone give cyanopyridone via Michael addition. Here, α,β−unsaturated
compound is known as acceptor and active methylene group containing
compound known as addender. It involves nucleophillic addition of carbanion
to the C=C of the acceptor.
THERAPEUTIC IMPORTANCE
Pyridone derivatives have been found to possess variety of therapeutic
activities as shown below.
1. Anticancer362
2. Antimicrobial363
3. Angitensin II antagonist364
N
H
O
N
N BrBr
( IV )
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4. Antiviral365
5. Anti HIV366
6. Herbicidal367
7. Pesticidal368
Salman A. S.369 has investigated cyanopyridone derivatives showing
interesting antifungal and antibacterial activities. Hussain Khan and co-
workers370,371 have prepared cyanopyridone derivatives (V) and (VI) and studied
their insecticidal and pesticidal activities.
Pednekar372 have documented antiviral, CNS depressant, bactericidal and
ulcer inhibitor activities of cyanopyridones. Upadhyay and co-workers373 have
formula ted cyanopyr idone der iva t ives  which showed ant i funga l  and
antileishmanial activities. E. Amer374  prepared 3-cyano-2-pyridone derivatives
(VII) displaying significant antimicrobial activity. Abou El-Fotooh and co-
workers375 have synthesised cyanopyridones (VIII) and reported them as
anticancer agent.
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 Coburn Craig et. al.376 have discovered some new pyridone derivatives as
thrombin inhibitors. M. G. Nizamuddin et. al.377 have prepared cynopyridone
derivatives (IX) and screened for their antifungal activity.
Recent ly ,  Nersesyan K.  e t .  a l .378  have inves t iga ted some new
cyanopyridones possessing genotoxic activity in marine cells and antitumor
activity. Xi Qi et. al.379 have investigated cyanopyridones useful as phosphatase
inhibitors and studied their biological activities. Darcq Michael. G. et. al.380 have
discovered some new cyanopyridone derivatives possessing antiviral activity,
Isobe Y. et. al.381 have prepared pyrimidine diones and evaluated them as
antiallergic agents.
Smith Terence382 has documented cyanopyridones useful as AMPA receptor
antagonists for the treatment of dimyelinating disorders and neurodenerative
disease. Devdas Balakudra et. al.383 have demonstrated pyridones as modulators
of P38 MAP kinase.
With an intension of preparing the compounds possessing better therapeutic
activity, we have undertaken the prepareation of cyanopyridones which have
been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
3-CYANO-4-[1',N-PHENYL-3'-p-BROMOPHENYL
P Y R A Z O L - 4 ' - Y L ] - 6 - A R Y L - 1 , 2 - D I H Y D R O - 2 -
PYRIDONES
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SECTION-I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-[1',N-
PHENYL-3'-p-BROMOPHENYL PYRAZOL-4'-YL]-6-ARYL-1,2-DIHYDRO-
2-PYRIDONES
The growing potent literature of recent years demonstrates that the
cyanopyridone derivatives are used as better therapeutic agents. Prompted by
these facts, the preparation of cyano pyridone derivatives of type (IX) by the
condensation of 1-aryl-3-[1',N-phenyl-3'-p-bromophenyl-pyrazol-4'-yl]-2-
propene-1-ones with ethylcyanoacetate in presence of ammonium acetate.
The constitution of the newly synthesised compounds have been supported
by using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared with
standard drugs. Some compounds have been found to have moderate activity as
compared to known antibiotics recorded on Graphical Chart No. 9.
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IR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-p-BROMOPHENYL PYRAZOL-
4'-YL)-6-p-ANISYL-1,2-DIHYDRO-2-PYRIDONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2975 2975–2950 498
–CH
3
C – H str  (sym.) 2869 2880–2860 "
C – H def. (asym.) 1465 1470–1435 "
C – H def. (sym.) 1367 1385–1350 "
Aromatic C – H str. 3070 3080–3030 503
C – H i.p. def. 1099 1125–1090 "
1056 1070–1000 "
C – H o.o.p def. 819 835–810 "
Pyrazole C = N str. 1610 1610–1590 499
moiety C = C str. 1527 1585–1480 ''
C – N str. 1344 1350–1200 "
C – Br str. 586 600–500 498
Ether C – O – C (asym.) 1238 1275–1200 503
C – O – C (sym.) 1029 1075–1020 "
Pyridone C ≡ N str. 2218 2240–2120 498
ring C = O str. 1732 1760–1655 "
N – H str. 3444 3450–3250 "
N – H def. 1593 1650–1580 "
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PMR SPECTRAL STUDY OF 3-CYANO-4-[1',N-PHENYL-3'-p-BROMOPHENYL PYRAZOL-
4'-YL]-6-ARYL-1,2-DIHYDRO-2-PYRIDONES
Internal Standard : TMS; Solvent : CDCl3;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 3.85 3H singlet Ar-OCH
3
2. 6.23 1H singlet CHy
3. 6.93-6.96 Jih=9 2H doublet Ar-Hii'
4. 7.38 1H triplet Ar-Hc
5. 7.45-7.53 4H multiplet Ar-Hhh'
Ar-Hb,Ar-Hd
6. 7.55-7.59 4H multiplet Ar-Hgg'
Ar-Ha,Ar-He
7. 7.81-7.84 Jfg=9 2H doublet Ar-Hff'
8. 8.59 1H singlet CHx
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-[1',N-
PHENYL-3'-p-BROMOPHENYL PYRAZOL-4'-YL]-6-ARYL-1,2-DIHYDRO-
2-PYRIDONES
(A) Synthesis  o f  N-phenylamine-α -methyl - α -p -bromophenyl
azomethine
See [B], Part-I, Section-I (A).
(B) Synthesis of 1,N-phenyl-3-p-bromophenyl-4-formyl pyrazole
See [B], Part-I, Section-I (B).
(C) Synthesis of 1-p-anisyl-3-(1',N-phenyl-3'-p-bromophenyl pyrazol-
4'-yl)-2-propene-1-one
To a well stirred solution of 1,N-phenyl-3-p-bromophenyl-4-formylpyrazole
(3.10g, 0.01M) and p-methoxyacetophenone (1.50g, 0.01M) in ethanol (25 ml),
40% NaOH added till the solution was basic. The reaction mixture was stirred for
24 hrs. The content was poured onto crushed ice, acidified, filtered and crystallised
from ethanol. Yield 3.71g, 81% m.p. 129oC. (C25H19BrN2O2 : required C, 65.37;
H, 4.17; N, 7.36 found C, 65.38; H, 4.15; N, 7.31%).
TLC solvent system : Acetone : Benzene (2 : 8).
(D) Synthesis of 3-Cyano-4-[1',N-phenyl-3'-p-bromophenyl pyrazol-4'-
yl]-6-p-anisyl-1,2,-dihydro-2-pyridone
A mixture of 1-p-anisyl-3-(1',N-phenyl-3'-p-bromophenyl-pyrazol-4'-yl)-2-
propene-1-one (4.59g, 0.01M) ethylcyanoacetate (1.13g, 0.01M) and ammonium
acetate (5.92g, 0.08M) in absolute alcohol (20 ml) was refluxed for 18 hrs. The
reaction mixture was poured onto crushed ice, filtered and crystallised from
ethanol Yield 3.6g, 79% m.p.>300oC. (C28H19N4O2Br : Required : C, 64.26;
H, 3.66; N, 10.70; Found : C, 64.21; H, 3.64; N, 10.65%).
Similarly, other substituted pyridones have been prepared. The physical
data are recorded in Table No. 9.
(E) Antimicrobial activity of 3-Cyano-4-(1',N-phenyl-3'-p-bromophenyl
pyrazole-4'-yl)-6-aryl-1,2-dihydro-pyridones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F).
The zone of inhibition of the test solution are recorded in Graphical Chart No. 9.
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TABLE NO. 9 : PHYSICAL CONSTANTS OF 3-CYANO-4-[1',N-PHENYL-3'-p-BROMOPHENYL PYRAZOL-4'-YL)-
6-ARYL-1,2-DIHYDRO-2-PYRIDONES
Sr.
No.
1
9a C
6
H
5
- C
27
H
17
BrN
4
O 493.3 164 0.82 76 11.36 11.32
9b 4-CH
3
-C
6
H
4
- C
28
H
19
BrN
4
O 507.3 210 0.79 69 11.04 11.00
9c 4-OCH
3
-C
6
H
4
- C
28
H
19
BrN
4
O
2
523.3 >300 0.86 79 10.70 10.65
9d 4-Cl-C
6
H
4
- C
27
H
16
BrClN
4
O 527.7 155 0.81 67 10.62 10.66
9e 4-F-C
6
H
4
- C
27
H
16
BrFN
4
O 511.3 138 0.75 72 10.96 10.94
9f 4-Br-C
6
H
4
- C
27
H
16
Br
2
N
4
O 572.2 178 0.83 68 9.79 10.77
9g 3-NO
2
-C
6
H
4
- C
27
H
16
BrN
5
O
3
538.3 140 0.84 74 13.01 13.03
9h 4-NO
2
-C
6
H
4
- C
27
H
16
BrN
5
O
3
538.3 150 0.77 75 13.01 13.05
9i 4-NH
2
-C
6
H
4
- C
27
H
18
BrN
5
O 508.3 148 0.76 58 13.78 13.74
9j 2-OH-C
6
H
4
- C
27
H
17
BrN
4
O
2
509.3 136 0.68 62 11.00 11.04
9k 4-OH-C
6
H
4
- C
27
H
17
BrN
4
O
2
509.3 160 0.78 73 11.00 11.03
9l 2,4-(Cl)
2
-C
6
H
3
- C
27
H
15
BrCl
2
N
4
O 562.2 180 0.74 59 9.96 9.92
*TLC Solvent System :Ethyl acetate : Hexane (1 : 8)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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B.coccus 15 18 12 10 13 18 11 15 19 12 10 11 17 21 16
B.subtilis 12 19 13 11 14 17 10 20 17 12 14 13 15 21 22
P.vulgaris 17 14 20 10 17 11 14 18 10 18 13 15 16 19 15
E.coli 16 11 10 18 14 15 17 12 13 11 16 12 19 18 20
A.niger 11 17 14 15 13 21 10 14 11 16 10 17 0 0 0
9a 9b 9c 9d 9e 9f 9g 9h 9i 9j 9k 9l Amoxycillin
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GRAPHICAL CHART NO. 9 :  3-CYANO-4-(1’,N-PHENYL-3’-p-BROMOPHENYL-PYRAZOL-4’-
                                                         YL)-6-ARYL-1,2-DIHYDRO-2-PYRIDONES
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
It has been concluded from the experimental data that all the cyanopyridones
of type (IX) are active against different strains of Gram positive and Gram negative
bacteria.
The signif icant activity was observed in compounds bearing R=4-
methylphenyl, 4-bromophenyl and 4-aminophenyl against B.coccus and
B.subtilis.
The maximum activi ty was observed in compounds bearing R=4-
methoxyphenyl, 4-nitrophenyl and 2-hydroxyphenyl against P.vulgaris and R=4-
chlorophenyl against E.coli.
Antifungal activity :
All the compounds exhibited mild activi ty against A.niger  except
compounds bearing R=4-bromophenyl which showed good activity against
A.niger.
                    PART-III
                  STUDIES ON
         IMIDAZOLINONES
INTRODUCTION
Imidazolinone is a five membered heterocycle having 2-nitrogen atoms
at the 1 and 3-positions and C=O group at following positions : 2-oxo-imidazoline
(I), 4-oxo-imidazoline (II), 5-oxo-imidazoline (III).
A. W. Hoffmann384 for the first time discovered 5-oxo-imidazoline by
heating N'-diacetylethylene diamine in a stream of dry hydrogen chloride.
Moreover  some compounds were prepared by A. Ladenburg385 by the fusion of
two equivalents of sodium acetate with one equivalent of ethylene diamine
dihydrochloride.
SYNTHETIC ASPECT
Various methods have been reported for the synthesis of imidazolinones
in literature. Aminolysis of oxazolone with amine leads to the formation of
imidazolinones which have been reported in literature386.
1. Hisato Takeuchi et al.387 have synthesised imidazolinones by the reaction
of azido substituted imides with triphenylphosphine or tributylphosphine.
N
N
H
O
N
N
H
O
N
N
H
O
1
2
34
5
1
2
34
5
1
2
34
5
(III)(II)(I)
R3
N3
O
N
R2
O
R1
Ph3P  or Bu3P
N
R3
O
R2
R1
(IV)
159
2. Jean Michel Lerestif et. al.388 have synthesised imidazolinone from α-
aminoester.
3. Rao Y. S. and Filler R389 have prepared 2-arylimidazolin-5-ones by the
treatment of an oxazolone intermediate with an aryl / alkylamine.
MECHANISM
Azalactone reacts with variety of compounds such as water, alcohol, amines
and hydrogen halides. Amides of α-acylamino acrylic acids obtained from the
condensat ion of  aza lac tone and pr imary amine can be conver ted to
imidazolinones as shown under.
The ring closure can be effected under a variety of conditions. Substituted
anilides have been converted to imidazolinone derivatives by the action of POCl3.
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N R4
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THERAPEUTIC IMPORTANCE
Imizapyr is a broad spectrum imidazolinone herbicide used to kill unwanted
plants in industrial sites, coniferous forests, railroad rights of way, rubber
plantations, oil palm plantation and sugarcane. Imazapyr kills plants by inhibiting
the enzyme used when plant synthesise branched chain amino acids. The name
of this enzyme is acetohydroxyacid syntheses.390 Various imidazolinones are
known to exhibit a broad spectrum of biological activities such as.
1. Antitubercular391
2. Antiviral392
3. Antiinflammatory393-395
4. Antimicrobial396
5. Anticonvulsant397,398
6. Antiparkinsonian399,400
7. Anthelmintic401
8. Antihistaminic402
9. Anticancer403,404
10. Antidiabetic405
11. Bactericidal406,407
12. Fungicidal408,409
13. Glucogon Antagonists410
14. Hypertensive411
15. Insecticidal412
16. Potent CNS depressant413,414
17. Sedative and hypnotics415
18. Thrombin inhibitor416
Siew Siew Pang et. al.417 have discovered some new imidazolinone
derivatives and reported their herbicidal activity. Imam Hidayat et. al.418 have
reported ALS-inhibitory activity of imidazolinones. Keun-Jin Oh et. al.419 have
investigated some imidazolinone derivatives abolished the enzymatic activity as
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well as the binding affinity for the cofactor FAD (Flavin adenine dinucleotide).
Rama Sharma and co-workers420 have formulated 5-oxo-imidazolines possessing
potential antimicrobial activity. Solankee A.421 have synthesised some
imidazolinone derivatives (VII) and screened for their anticancer activity.
Yehudit Zohar et. al.422 have discovered some imidazolinone derivatives
and studied their antituberculosis activity. Armando Rossello et. al.423 have found
that imidazolinones are potential antifungal agent. Muchii Dalsuke et. al.424 have
synthesised new imidazolones as a telomerase inhibitors and antitumor agents.
Mimi L. Quan et. al.425 have synthesised imidazolinone derivatives (VIII) as
nonpeptide angiotensin II receptor antagonists.
Jean M. R. et. al.426 have discovered imidazolinones and tested as
antileishmanial agents. Irene M. L. et. al.427 have investigated some imidazolinone
derivatives possessing antireteroviral activity. Lee Jin Ho et. al.428 have formulated
imidazolinones and tested for their anticancer activity. Ozaki Satoshi et. al.429
have reported imidazolinones useful as analgesic and antagonists. Wepplo Peter
John et. al.430 have prepared imidazolinones showing herbicidal activity. El-Sayed
A. S.431 has synthesised imidazolinone derivatives (IX) and screened for their
antibacterial and antifungal activities.
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Recently, Dung Tien Le et. al.432 have reported imidazolinones as
herbicide. Hashmukh Joshi and co-workers433 have isolated imidazolinones and
tested for their anticonvulsant and antimicrobial activity. Yong In Kuk et. al.434
have investigated some imidazolinones and reported them an herbicides and
Acetolactuse synthease (ALS) inhibitor. Declera et. al.435 have documented anti
HIV activity of some new imidazoline derivatives. Ding Ming-Wu et. al.436 have
discovered imidazolinones and studied their antifungal activity. C. Alister and
co-workers437 have documented herbicidal activity of imidazolinone derivatives.
Aleksey N. Vasiliev et. al.438 have synthesised imidazolinone derivatives (X) and
reported their herbicidal activity.
With a view to getting better therapeutic agents, it was contemplated to
synthesise imidazolinones  to enhance the overall activity of resulting compound
which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1,N-ARYL-2-ALKYL/ARYL-4-(1' ,N-PHENYL-3'-p-
BROMOPHENYL-4 ' -PYRAZOLYL METHINO)-
IMIDAZOLIN-5-ONES
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SECTION-I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-ALKYL/
ARYL -4 - ( 1 ' ,N -PHENYL -3 ' - p -BROMOPHENYL -4 ' -PYRAZOLYL
METHINO)-IMIDAZOLIN-5-ONES
Imidazolinone derivatives occupy a unique place in field of medicinal
chemistry due to wide range of biological activities exhibited by them. Looking
at the interesting therapeutic activity of imidazolinones it was considered to
synthesise a series of imidazolinones of type (X) for obtaining biologically potent
agents which were prepared by the condensation of azalactone with different
aromatic amines.
The constitution of the synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have moderate activity
as compared to known antibiotics recorded on Graphical Chart No. 10.
The synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37 Rv at concentration of 6.25 µg/ml using Rifampin as standard
drug.
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IR SPECTRAL STUDY OF 1,N-p-METHYLPHENYL-2-PHENYL-4-(1',N-PHENYL-3'-p-
BROMOPHENYL-4'-PYRAZOLYL METHINO)-IMIDAZOLIN-5-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2952 2975–2950 498
–CH
3
C – H str  (sym.) 2860 2880–2860 ''
C – H i.p. (def.) 1436 1470–1435 "
C – H o.o.p (def.) 1382 1385–1370 "
Aromatic C – H str. 3064 3080–3030 503
C = C str. 1508 1520–1480 "
C – H i.p. (def.) 1098 1125–1090 "
1038 1070–1000 "
C – H o.o.p (def.) 837 835–810 ''
Pyrazole C = N str. 1596 1610–1590 499
moiety C – N str. 1218 1230–1220 "
C – Br str. 530 600–500 498
Imidazolinone C = O str. 1670 1770–1655 "
ring C = N str. 1631 1650–1550 "
C – N str. 1244 1260–1220 "
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PMR SPECTRAL STUDY OF 1,N-METHYLPHENYL-2-PHENYL-4-(1',N-PHENYL-3'-p-
BROMOPHENYL-4'-PYRAZOLYL METHINO)-IMIDAZOLIN-5-ONE
Internal Standard : TMS; Solvent : CDCl3 ;  Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 2.34 3H singlet Ar-CH
3
2. 7.17-7.20 Jhi=9 2H doublet Ar-Hhh'
3. 7.23 1H singlet Ar-Hl
4. 7.30-7.33 Jih=9 2H doublet Ar-Hii'
5. 7.41-7.44 Jgf=9 2H doublet Ar-Hgg'
6. 7.51-7.60 8H multiplet ArHa,b,d,e
Ar-Hj,k,m,n
7. 7.66 1H triplet Ar-Hc
8. 7.77-7.79 Jfg=7.5 2H doublet Ar-Hff'
9. 8.20 1H singlet Ar-Hx
10. 8.77 1H singlet Hy
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-ALKYL/
ARYL-4-(1',N-PHENYL-3'-p-BROMOPHENYL-4'-PYRAZOLMETHINO)-
IMIDAZOLIN-5-ONES
(A) Sythesis of 1,N-Phenyl-3-p-bromophenyl-4-formyl pyrazole
See [B], Part-I, Section-I (B).
(B) Synthesis of  2-Phenyl-4-(1 ' ,N-phenyl-3 ' -p-bromophenyl-4 ' -
pyrazolylmethino)-oxazolin-5-one
A mixture of 1,N-phenyl-3-p-bromophenyl-4-formyl pyrazole (3.26g,
0.01M), acetic anhydride (7.6ml, 0.075M), sodium acetate (2.0g, 0.025M) and
hippuric acid (4.4g, 0.025M) was heated on waterbath for 4 hrs. Resulting mass
was poured onto crushed ice, filtered, washed with hot water and crystallised
from DMF. Yield, 2.31g, 71%, m.p. 152oC, (C25H16BrN3O7 : Required C: 63.84;
H: 3.43; N: 8.93; Found C : 63.80; H: 3.47; N: 8.97%).
TLC solvent system : Ethylacetate : Hexane (2 : 8)
(C) Synthesis of 1,N-Methylphenyl-2-phenyl-4-(1',N-phenyl-3'-p-
bromophenyl-4'-pyrazolylmethino)-imidazolin-5-one
A mixture of 2-phenyl-4-(1',N-phenyl-3'-p-bromophenyl-4'-pyrazolyl
methino)-oxazolin-5-one (4.70g, 0.01M) and p-toludine (1.07g, 0.01M) in dry
pyridine (20 ml) was refluxed for 12 hrs. Resulting mass was poured onto crushed
ice and neutralised with HCl, filtered and crystallised from DMF. Yield, 3.24g,
69%, m.p. 250oC (C32H23BrN4O : Required C: 68.72; H: 4.14; N: 10.01; Found
C: 68.76; H: 4.10; N: 10.05%).
TCL solvent system : Acetone : Benzene (1.5 : 8.5).
Similarly, other imidazolin-5-ones have been prepared. The physical data
are recorded in Table No. 10.
(D) Antimicrobial activity of 1,N-Aryl-2-alkyl/aryl-4-(1',N-phenyl-3'-p-
bromophenyl-4'-pyrazolylmethino)-imidazolin-5-ones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 10
Antitubercular  screening of the compounds of type (X) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I,
Section-I (F) and the percentage of inhibition data of the compounds are
recorded in Table No. 10a.
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TABLE NO. 10 : PHYSICAL CONSTANTS OF 1,N-ARYL-2-ALKYL/ARYL-4-(1',N-PHENYL-3'-p-BROMOPHENYL-4'-
PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONES
Sr.
No.
1
10a 4-CH
3
-C
6
H
4
- C
32
H
23
BrN
4
O 559.4 250 0.64 69 10.01 10.05
10b 2-OCH
3
-C
6
H
4
- C
32
H
23
BrN
4
O
2
575.4 160 0.69 72 9.74 9.70
10c 4-OCH
3
-C
6
H
4
- C
32
H
23
BrN
4
O
2
575.4 144 0.72 85 9.74 9.78
10d 3-Cl-C
6
H
4
- C
31
H
20
BrClN
4
O 579.8 150 0.80 63 9.66 9.62
10e 4-Cl-C
6
H
4
- C
31
H
20
BrClN
4
O 579.8 158 0.68 76 9.66 9.68
10f 4-F-C
6
H
4
- C
31
H
20
BrFN
4
O 563.4 194 0.75 65 9.94 9.98
10g 3-NO
2
-C
6
H
4
- C
31
H
20
BrN
5
O
3
590.4 120 0.77 88 11.86 11.82
10h 4-NO
2
-C
6
H
4
- C
31
H
20
BrN
5
O
3
590.4 155 0.74 74 11.86 11.88
10i 3-Cl,4-F-C
6
H
3
- C
31
H
19
BrClFN
4
O 597.8 130 0.67 66 9.37 9.33
10j 2,4-di-CH
3
-C
6
H
3
- C
33
H
25
BrN
4
O 573.4 180 0.81 75 9.77 9.73
10k 2,4-di-Cl-C
6
H
3
- C
31
H
19
BrCl
2
N
4
O 614.3 150 0.73 67 9.12 9.16
10l 3,4-di-Cl-C
6
H
3
- C
31
H
19
BrCl
2
N
4
O 614.3 126 0.84 82 9.12 9.08
*TLC Solvent System : Acetone : Benzene  (1.5 : 8.5)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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B.coccus 20 11 9 10 13 17 16 14 12 17 10 11 17 21 16
B.subtilis 16 17 14 11 8 18 17 12 14 15 13 9 15 21 22
P.vulgaris 16 17 13 11 18 12 10 17 11 10 13 15 16 19 15
E.coli 14 11 13 10 17 19 12 16 14 17 12 9 19 18 20
A.niger 17 18 10 15 15 20 14 12 8 11 19 12 0 0 0
10a 10b 10c 10d 10e 10f 10g 10h 10i 10j 10k 10l Amoxycillin
Benzoy
lpenicill
in
Ciprofl
oxacin
E
m
GRAPHICAL CHART NO. 10 :  1,N-ARYL-2-ALKYL/ARYL-4-(1’,N-PHENYL-3’-p-BROMOPHENYL
                                                           -4’-PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONES
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
From the experimental data it has been concluded that the compounds
bearing R=4-methylphenyl, 4-fluorophenyl and 2,4-dimethylphenyl have
displayed considerable activity against B.coccus. The compounds bearing R=2-
methoxyphenyl, 4-fluorophenyl and 3-nitrophenyl have shown maximum activity
against B.subtilis.
In case of Gram negative bacterial strains, the significant activity was
displayed by the compounds bearing R=2-methoxyphenyl, 4-chlorophenyl and
4-nitrophenyl against P.vulgaris  and R=4-chlorophenyl, 4-fluorophenyl and
2,4-dimethylphenyl against E.coli.
Antifungal activity :
All the compounds displayed mild activity except compound bearing R=4-
fluorophenyl against A.niger.
The antibacterial activity was compared with standard drugs viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
Antitubercular activity :
Almost all compounds were found to be less active against Mycobacterium
tuberculosis H37Rv except 2-methoxyphenyl.
The antitubercular activity data have been compared with standard drug
Rifampin.
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Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295515 BSA-137 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 49 - Mic Rifampin =
0.25 µg/ml
@ 98% Inhibition
295516 BSA-138 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 32 -
295517 BSA-139 2-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 84 - "
295518 BSA-140 2,4-(CH
3
)
2
-C
6
H
3
-Alamar H
37
Rv >6.25 15 - "
295519 BSA-141 2,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 37 - "
295520 BSA-142 3,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 56 - "
295521 BSA-143 3-Cl,4-F-C
6
H
3
- Alamar H
37
Rv >6.25 34 - "
295522 BSA-144 3-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 10 - "
295523 BSA-145 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 10 - "
295524 BSA-146 3-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 15 - "
295525 BSA-147 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 55 - "
295526 BSA-148 4-F-C
6
H
4
- Alamar H
37
Rv >6.25 50 - "
Mtb
Strain
Mic
µg/ml
%
Inhib
Where,
R =
Activity
TABLE NO. 10a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
NN
Br
N
N
R2
R1
O
                     PART-IV
                  STUDIES ON
                          NITRILES
INTRODUCTION
Nitriles are reported to possess various therapeutic activities but due to
their high toxicity, they have low therapeutic importance. The term "Nitrile" was
first introduced by Febung439 in 1844. The first synthesis of nitrile has been
reported by Wholer and Liebig440 in 1832 and poleuze441 in 1834. They are
very much useful as intermediates for various products such as acrylonitrile for
plastic synthetic rubber and fibers, phthalo nitrile for dye stuff. The simplest form
of the organic nitriles is acetonitrile, often used as a solvent. Moreover nitrile
gloves are also available which reduces pesticide and other hazardous chemicals
exposure on your hands.
SYNTHETIC ASPECTS
Few recent methods for the preparation of nitriles are as mentioned below.
1. E. A. Letts442 has synthesised nitriles by the condensation of aromatic acids
with metal thiocyanates.
2. Biswanath Das et. al.443 have prepared nitriles from aryl/alkyl aldehydes
on treatment with NH2OH
.HCl under microwave irradiation in presence of
NaHSO4
/ SiO2 / HY-zeolite or silica chloride.
3. Stephen A. Dibiase et. al.444 have synthesised E-& Z-cinnamonitrile from
aryl aldehyde or ketones in presence of acetonitri le and potassium
hydroxide.
R COOH + KSCN R CN + CO2 + KHS
(II)
(I)
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R CHO
NH2OH.HCl
catalyst
R CN
Ar CHO
CH3CN
KOH
Ar
N
(III)
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MECHANISM
The mechanism of nitrile is shown as under.
THERAPEUTIC IMPORTANCE
They shows various therapeutic activities which are described as under.
1. Antihypertensive445
2. Antimicrobial446
3. Antihypoxic447
4. Antiinflammatory448
5. Antiarrythemic449
6. Central nervous system agent450
7. Fungicidal451
8. Pesticidal452
Shibata yasushi and co-workers453 have reported nitriles as insecticides.
Parlo Sanna et. al.454 have synthesised nitriles (IV) and screened for their
ant i tubercular  act iv i ty.  Yogihara and co-workers455 have documented
antimicrobial and antiinflammatory activity of nitriles. Nosyrava et. al.456 have
formulated novel nitriles possessing muscle relaxant activity. Valmajer Juliya et.
al.457 have tested some new nitriles as anticonvulsant agent. Collin Xavier and
co-workers458 have synthesised nitriles and screened for their antifungal activity.
O
H
R
+ CN
OH
CN
R
OH
CN
H
R
R1-NH2
-H2O
NH
CN
H
R
R1
H+
..
1
Suzana Jovanovic et. al.459 have suggested antiestrogenic activity of some
nitrile derivatives. Bernard M. et. al.460 have investigated nitriles as thromboxane
receptor antagonists. Iwanowicz E. J. et. al.461 have synthesised nitriles (V) and
found preventing and treating IMPDH associated disorders, such as transplant
rejection and autoimmune disease.
Recently, Olivier Nicolas and co-workers462 have discovered nitrile
derivatives possessing moderate antimalarial activity. S. Srinivasan et. al.463 have
investigated nitriles which showed antimicrobial activity. Ian J. S. Fairlamb et.
al.464 have prepared nitrile derivatives and tested for their antimicrobial activity.
M. Hiroshi et. al.465 have investigated some new nitriles and studied their pesticidal
and marinantifouling activity.
Nurolaini Kifli et. al.466 have discovered nitriles and reported their antiviral
activity. Marion Nipper et. al.467have prepared nitriles useful as antimicrobial
agent .  Miros lav Otmar e t .  a l . 468 have formulated n i t r i les  possess ing
antiproliferative activity.
N
N
N
NH2
N
(IV)
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N N
N
NH2
S
CH3
N
(V)
CONTRIBUTION FROM OUR LABORATORY
F. M. Bharmal and H. H. Parekh469 have synthesised newer acetonitriles
(VI) bearing quinoline moiety and tested them as antimicrobial agent.
Looking to the interesting properties of nitriles, we have synthesised some
new nitriles, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF α-
ARYLAMINO-(1',N-PHENYL-3'-p-BROMOPHENYL-
4'-PYRAZOLYL)-ACETONITRILES
(VI)
N Cl
N
NH
R
CH3
R = Aryl
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SECTION-I
SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-
(1',N-PHENYL-3'-p-BROMOPHENYL-4'-PYRAZOLYL)-ACETONITRILES
Recently much interest has been focused on the synthesis and biodynamic
activities of nitriles. With an intention for preparing  agents with better therapeutic
potency, the nitriles of type (XI) have been synthesised by the reaction of 1,N-
phenyl-3-p-bromophenyl-4-formyl pyrazole with different aromatic amines in the
presence of potassium cyanide and glacial acetic acid at 0-5oC.
The constitution of the synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg. The biological activities of the synthesised compounds have been
compared with standard drugs. Some compounds have been found to have
moderate activity as compared to known antibiotics recorded on Graphical Chart
No. 11.
The synthesised compounds have been screened for their in vitro
biological assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37 Rv at concentration of 6.25 µg/ml using Rifampin as standard
drug.
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R = ArylType - (XI)
NN
Br
NH NR
REACTION SCHEME
NN
Br
NH NR
R NH2
KCN
gl.CH3COOH
0-5  C
o
NN
Br
CHO
DMF
POCl3
N
CH3
NH
Br
Methanol
gla. CH3COOH
NH2NH
O
Br
CH3
+
Type - (XI) R = Aryl
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IR SPECTRAL STUDY OF α-p-ANISYLAMINO-(1',N-PHENYL-3'-p-BROMOPHENYL-4'-
PYRAZOLYL)-ACETONITRILE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2950 2975–2950 498
–CH
3
C – H str  (sym.) 2875 2880–2860 "
C – H i.p. (def.) 1461 1470–1435 "
C – H o.o.p (def) 1361 1385–1370 "
Aromatic C – H str. 3066 3080–3030 503
C = C str. 1512 1585–1480 "
C – H i.p. (def.) 1128 1125–1090 "
1028 1070–1000 "
C – H o.o.p (def.) 831 835–810 "
Pyrazole C = N str. 1602 1610–1590 499
moiety C – N str. 1226 1230–1220 ''
C – Br str. 582 600–500 498
Nitrile C ≡ N str. 2237 2240–2220 500
N – H str. (sym.) 3319 3350–3200 ''
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NN
Br
NH
N
H3CO
PMR SPECTRAL STUDY OF α-p-ANISYLAMINO-(1',N-PHENYL-3'-p-BROMOPHENYL-
4'-PYRAZOLYL)-ACETONITRILE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 3.79 3H singlet Ar-OCH
3
2. 5.29 1H singlet -CHy (nitrile)
3. 6.78-6.81 Jih=9 2H doublet Ar-Hii'
4. 6.87-6.90 Jhi=9 2H doublet Ar-Hhh'
5. 7.09-7.14 2H triplet Ar-Hb,Ar-Hd
6. 7.36 1H triplet Ar-Hc
7. 7.47-7.53 2H triplet Ar-Ha,Ar-He
8. 7.75-7.82 2H + 2H multiplet Ar-Hff',Ar-Hgg'
9. 8.31 1H singlet Ar-Hx
NN
Br
NH
N
H3CO
a
b
c
d
e
x
f g
g'f'
y
h'i'
hi
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EXPANDED AROMATIC REGION
NN
Br
NH
N
H3CO
a
b
c
d
e
x
f g
g'f'
y
h'i'
hi
NN
Br
NH
N
H3CO
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N
N
N H
O
CH 3
N
B r
N
N
N
O
CH 3
B r
N
N
N
CH 3
m/z=459
N
N
N H
O
CH 3
B r
m/z=434
m/z=432
m/z=416
N N
N H 2
N
+
m/z=352
NH
N
N H
O
CH 3
m/z=279
NH
N
N H
O
CH 3
N
m/z=230
NH
N
H
N H
N H 2
m/z=206
NH
N H 2
N H
N
m/z=190
CH 3
N HO
CH 3
N
m/z=176
BASE PEAK
+
+
+
+
+
++
+
+
+
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-
(1',N-PHENYL-3'-p-BROMOPHENYL-4'-PYRAZOLYL)-ACETONITRILES
(A) Sythesis of N-phenylamine-α-methyl-α-p-bromophenyl azomethine
See [B], Part-I, Section-I (A)
(B) Synthesis of 1,N-phenyl-3-p-bromophenyl-4-formyl pyrazole
See [B], Part-I, Section-I (B)
(C) Synthesis of α -p-Anisylamino-1,N-phenyl-3-p-bromophenyl
pyrazol-4-yl-acetonitrile
1,N-pheny-3-bromophenyl-4-formyl pyrazole (3.26g, 0.01M) dissolved in
ethanol (25ml) was added to potassium cyanide (0.64g, 0.01M) dissolved in water
(15 ml) followed by glacial acetic acid (12 ml). The contents were then stirred for
5 minutes to form cyanohydrine at 0oC. p-Anisidine (1.23g, 0.01M) dissolved in
methanol was added to the reaction mixture, contents were stirred at room
temperature for  24 hrs. The content was poured onto curshed ice. The solid
product was filtered and crystallised from ethanol. Yield, 2.78g, 85%, m.p. 154oC,
(C24H19BrN4O : Required : C : 62.75; H, 4.17; N, 12.20; Found C, 62.71; H,
4.21; N, 12.24%).
TLC solvent system : Acetone : Benzene (1 : 9)
Similarly other nitriles were prepared. The physical data are recorded in
Table No. 11.
(D) Antimicrobial activity of α−Arylamino-1,N-phenyl-3-p-bromophenyl
pyrazol-4-yl-acetonitriles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 11.
Antitubercular  screening of the compounds of type (XI) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-I
(F) and the percentage of inhibition data of the compounds are recorded in Table
No. 11a.
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TABLE NO. 11 : PHYSICAL CONSTANTS OF α-ARYLAMINO-(1'-N-PHENYL-3'-p-BROMOPHENYL-4'-PYRAZOLYL)-
ACETONITRILES
Sr.
No.
1
11a 2-CH
3
-C
6
H
4
- C
24
H
19
BrN
4
443.3 164 0.82 72 12.64 12.61
11b 4-CH
3
-C
6
H
4
- C
24
H
19
BrN
4
443.3 184 0.85 77 12.64 12.68
11c 4-OCH
3
-C
6
H
4
- C
24
H
19
BrN
4
O 459.3 154 0.77 85 12.20 12.24
11d 3-Cl-C
6
H
4
- C
23
H
16
BrClN
4
463.7 172 0.69 62 12.08 12.12
11e 4-Cl-C
6
H
4
- C
23
H
16
BrClN
4
463.7 169 0.84 66 12.08 12.04
11f 2-F-C
6
H
4
- C
23
H
16
BrFN
4
447.3 127 0.85 79 12.53 12.57
11g 4-F-C
6
H
4
- C
23
H
16
BrFN
4
447.3 172 0.67 80 12.53 12.49
11h 4-Br-C
6
H
4
- C
23
H
16
Br
2
N
4
508.2 178 0.83 73 11.02 11.06
11i 3-Cl,4-F-C
6
H
3
- C
23
H
15
BrClFN
4
481.7 146 0.76 78 11.63 11.67
11j 2,4-di-CH
3
-C
6
H
3
- C
25
H
21
BrN
4
457.3 140 0.75 84 12.25 12.21
11k 3,4-di-Cl-C
6
H
3
- C
23
H
15
BrCl
2
N
4
498.2 155 0.74 69 11.25 11.21
11l 2,5-di-Cl-C
6
H
3
- C
23
H
15
BrCl
2
N
4
498.2 128 0.82 76 11.25 11.29
*TLC Solvent System :Acetone : Benzene (1 : 9) (11a - 11l)
(4 : 6) (11c, 11i, 11j, 11k)
Rf*
Value
6
Yield
%
7
Molecular
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B.coccus 13 17 19 13 11 12 10 11 17 18 13 12 17 21 16
B.subtilis 18 17 10 12 11 15 11 10 13 19 17 10 15 21 22
P.vulgaris 13 11 17 18 12 14 16 15 17 18 13 11 16 19 15
E.coli 12 10 11 16 14 18 12 10 18 13 12 10 19 18 20
A.niger 13 18 14 16 17 19 15 20 18 14 13 13 0 0 0
11a 11b 11c 11d 11e 11f 11g 11h 11i 11j 11k 11l Am oxycillin
Benzoy
lpenicill
in
Ciprofl
oxacin
E
m
GRAPHICAL CHART NO. 11  :  á-ARYLAMINO-(1’,N-PHENYL-3’-p-BROMOPHENYL-4’-
                                                            PYRAZOLYL)-ACETONITRILES
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
It has been observed from the experimental data that all compounds of type
(XI) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
Almost all compounds were found to be inactive against B.coccus except
R=2,4-dimethylphenyl. However, comparatively good activity was observed in
compounds with R=2-methylphenyl and 2,4-dimethylphenyl against B.subtilis.
The compounds bearing R=3-chlorophenyl and 2,4-dimethylphenyl have
shown good activity against P.vulgaris. The highest activity was observed in
compounds bearing R=2-fluorophenyl and 2,5-dichlorophenyl against E.coli.
Antifungal activity :
All the compounds exhibit ied mild activity against A.niger  except
compound bearing R=4-bromophenyl which showed good activity against
A.niger.
The antibacterial activity was compared with standard drugs viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
Antitubercular activity :
All the compounds displayed mild activity except compounds bearing R=3-
chloro,4-f luorophenyl and 3,4-dichlorophenyl against Mycobacterium
tuberculosis H37Rv,
The antitubercular activity data have been compared with standard drug
Rifampin.
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Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295455 BSA-77 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 40 - Mic Rifampin =
0.25 µg/ml
@ 98% Inhibition
295456 BSA-78 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 14 -
295457 BSA-79 2-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 14 - "
295458 BSA-80 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295459 BSA-81 3-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 18 - "
295460 BSA-82 2-F- C
6
H
4
- Alamar H
37
Rv >6.25 40 - "
295461 BSA-83 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 20 - "
295462 BSA-84 4-Br- C
6
H
4
- Alamar H
37
Rv >6.25 39 - "
295463 BSA-85 3-Cl, 4-F-C
6
H
3
- Alamar H
37
Rv >6.25 61 - "
295464 BSA-86 2,4-(CH
3
)
2
-C
6
H
3
-Alamar H
37
Rv >6.25 22 - "
295465 BSA-87 3,4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 70 - "
295466 BSA-88 2,5-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 28 - "
Mtb
Strain
Mic
µg/ml
%
Inhib
Where,
R =
Activity
TABLE NO. 11a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
NN
Br
NH NR
                               [C]
STUDIES  ON  MICROWAVE
INDUCED SYNTHESIS OF
       2,3-DIHYDRO-1,3,4-
THIADIAZOLOTRIAZOLES
INTRODUCTION
The term microwave was introduced just before World war-II. Microwave
radiation is a descriptive term used to identity electromagnetic waves in frequency
spectrum ranging from 1 Giga Hertz (109 Hz) to 30 Giga Hertz. These waves
present several interesting and unusual features not found in other portions of
the electromagnetic spectrum. These features make"microwaves" uniquely suitable
for several useful applications like industrial, scintific, domestic and medicinal.
In recent years, the application of microwave heating in organic chemistry
are of much interest. In the era of global warming, Microwave assisted reactions
are of very much enviromently friendly as compared to conventional reactions.
The advantages of microwave heating are decreased in rate of reaction and time,
cleaner reactions, easier work up and better yields. It is also generally observed
that the purity of products is improved due to shorter reaction period at high
temperature and the absence of local overheating on the reaction walls which
occurs under conventional heating.
Microwave heating is distinguished primarily by being a radiant process. Its
relationship to ordinary heat is of much interest. Regular heat rays differ in
frequency and properties. In the conventional method, heat is generated by
molecular collisions which accomplish the energy transfer while microwaves cause
heating through the absorption of energy quanta. Microwave generate
instantaneous " incore" heating of materials, in a homogeneous and selective
manner, especially those with poor heat conduction properties.
When molecules with permanent dipole are submitted to an electric field,
they become aligned. If this field oscillates, the orientation changes at each
alternation. The strong agitation provided by the reorientation of molecules, in
phase with the electrical field excitation, caused an intense internal heating, upto
10oC per second, when powerful waves are used.
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The main interests can thus be listed as the rapid transfer of energy into the
bulk of the reaction mixture. Without inertia since only the product is heated and
the ease of utilisation. Further more, as the depth of magnitude as the wavelength
microwaves interact with substances of appreciable thickness (about 10 cm).
The interfacial polarisation, the Maxwell-Wagner effect, may also contribute
to the heating effect when the conducting particles are in contact with a non
conducting medium, e.g. in heterogenous reactions. It is particularly convenient
that qualitatively the larger the dielecric constant, the greater the coupling with
microwaves. Thus solvents such as water, methanol, DMF, ethyl acetate,
chloroform, acetone acetic acid, dichloromethane and R-spirit are all heated when
irradiated with microwaves. Non-polar solvents like carbon tetrachloride (CTC),
toluene, xylene do not couple and therefore do not heat with microwave
irradiation.
The rapid heating of food stuffs in microwave oven is routinely used by a
significant proportion of mankind. However people have recognised other
potential applications for this method of heating and scientists engaged in a
number of disciplines have applied the rapid heating associated with microwave
technology to a number of useful processes. These includes the preparation of
samples for analysis470, application to waste treatment471, polymer technology472,
drug release/targeting473 and ceramics. The technique has also found use in a
range of decomposition474 processes including hydrolysis of proteins and
peptides.
In the recent years, MORE (Microwave induced Organic Reaction
Enhancement) technique has become very popular. It has been reported that the
rate of  var iety of  organic react ion such as Diels  Alder475,476 Claisen
react ion477,478,  Oxidat ion479-481,  Reduct ion482,  Diacetylat ion483-485,
Ester i f icat ion486 Hydrolys is  of  esters487,488,  Doenr Condensat ion489,
Konevenagel candensation490 could be enhanced by microwave irradiation.
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Generally, commercial microwave oven is being used  in the chemical
laboratory at a frequincy of 2450 MHz. The first application of microwave oven
in organic synthesis began very recently. By the first experiments of Gedye and
Giguere, the evidence for dramatic acceleration in some classical organic reactions
established, and these were ascribed to temperature and pressure effects, when
performed in closed Teflon vessels. The reaction can be carried out in teflon,
polystyrene and glass vessels since these are transparent to microwaves.
Microwave irradiation has also been applied for carrying out reactions in open
vessels using organic solvents. The relatively low cost of modern domestic
microwave oven makes them reasonably readily available to academic and
industrial chemists.
Since solvents were used in these experiments, some problems with safe
operation appeared and sometimes explosion resulted. Further development
demonstrated the potential of solvent free reaction to solve these problems and
to facilitate the scale-up of preparative runs. Recently, reactions under dry
conditions using inorganic reagents are gaining more attention because of their
enhance selectivity and milder conditions than those associated with conventional
homogeneous reaction procedures. It should  be noted that some of the inorganic
additives reach temperatures in excess of 1000oC very rapidly and decomposition
of materials may be problematic, therefore some precautions regarding
superheating and associated fire hazards or explosions are taken.
Detail review on "Microwave Assisted Reactions" by S. Caddick491, involves
variety of unusual chemical reactions like,
1. Aromatic Substitution Reactions
2. Alkane Functionalisation
3. Catalytic Transfer Hydrogenation
4. Oxime Synthesis
5. Radical Reactions
6. Peptide Synthesis
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7. Rearrangements
8. Pericyclic Reactions
Dihydrothiadiazoles have attracted considerable attention as they appeared
of interest to possess wide range of pharmacological activities. Synthetic aspect
and therapeutic importance of 2,3-dihydro-1,3,4-thiadiazoles have been already
discussed in [A], Part-I, studies on 1,3,4-thiadiazolotriazoles.
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SECTION-I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-o-
CHLOROBENZYL-2,3-DIHYDRO-1,2,4-TRIAZOLO [3,4-b]-1,3,4-
THIADIAZOLES BY CONVENTIONAL METHOD
Dihydrothiadiazoles play a vital role owing of their wide range of
pharmacological activity. With a view to getting better therapeutic agents and to
evaluate it 's pharmacological profile, different type of dihydrothiadiazole
derivatives of type (XII) have been prepared by the condensation of 3-mercapto-
4,N-amino-5-o-chlorobenzyl-1,2,4-triazoles with different aromatic aldehydes in
presence of p-toluenesulphonic acid.
The constitution of newly synthesised compounds have been supported by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
All the compounds have been screened for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40µg. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have  moderate activity
as compared to known antibiotics recorded on Graphicla Chart No. 12.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37 Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
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N
N
N
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N
H
R
R = ArylType - (XII)
REACTION SCHEME
Cl
N
N
N
S
N
H
R
R - CHO
p-Ts-OH
Cl
N N
N
SH
NH2
NH2.NH2.H2O
Cl
O
NH NH
S
S   K
+-
EtOH, KOH
CS2
Cl
O
NH NH2
DMF
Type - (XII) R = Aryl
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IR SPECTRAL STUDY OF 2-p-METHOXYPHENYL-4-o-CHLOROBENZYL-2,3-DIHYDRO-
1,2,4-TRIAZOLO [3,4-b]-1,3,4-THIADIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2933 2975–2950 498
–CH
3
C – H str  (sym.) 2849 2880–1860 ''
C – H def. (asym.) 1445 1470–1435 ''
C – H def. (sym.) 1363 1385–1370 ''
Aromatic C – H str. 3051 3080–3030 503
C = C str. 1581 1585–1480 ''
C – H i.p. def. 1109 1125–1090 ''
1050 1070–1000 ''
C – H o.o.p def. 829 835–810 ''
Triazole C = N str. 1598 1612–1593 504
C – N str. 1164 1350-1200 498
N – N str. 1024 1050–1010 ''
C – Cl sr. 757 800–600 503
Ether C – O – C str. (asym.) 1252 1275–1200 498
C – O – C str. (sym.) 974 1075–1020 ''
Thiadiazole N – H str. 3432 3450–3200 ''
N – N str. 1024 1050–1010 ''
C – S – C str. 695 720–570 503
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmD IHY DROT HIA D IAZOL E 4-OCH3 
 537.1
 577.6
 695.3
 757.0
 829.3
 974.9
1024.1
1050.2
1109.0
1164.9
1252.7
1274.9
1315.4
1363.6
1445.5
1581.5
1598.9
1653.8
2849.6
2933.5
3051.2
3432.1
Cl
N
N
N
S
N
H
OCH3
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PMR SPECTRAL STUDY OF 2-p-METHOXYPHENYL-4-o-CHLOROBENZYL-2,3-
DIHYDRO-1,2,4-TRIAZOLO-[3,4-b]-1,3,4-THIADIAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J Value Relative No. Multiplicity Inference
No. (δ ppm) In Hz of Protons
1. 3.88 3H singlet Ar-OCH
3
2. 4.29 2H singlet -CH
2
3. 6.96 Jfe=9 2H doublet Ar-Hff'
4. 7.19-7.29 3H multiplet Ar-Hb, Ar-Hc
Ar-Hd
5. 7.37-7.40 1H triplet Ar-Ha
6. 7.78 Jef=9 2H doublet Ar-Hee'
7. 10.11 1H singlet -CHg-
8. 10.97 1H singlet -NHh-
Cl
N
N
N
S
N
H
OCH3
d
c
b
a h g
e
f
e'
f'
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EXPANDED AROMATIC REGION
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SECTION-II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-o-
CHLOROBENZYL-2,3-DIHYDRO-1,2,4-TRIAZOLO [3,4-b]-1,3,4-
THIADIAZOLES BY MICROWAVE METHOD
As a part of our research program towards the non traditinal approach to
the experimental set up of organic reactions, the concept of "Microwave induced
Organic Reaction Enhancement" (MORE) chemistry has been utilised for rapid
and efficient synthesis of some dihydrothiadiazoles which is described as under.
The synthesis was carried out by irradiating condensation of 3-mercapto-4,N-
amino-5-o-chlorobenzyl-1,2,4-triazol with different aromatic aldehydes in
presence of p-toluenesulphonic acid.
Various preparations of the dihydro thiadiazoles by microwave irradiations
are available in literature.492-497
The constitution of the synthesised compounds have been supported by
using elemental analysis,  infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography. In mass
spectromatry m/z value indicates the molecular weight, i.e. when R=4-methoxy
phenyl, molecular weight=358 m/z.
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation
source and data are compared in terms of yield and reaction period have been
cited in Table No. 12a.
Cl
N
N
N
S
N
H
R
R - CHO
p-Ts-OH
Cl
N N
N
SH
NH2
DMF
microwave irradiation
8 - 10 min
R = ArylType - (XIII)
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TABLE NO. 12a : COMPARISION OF CONVENTIONAL METHOD AND
MICROWAVE INDUCED SYNTHESIS OF 2-ARYL-4-o-
CHLOROBENZYL-2,3-DIHYDRO-1,2,4-TRIAZOLO [3,4-b]-
1,3,4-THIADIAZOLES
12a C6H5- 10 54 8 79 190
12b 4-CH3-C6H4- 14 66 9 76 202
12c 4-OCH3-C6H4- 12 72 12 89 198
12d 2-Cl-C6H4- 12 56 6 77 160
12e 4-Cl-C6H4- 12 58 10 80 192
12f 4-F-C6H4- 12 62 8 74 196
12g 3-OH-C6H4- 11 49 8 68 165
12h 2-NO2-C6H4- 13 64 8 78 180
12i 3-NO2-C6H4- 13 68 8 72 > 300
12j 3-OCH3,4-OH-C6H3- 12 59 10 81 208
12k 3,4-(OCH3)2-C6H3- 12 69 10 85 170
12l 9-C14H9- 10 75 6 84 142
Comp.
No.
ThermalR Microwave
Reaction
Period (hr.)
Yield
%
Reaction
Period (min.)
Yield
%
M.P.
oC
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-o-
CHLOROBENZYL-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4,-b]-1,3,4-
THIADIAZOLES
[A] Synthesis of potassium o-chlorophenylacetamido dithiocarbamate
See [A], Part-I, Section-I (C).
[B] Synthesis of 3-Mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
SECTION-I :
[A] Synthesis of 2-p-methoxyphenyl-4-o-chlorobenzyl-2,3-dihydro-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles by conventional method.
A mixture of 3-mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole (2.40g,
0.01M), p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene
sulphonic acid (50 mg) was refluxed for 12 hrs. The reaction mixture was poured
onto crushed ice. The product was isolated and crystallised from ethanol. Yield
1.72g, 72%, m.p. 198oC, (C17H15ClN4OS : Required : C, 56.90; H, 4.21; N,
15.61; Found : C, 56.86; H, 4.25; N, 15.57%).
TLC solvent system : Acetone : Benzene (4 : 6).
Similarly, other derivatives were synthesised. The physical data are recorded
in Table No. 12.
(B) Antimicrobial activity of 2-Aryl-4-o-chlorobenzyl-2,3-dihydro-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazoles.
Antimicrobial testing was carried out as described in [A] Part-I, Section-I, (F).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 12.
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Antitubercular  screening of the compounds of type (XII) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-
I (F) and the percentage of inhibition data of the compounds are recorded in
Table No. 12a.
SECTION - II
(A) Synthesis of 2-p-methoxyphenyl-4-o-chlorobenzyl-2,3-dihydro-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles by microwave method.
A mixture of 3-mercapto-4,N-amino-5-o-chlorobenzyl-1,2,4-triazole (2.40g,
0.01M) p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene
sulphonic acid (50 mg) was irradiated in a microwave oven for 8-10 min at 280
watts. The contents were cooled and poured onto crushed ice. The product was
isolated and crystallised from ethanol. Yield 2.14g, 89%, m.p. 198oC.
Similarly other derivatives have been synthesised.
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Molecular
Weight
4
R
2
M.P.
oC
5
% of Nitrogen
Calcd.
8
Found
9
TABLE NO. 12 : PHYSICAL CONSTANTS OF 2-ARYL-4-o-CHLOROBENZYL-2,3-DIHYDRO-1,2,4-TRIAZOLO[3,4,-b]-
1,3,4-THIADIAZOLES
Sr.
No.
1
12a C
6
H
5
- C
16
H
13
ClN
4
S 328.8 190 0.80 54 17.04 17.08
12b 4-CH
3
-C
6
H
4
- C
17
H
15
ClN
4
S 342.8 202 0.74 66 16.34 16.30
12c 4-OCH
3
-C
6
H
4
- C
17
H
15
ClN
4
OS 358.8 198 0.78 72 15.61 15.57
12d 2-Cl-C
6
H
4
- C
16
H
12
Cl
2
N
4
S 363.2 160 0.79 56 15.42 15.38
12e 4-Cl-C
6
H
4
- C
16
H
12
Cl
2
N
4
S 362.2 192 0.81 58 15.42 15.46
12f 4-F-C
6
H
4
- C
16
H
12
ClFN
4
S 346.8 196 0.76 62 5.48 5.44
12g 3-OH-C
6
H
4
- C
16
H
13
ClN
4
OS 344.8 165 0.75 49 16.25 16.27
12h 2-NO
 2
-C
6
H
4
- C
16
H
12
ClN
5
O
2
S 373.8 180 0.64 64 18.73 18.77
12i 3-NO
2
-C
6
H
4
- C
16
H
12
ClN
5
O
2
S 372.8 >300 0.70 68 18.73 18.70
12j 3-OH,4-OCH
3
-C
6
H
3
- C
16
H
15
ClN
4
O
2
S 374.8 208 0.80 59 14.95 14.92
12k 3,4-(OCH
3
)
2
-C
6
H
3
- C
18
H
17
ClN
4
O
2
S 388.8 170 0.66 69 14.41 14.37
12l 9-C
14
H
9
C
23
H
16
ClN
4
S 429.9 142 0.68 75 16.29 16.26
*TLC Solvent System :Ethyl acetate : Hexane (1 : 9) (12a - 12l)
(4 : 6) (12c, 12i, 12j, 12k)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
204
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B.coccus 13 9 16 15 11 17 16 17 18 20 11 8 17 21 16
B.subtilis 10 20 13 11 17 8 12 18 17 9 11 10 15 21 22
P.vulgaris 13 13 12 12 11 15 17 14 17 18 11 14 16 19 15
E.coli 17 18 14 11 13 14 12 17 13 12 8 19 19 18 20
A.niger 15 17 11 12 14 15 17 16 14 13 18 20 0 0 0
12a 12b 12c 12d 12e 12f 12g 12h 12i 12j 12k 12l Amoxycillin
Benzoy
lpenicill
in
Ciprofl
oxacin
GRAPHICAL CHART NO. 12  :  2-ARYL-4-o-CHLOROBENZYL-2,3-DIHYDRO-1,2,4-
                                                            TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
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RESULTS & DISCUSSION
ANTIMICROBIAL ACTIVITY :
Antibacterial activity :
I t  has  been conc luded f rom the  exper imenta l  da ta  tha t  a l l  the
dihydrothiadiazole derivatives (XII) markedly inhibit the growth of Gram positive
bacteria and also Gram negative bacteria.
All compounds show moderate activity against Gram positive bacteria.
However, maximum activity was observed in compounds bearing R=2-
fluorophenyl, 4-nitrophenyl, 3-nitrophenyl and 3-hydroxy,4-methoxyphenyl
against B.coccus whereas R=4-methylphenyl, 4-chlorophenyl, 2-nitrophenyl
and 3-nitrophenyl against B.subtilis.
In case of Gram negative bacterial strains, the maximum activity was
displayed by the compounds bearing R=3-hydroxyphenyl, 3-nitrophenyl and
3-hydroxy,4-methoxyphenyl against P.vulgaris. While the compounds with
R=phenyl,4-methylphenyl and 9-anthryl have shown considerable activity
against E.coli.
Antifungal activity :
The antifungal data revealed that compounds were least toxic to the fungal
strain. However, mild activity was shown by the compound bearing R=9-anthryl
against A.niger.
The antibacterial activity was compared with standard drugs viz. Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
Antitubercular activity :
Almost all compounds were found to be inactive against Mycobacterium
tuberculosis H37Rv except 4-chlorophenyl and 9-anthryl.
The antitubercular activity data have been compared with standard drug
Rifampin.
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295431 BSA-53 C
6
H
4
- Alamar H
37
Rv >6.25 0 - Mic Ri fampin =
0.25 µg/ml
@ 98% Inhibit ion
295432 BSA-54 4-OCH
3
-C
6
H
4
-Alamar H
37
Rv >6.25 0 -
295433 BSA-55 2-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295434 BSA-56 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 15 - "
295435 BSA-57 4-F-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295436 BSA-58 3-OH- C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295437 BSA-59 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295438 BSA-60 2-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295439 BSA-61 3-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295440 BSA-62 3-OCH
3
,4-OH-C
6
H
3
- Alamar H
37
Rv >6.25 0 - "
295441 BSA-63 3,4-(OCH
3
)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 0 - "
295442 BSA-64 9-C
14
H
9
- Alamar H
37
Rv >6.25 38 - "
Mtb
Strain
Mic
µg/ml
%
Inhib
Where,
R =
Activity
TABLE NO. 12a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
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LIST OF
      NEW
 COMPOUNDS
R R R
2-CH3-C6H4-
4-CH3-C6H4-
3-OCH3-C6H4-
4-OCH3-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-Br-C6H4-
4-NO2-C6H4-
2-NH2-C6H4-
2-OH-C6H4-
2-OCOCH3-C6H4-
2,4-(OH)2-C6H3-
-CH2-C6H4
-CH=CH-C6H5
C5H4N-
H
6-CH3
8-CH3
6-OCH3
8-OCH3
6-Cl
7-Cl
8-Cl
8-F
6,8-(CH3)2
6,7-(Cl)2
6-F, 7-Cl
C6H5-
2-CH3-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
2-Cl-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
2-F-C6H4-
4-F-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
2,5-(Cl)2-C6H3-
3,4-(Cl)2-C6H3-
2,4-(CH3)2-C6H3-
3-Cl,4-F-C6H3-
Cl N N
N
S
N
N
R
Cl
N
N
N
S
N R
Cl
N N
N
SH
R
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R R R
2-CH3-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
2-Cl-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-Br-C6H4-
2-OH-C6H4-
4-OH-C6H4-
2-NH2-C6H4-
4-NH2-C6H4-
4-NO2-C6H4-
C6H5-
4-OCH3-C6H4-
2-Cl-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-NO2-C6H4-
3-NO2-C6H4-
2-OH-C6H4-
4-OH-C6H4-
9-C14H9-
3-OH, 4-OCH3-C6H3-
3,4-(OCH3)2-C6H3-
C6H5-
2-CH3-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-NO2-C6H4-
4-COOH
3-Cl, 4-F-C6H3-
2,4-di-Cl-C6H3-
2,5-di-Cl-C6H3-
3,4-di-Cl-C6H3-
Cl
N N
O
R
Cl
N N
N
SH
N
R
N
N
Br
S
N
N R
R
O
239
R R R
C6H5-
2-CH3-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-NO2-C6H4-
4-COOH-C6H4-
3-Cl, 4-F-C6H3-
2,4-di-Cl-C6H3-
2,5-di-Cl-C6H3-
3,4-di-Cl-C6H3-
C6H5-
2-CH3-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-NO2-C6H4-
4-COOH-C6H4-
3-Cl, 4-F-C6H3-
2,4-di-Cl-C6H3-
2,5-di-Cl-C6H3-
3,4-di-Cl-C6H3-
C6H5-
4-CH3-C6H4-
4-OCH3-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-Br-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
4-NH2-C6H4-
2-OH-C6H4-
4-OH-C6H4-
2,4-di-Cl-C6H3-
N
N
Br
S
N
N R
R
NH NH
O
N
N
Br
S
N
N R
R
NH NH
S
N
N
Br
NH
O
R
N
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R R R
4-CH3-C6H4-
2-OCH3-C6H4-
4-OCH3-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
4-F-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
3-Cl, 4-F-C6H3-
2,4-di-CH3-C6H3-
2,4-di-Cl-C6H3-
3,4-di-Cl-C6H3-
2-CH3-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
2-F-C6H4-
4-F-C6H4-
4-Br-C6H4-
3-Cl, 4-F-C6H3-
2,4-di-CH3-C6H3-
3,4-di-Cl-C6H3-
2,5-di-Cl-C6H3-
C6H5-
4-CH3-C6H4-
4-OCH3-C6H4-
2-Cl-C6H4-
4-Cl-C6H4-
4-F-C6H4-
3-OH-C6H4-
2-NO2-C6H4-
3-NO2-C6H4-
3-OCH3,4-OH-C6H3-
3,4-(OCH3)2-C6H3-
9-C14H9-
NN
Br
N
N
R2
R1
O
NN
Br
NH NR Cl
N
N
N
S
N
H
R
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